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Abstract 
The opening chapter details investigations undertaken into heteroallylation methodology developed 
within the France group. The first section gives an overview of the existing strategies for palladium-
catalysed alkene difunctionalisation reactions which construct a new nitrogen-containing 
heterocycle. Particular attention is devoted to the construction of new carbon–carbon bonds and the 
relative lack of methods to construct new sp3–sp3 C–C bonds. 
 
The second section details the results of a mechanistic investigation into the previously developed 
oxyallylation methodology. The investigation successfully provided evidence that an isohypsic-
palladium(II) catalysed mechanism was operative. 
 
 
 
The third section discusses attempts towards the extension of the heteroallylation methodology to 
include the construction of nitrogen-containing heterocycles. Initial attempts focussed on the 
aminoallylation of tosylamides, from which four new heterocycles were synthesised. Further 
investigations with hydroxamates allowed the synthesis of three further heterocycles, but the results 
demonstrate the potential for a greater substrate scope in the future. 
 
 
 
The fourth section details experimental procedures and compound data. 
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The second chapter details research undertaken towards the validation of a novel therapeutic target 
for the treatment of parasitic nematode infections. The first section details the current treatments and 
the growing levels of resistance to these treatments. Furthermore, previously published data 
concerning nematode astacins, the proposed new target, is presented, providing information which 
was utilised for the design of the new inhibitors. 
 
The second section discusses the design and synthesis of proposed nematode astacin inhibitors, and 
details the biological testing results gathered by our collaborators. Two compounds, in particular, 
were demonstrated to be the most potent known compounds against the new therapeutic target. Taken 
together, the results demonstrate a start point towards to goal of a new class of nematode-infection 
therapeutics. 
 
 
 
The third section details experimental procedures and compound data. 
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Chapter 1: Investigations into a Palladium-Catalysed 
heterocyclisation-allylation process: Mechanistic insights 
and expansion of reaction scope 
1.1: Palladium-Catalysed alkene difunctionalisation: Synthesis of 
Nitrogen-Containing Heterocycles 
1.1.1: Background 
Nitrogen-containing heterocycles are prevalent in natural products, and have been subject to 
significant chemical research due to their pharmacological and biological activities.[1] In particular, 
pyrrolidines and piperidines[2] are common architectures in alkaloid natural products, including 
tropane alkaloids (e.g. atropine),[3] and opioid alkaloids (e.g. codeine). Molecules containing 
aminocyclic functionality are known to exhibit a diverse range of pharmacological activities and 
many alkaloids are considered vital medicines (Figure 1.1). [1,4] 
 
 
Figure 1.1: Representative alkaloid natural products 
 
Synthetic alkaloids have also been demonstrated to exhibit powerful pharmacological activity. 
Aripiprazole, an antipsychotic drug marketed for the treatment of schizophrenia, is currently one of 
the world’s highest grossing drugs, with sales of ca. $6.5 billion in 2013 (Figure 1.2).[5] 
 
 
Figure 1.2: Structure of aripiprazole 
 
The construction of nitrogen-containing heterocycles is consequently of great importance and novel 
efficient methods are highly sought after. Reports on synthetic protocols towards the formation of 
nitrogen-containing heterocycles are extensive and wide-ranging. Current strategies for the 
construction of aminocycles via C–N bond formation include, but are not limited to, 
halolactamisation,[6,7] hetero-Diels–Alder reactions,[8] and alkene functionalisation reactions 
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catalysed by a range of transition metals.[9] Recent efforts have allowed significant growth in the 
field of enantioselective C–N bond formation,[10] adding key reactions to the chemists’ toolbox. 
 
Palladium-catalysed alkene functionalisation is the most common method for the construction of 
nitrogen-containing heterocycles via transition metal catalysis.[9,11,12] This report will describe the 
wide range of multiple-bond forming reactions which have been coupled with palladium-catalysed 
aminocyclisation. 
 
Aza-Wacker Reaction 
Over the past 100 years, the field of transition-metal catalysis has been subject to much research and 
palladium-catalysed transformations have been among the most heavily investigated. Since the 
1970s, huge advances have been made and the importance of palladium catalysis was highlighted by 
the award of the 2010 Nobel Prize in Chemistry to Richard Heck, Akira Suzuki and Ei-Ichi Negishi 
for their contributions to palladium catalysed cross-coupling reactions (Scheme 1.1).  
 
 
Scheme 1.1: General Cross-Coupling Mechanism 
 
The reactivity of palladium cross-couplings relies on the oxidative addition of palladium into a 
carbon–halogen bond, yielding an organopalladium(II) intermediate. However, for the application of 
palladium catalysis to alkene difunctionalisation it was necessary to utilise different reactivity: the 
coordination of the alkene by a Lewis acidic palladium salt. The traditional nucleophilic nature of 
the alkene is reversed, increasing electrophilicity and activating to nucleophilic attack. 
 
The genesis of the aza-Wacker reaction occurred in the late 19th century, with the discovery of the 
Wacker reaction. The Wacker reaction is the addition of water across an alkene, catalysed by a 
palladium salt. The process was commercialised in the 1950s after the procedure was made more 
efficient through the use of an oxidant (Scheme 1.2).[13] Coordination of the palladium catalyst across 
ethylene gives rise to complex 1.1 which facilitates the nucleophilic addition of water, leading to 
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alkylpalladium(II) intermediate 1.2. β-Hydride elimination from alkylpalladium (II) intermediate 1.2 
yields palladium(0) and enol 1.3, the latter of which will rapidly tautomerise to produce acetaldehyde 
1.4. The resulting Pd(0) was reoxidised to Pd(II) using a copper salt, thus completing the catalytic 
cycle. There is still, however, much debate regarding the mechanism of the Wacker process, 
primarily over the mechanism of the oxypalladation.[14] 
 
 
Scheme 1.2: Mechanism of the Wacker process 
 
Further research showed that palladium(II) salts could facilitate the nucleophilic attack of a wide 
range of nucleophiles onto activated alkenes (Scheme 1.3). Early research from Hosokawa and co-
workers was centred on the utilisation of oxygen nucleophiles.[15]  
 
 
Scheme 1.3: Nucleophilic addition onto activated alkenes 
 
In 1974 Hegedus and co-workers provided evidence for addition of nitrogen nucleophiles across a 
palladium-activated alkene. Addition of diethylamine to activated ethylene, followed by 
hydrogenation of the resultant diethylethyleneamine, produced triethylamine in high yields (Eq. 
1.1).[16] 
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While not a viable commercial synthesis of triethylamine, the report provided proof of concept for 
the aza-Wacker process, which would be rapidly expanded upon. Further work from Hegedus et al. 
utilised tethered nucleophiles, demonstrating the first example of palladium-catalysed 
aminocyclisation (Eq. 1.2).[17] The reaction represents an efficient synthesis of indoles under tolerant 
reaction conditions, albeit with stoichiometric palladium. 
 
 
 
The proposed mechanism for the reaction is shown below (Scheme 1.4). Aminopalladation of 2-
allylaniline rapidly proceeds via a 5-exo-trig cyclisation to give alkylpalladium(II) intermediate 1.5. 
β-Hydride elimination afforded exocyclic methylene indoline 1.6. Indoline 1.6 was not observed 
however, due to rapid isomerisation of the alkene into conjugation, yielding 2-methylindole. 
 
 
Scheme 1.4: Mechanism for 2-methylindole synthesis 
 
In 1978, Hegedus et al. introduced an oxidant to the above reaction, allowing it to proceed 
catalytically in palladium (Eq. 1.3).[18] The mechanism proceeds via the same pathway as described 
above. 
 
 
 
Since this work was undertaken, there have been many reports of oxidative and non-oxidative 
aminocyclisation reactions facilitated by palladium(II) salts. The reactions generally have broad 
scope and are air- and moisture-tolerant.[19] 
1.1.2: Multiple-bond forming strategies 
It was recognised that alkylpalladium(II) intermediate 1.8, formed by aminopalladation of alkene 1.7 
during the aza-Wacker reaction, could be utilised for further transformations, rather than allowing it 
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to terminate via β-hydride elimination (Scheme 1.5). The proposed strategy would allow more rapid 
and efficient building of molecular complexity. 
 
 
Scheme 1.5: Potential for further transformation 
 
Alkylpalladium(II) intermediates (e.g. 1.8) have been demonstrated to participate in a large number 
of transformations. The known examples of aminocyclisation-difunctionalisation reactions catalysed 
by palladium(II) salts are summarised below (Scheme 1.6). In each case, a new nitrogen-containing 
heterocycle is formed by C–N bond formation, and a second bond is formed to an sp3 hybridised 
carbon centre. Extensive research has been undertaken towards the formation of a second carbon–
carbon bond. Examples include formation of new sp3–sp2 C–C bonds (Products 1.11 and 1.12), as 
well as new sp3–sp bonds (product 1.13). The formation of new carbon–oxygen, carbon–halogen 
(product 1.14) and of a second new carbon–nitrogen bond (product 1.15) have also been achieved 
under a wide range of methodologies.[20] 
 
 
Scheme 1.6: Summary of Pd(II)-catalysed aminocyclisation-difunctionalisation reactions 
 
Mechanistic considerations 
Each of the reactions discussed in the following sections share a common first step: intramolecular 
aminopalladation. Aminopalladation is known to occur via one of two mechanisms: cis- or trans-
aminopalladation (Scheme 1.7). Cis-aminopalladation, in which nucleophilic attack occurs via a pre-
coordinated amine, leads to syn-alkylpalladium intermediates (1.17). Trans-aminopalladation occurs 
from direct alkene coordination to palladium, followed by nucleophilic attack of the amine, leading 
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to anti-alkylpalladium intermediates (1.18).[12] The specific mechanism will control the 
stereochemical outcome of aminopalladation and will consequently have important implications on 
attempts to develop enantio- or diastereo-selective oxidative amination reactions.[10,21] 
 
 
Scheme 1.7: Cis- vs Trans-aminopalladation 
 
The mechanism of aminopalladation has been investigated thoroughly in several systems and a 
number of sophisticated mechanistic experiments have been utilised.[20] It has been demonstrated that 
even small changes in substrate or in reaction conditions can have a profound effect on the 
mechanism of aminopalladation.[20,21] 
 
A further consideration when proposing a second bond-forming event is the relative rate of β-hydride 
elimination (See Scheme 1.5). β-Hydride elimination is an intramolecular process and can rapidly 
terminate the reactivity of alkylpalladium(II) intermediates (e.g. 1.8). There are, however, strategies 
to circumvent β-hydride elimination (Scheme 1.8). Strategy 1 utilises geminally-disubstituted 
alkenes (e.g. 1.19). Alkylpalladium(II) intermediate 1.20, arising from aminopalladation of alkene 
1.19 does not contain a β-hydrogen atom and, consequently, cannot undergo β-hydride elimination. 
Strategy 2 involves stabilisation of alkylpalladium(II) intermediate 1.21, thus slowing the relative 
rate of β-hydride elimination. Strategy 3 involves a rapid transformation of alkylpalladium(II) 
intermediate 1.21, such as oxidation to alkylpalladium(IV) intermediate 1.23, and thus inhibiting β-
hydride elimination. 
 
Scheme 1.8: Strategies to circumvent β-hydride elimination 
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The following sections will contain a detailed discussion into a number of aminopalladation 
processes, leading to the formation of a new nitrogen-containing heterocycle and a range of new 
carbon–carbon and carbon–heteroatom bonds. 
1.1.3: Carboamination 
Carboamination reactions are processes which introduce a new carbon-nitrogen bond and a new 
carbon–carbon bond across an olefin (Eq. 1.4). Through the use of tethered nucleophiles, it is possible 
to synthesise a new nitrogen-containing heterocycle.  The second new bond is formed between an 
sp3-hydridised carbon and a sp-, sp2- or sp3-hybridised carbon. In the following sections, the range 
of transformations will be discussed in terms of the hybridisation of the second carbon. 
 
 
 
sp3–sp2 bond formation 
In the vast majority of aminocyclisation reactions followed by C–C bond formation the second bond 
is formed between an sp3-hydridised carbon and an sp2-hydridised carbon, such as pyrrolidone 1.26 
(Scheme 1.9). There is a large extent of potential transformations, for example, alkene-
carbopalladation (1.26, where Y = C) or carbonylation (1.26, where Y = O).  A representative range 
of these transformations will be discussed in the following sections. 
 
 
Scheme 1.9: General sp3–sp2 C–C bond forming carboamination 
 
Carbopalladation 
As has been discussed previously with regards to aminopalladation, alkenes can be activated by 
palladium(II) salts towards insertion of a nucleophile. Alkylpalladium(II) intermediates (e.g. 1.8, 
Scheme 1.10) have been demonstrated to undergo a similar process with alkenes (Scheme 1.11). This 
process, known as carbopalladation, is often terminated by β-hydride elimination to yield alkene 
products, such as 1.27.  
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Scheme 1.10: Trapping of alkylpalladium(II) intermediates by alkenes 
 
Early examples demonstrated that enones and acrylate esters were particularly suitable for 
carbopalladation with alkylpalladium(II) intermediates. In 1980, Hegedus and co-workers 
demonstrated the carboamination of o-allyl anilines (Scheme 1.11).[22] Treatment of methyl-
allylaniline 1.28 with a palladium(II) salt in the presence of methylvinylketone efficiently yielded 
desired indoline 1.32. The reaction was proposed to proceed via alkylpalladium(II) intermediate 1.30. 
It was necessary to utilise gem-disubstituted alkenes because alkylpalladium(II) intermediate 1.31, 
the product of aminopalladation of allylaniline 1.29, rapidly underwent β-hydride elimination to 
afford indole 1.34. 
 
 
Scheme 1.11: Carboamination via intermolecular carbopalladation 
 
Hegedus and co-workers demonstrated, through the introduction of a second tethered alkene, that 
intramolecular carboamination is an efficient method for the synthesis of fused heterocycles (Scheme 
1.12).[22] Treatment of acrylamide 1.35 with Pd(II) formed alkylpalladium(II) intermediate 1.36, 
which selectively underwent 5-exo-trig intramolecular carbopalladation to yield pyrrolizine 1.37 
(mixture of two alkene isomers). There was no observed formation of indolizine 1.38, a product of 
6-endo carbopalladation from alkylpalladium(II) intermediate 1.36. 
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Scheme 1.12: Carboamination via intramolecular carbopalladation 
 
In 2006, Yang et al. reported the first example of an enantioselective palladium(II)-catalysed 
carboamination, utilising the carbopalladation onto a tethered alkene (Scheme 1.13).[23] The use of 
sparteine as a ligand for palladium allowed aminopalladation of anilide 1.39 to proceed 
enantioselectively, affording alkylpalladium(II) intermediate 1.40. Alkylpalladium(II) intermediate 
1.40 was trapped via intramolecular carbopalladation with the enone moiety. Subsequent β-hydride 
elimination delivered desired aminocyclic pyrrolizine 1.41 with high optical purity. 
 
  
Scheme 1.13: Sparteine-mediated enantioselective carboamination 
 
Aminocarbonylation 
CO migratory-insertion is the addition of carbon monoxide into carbon–metal bonds, forming a 
metallo-acyl complex, eventually leading to new carbonyl units. This phenomenon has been 
observed for a wide range of transition metals, and the utilisation of migratory-insertion in palladium 
catalysis has been particularly well investigated.[24] In 1974 Heck et al. demonstrated the palladium-
catalysed esterification and amidation of aryl, benzyl and vinyl halides (Scheme 1.14).[25,26] The 
reactions demonstrated the trapping of acylpalladium(II) intermediate 1.42 by oxygen and nitrogen 
nucleophiles, providing proof of concept for multiple-bond forming strategies utilising palladium-
carbon monoxide migratory insertion strategies. 
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Scheme 1.14: Trapping of acylpalladium(II) intermediates with alcohols and amines 
 
The seminal example of aminocyclisation–carbonylation was reported by Yoshida et al. in 1988. The 
methodology demonstrated that alkylpalladium(II) intermediate 1.44, the product of 
aminopalladation of urea 1.43, could be rapidly trapped by carbon monoxide, preventing β-hydride 
elimination and furnishing a new carbonyl unit, eventually yielding cyclic urea 1.45 (Scheme 
1.15).[27] The reaction successfully furnishes a new nitrogen-containing heterocycle, and a new sp2–
sp3 C–C bond in a single step. 
 
 
Scheme 1.15: Palladium-catalysed aminocarbonylation 
 
The proposed mechanism for the reaction is shown below (Scheme 1.16). Aminopalladation of urea 
1.43 furnishes alkylpalladium(II) intermediate 1.44. Intermediate 1.44 rapidly undergoes migratory 
insertion with carbon monoxide, preventing β-hydride elimination and affording acylpalladium(II) 
intermediate 1.46. De-insertion by nucleophilic attack of methanol produces the desired product 1.45 
and Pd(0), the latter of which was reoxidised to complete the catalytic cycle. 
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Scheme 1.16: Catalytic cycle for Yoshida aminocarbonylation 
 
As was demonstrated by Heck (Scheme 1.14), it is possible to employ a range of nucleophiles to trap 
the acylpalladium(II) intermediate, giving access to a range of amide and ester products. Further 
investigations by Yoshida et al. exhibited the potential for using a tethered nucleophile, allowing the 
synthesis of two new heterocycles in a single step (Eq. 1.5).[27] When urea 1.47 was subjected to 
aminocarbonylation, bicyclic urea 1.48 was observed as a single product. 
 
 
 
The proposed mechanism for the formation of pyrimidone 1.48 is discussed below (Scheme 1.17). 
5-exo-trig aminopalladation of urea 1.47 yields alkylpalladium(II) pyrrolidine intermediate 1.50. 
Migratory insertion of carbon monoxide yields acylpalladium(II) intermediate 1.51 which undergoes 
nucleophilic displacement with the tethered methylamide moiety to yield the desired bicycle 1.48. 
This example is especially efficient as it installs two C–N bonds, both forming new heterocycles, and 
a new sp3–sp2 C–C bond. 
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Scheme 1.17: Proposed mechanism for the formation of pyrimidone 1.48 
 
A second report by Yoshida et al. demonstrated the use of tethered allylic alcohols to synthesise 
lactone containing bicyclic systems (Eq. 1.6).[28] Treatment of allylic alcohol 1.52 with a Pd(II) salt 
and carbon monoxide afforded lactone 1.53. Like the above reaction, two new fused heterocycles are 
synthesised in a single, high-yielding reaction. The work demonstrates efficient methodology for the 
synthesis of multiple heterocycles in a single step. The formation of 1.53 proceeds via the same 
mechanism as above (Scheme 1.17), instead trapping the acylpalladium(II) intermediate with the 
tethered allylic alcohol. 
 
 
 
Aminoarylation 
Wolfe et al. published a report describing an arylation-aminocyclisation protocol (Eq. 1.7). 
Treatment of napthyl bromide 1.55 with a palladium(0) catalyst and alkenylamine 1.54 afforded 2-
substituted pyrrolidine 1.56. The methodology allows for the synthesis of a range of substituted 
pyrrolidines under mild conditions, with an efficient catalyst system.[29] The methodology has also 
been demonstrated to allow the synthesis of substituted indolines.[30] 
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The full proposed mechanism is shown below (Scheme 1.18). Oxidative addition of Pd(0) with aryl 
bromide 1.57 yields arylpalladium(II) intermediate 1.58. Subsequent coordination to alkenylamine 
1.59 of the palladium(II) induces aminopalladation, which results in aryl-alkylpalladium(II) 
intermediate 1.60. Carbon–carbon bond forming reductive elimination from intermediate 1.60 results 
in desired pyrrolidine 1.61. The reaction was successfully able to avoid β-hydride elimination from 
alkylpalladium(II) intermediate 1.60 because the competing reductive elimination was more rapid. 
 
 
Scheme 1.18: Mechanism of Wolfe aminoarylation 
 
It was further noted that intramolecular delivery of the alkenylamine moiety would allow the 
synthesis of a second heterocycle/carbocycle, as well as the new aminocycle. This would demonstrate 
a more concise and efficient method towards vicinal-carbo/heterocycles (Scheme 1.19).[31] Treatment 
of arylbromide 1.60 with a palladium(0) catalyst yielded a mixture of pyrrolidines 1.61 and 1.62, the 
products of cis-aminopalladation and trans-aminopalladation respectively. It was discovered that the 
ligand had a significant effect on the mechanism of aminopalladation, and thus the stereoselectivity 
of the reaction. Utilising racemic BINAP resulted in no selectivity between cis- and trans-
aminopalladation processes, and thus an equal mixture of two diastereomers. 
Tricyclohexylphosphine provided the highest selectivity for cis-aminopalladation and thus allowed 
the development of diastereoselective aminoaylation reaction conditions. 
 
 
23 
 
 
Scheme 1.19: Diastereoselective intramolecular aminoarylation 
 
Furthermore, Wolfe and co-workers successfully demonstrated enantioselective arylamination 
reaction conditions, allowing the construction of 2-substituted pyrrolidine with high optical purity 
(Eq. 1.8).[32] The protocol allowed for synthesis of 2-(arylmethyl)pyrrolidines (e.g. 1.64) with high 
enantioselective induction by utilising (R)-Siphos-PE and demonstrated a range of aryl and vinyl 
coupling partners. The reaction proceeds via the same mechanism as shown above (Scheme 1.18). 
 
 
 
sp3–sp C–C bond formation 
In 2010, Waser et al. published a report on the oxyalkynylation of alkenes with tethered alcohol and 
carboxylic acid nucleophiles, leading to the synthesis of new oxygen-containing heterocycles 
(Scheme 1.20).[33] Within this paper there was a single example of a nitrogen nucleophile. When 
treated with a palladium(II) salt and TIPS-EBX, O-benzyl hydroxamate 1.65 underwent 
aminoalkynylation to yield lactone 1.66. The reaction, however, suffered from lack of 
chemoselectivity between amino- and oxyalkynylation, resulting in a substantial yield of imidate 
1.67. 
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Scheme 1.20: Waser oxyalkynylation reaction 
 
In 2011, the same group reported a general procedure for the palladium-catalysed aminoalkynylation 
of alkenes. Tosylamide 1.68 successfully underwent aminoalkynylation, producing pyrrolidone 1.69 
in high yield (Eq. 1.9).[34] By utilising tosylamides, rather than benzylhydroxamates, excellent 
chemoselectivity for aminocyclisation was observed and a range of nitrogen-containing heterocycles 
were constructured. 
 
 
 
The role of the hypervalent iodide species remains consistent between the oxyalkynylation and 
aminoalkynylation reactions: a strong oxidant to allow the oxidation of alkylpalladium(II) 
intermediates to alkylpalladium(IV). The full mechanism is described below (Scheme 1.21). 
Aminopalladation of tosylamide 1.68 by a palladium(II) salt will produce alkylpalladium(II) 
intermediate 1.70. Oxidative addition into the iodo-alkynyl bond of the hypervalent iodide species 
yields alkylpalladium(IV) intermediate 1.71, which undergoes reductive elimination to afford 
pyrrolidone 1.69 and recycle the palladium(II) salt. 
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Scheme 1.21: Mechanism of Waser Aminoalkynylation 
 
The methodology was limited to the aminocyclisation of sulfonyl-protected amides, carbamates and 
ureas, although the group has demonstrated the reduction of pyrrolidone 1.73 to the respective 
pyrrolidine. The methodology has been applied towards the synthesis of alkaloid (±)-
trachelanthamidine, demonstrating the potential for reduction to the pyrrolidine, as well as efficient 
N-sulfonyl group deprotection (Scheme 1.22). 
 
 
Scheme 1.22: Synthesis of (±)-trachelanthamidine 
 
Towards the goal of direct pyrrolidine synthesis from the aminoalkynylation of amines, Waser and 
co-workers developed a palladium(0)-catalysed system (Eq. 1.10).[35] Treatment of alkenyl 
carbamate 1.74 with palladium(0) and an alkynyl bromide allowed the construction of a range of 2-
alkynyl pyrrolidines 1.75. 
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While pyrrolidine 1.75 was structurally similar to the products formed by the previously discussed 
aminoalkynylation methodology (Eq. 1.9), the process is mechanistically distinct (Scheme 1.23). The 
mechanism was reminiscent of Wolfe and co-workers aminoarylation reaction (Scheme 1.18). 
Oxidative addition into the alkynyl-bromide bond yields alkynylpalladium(II) intermediate 1.76, 
which then catalyses the aminopalladation process with alkenylcarbamate 1.74 to yield  
alkylpalladium(II) intermediate 1.77. Subsequent reductive elimination from alkylpalladium(II) 
intermediate 1.77, producing 2-alkenyl pyrrolidine 1.75. 
 
 
Scheme 1.23: Mechanism for Pd(0)-catalysed aminoalkynylation 
 
While the initial account was limited to the introduction of silyl-protected acetylenes, a further report 
demonstrated increased scope of alkynylation using alkyl-bromoacetylenes, allowing the synthesis 
of linear and branched alkyl-alkynyl pyrrolidines (Scheme 1.24).[36] The methodology was 
particularly important because it represent the first aminoalkynylation reaction using aliphatic 
bromoacetylenes. 
 
 
Scheme 1.24: Scope of dialkyl-alkyne synthesis 
 
The report also discussed a one-pot aminoalkynylation-hydrogenation procedure, allowing the 
indirect synthesis of a new sp3–sp3 C–C bond (Eq. 1.11). The reaction was efficient in synthesising 
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2-alkyl substituted pyrrolidines, but as a method for sp3–sp3 C–C bond formation, it has a significant 
lack of functional group tolerance due to the utilisation of hydrogenation reaction conditions. 
 
 
 
Conventional approaches to aminopalladation, and all of those described previously in this report, 
utilise a nucleophilic nitrogen species in conjunction with an oxidising species for carbon–carbon 
bond formation. In 2015, Bower and co-workers demonstrated an umpolung approach towards 
aminopalladation, utilising an electrophilic amine species (Eq. 1.12).[37] Treatment of O-
pentafluorobenzyloxime 1.80 with a Pd(0) catalyst and an alkynylboronic acid resulted in 2-
substituted dihydropyrrole 1.82. This approach allowed the utilisation of the vast range of 
commercially available metalloid-coupling reagents. O-Pentafluorobenzoyloximes have previously 
demonstrated strong reactivity towards oxidative addition with palladium(0) catalysts, yielding 
alkylidene amino-palladium species, which have, in turn, shown strong reactivity to insertion into 
tethered alkenes in amino-Heck processes.[38] 
 
 
 
Like the reports by Waser and co-workers above, the reaction creates a new nitrogen-containing 
heterocycle and a new sp3–sp C–C bond, however, in this case it occurs via a mechanistically distinct 
approach (Scheme 1.25). Oxidative addition of the palladium(0) catalyst into the oxime N–O bond 
leads to iminopalladium(II) intermediate 1.84. Iminopalladation onto the tethered alkene will yield 
alkylpalladium(II) intermediate 1.85. In the case of the alkynylation work, R1 = methyl, so β-hydride 
elimination from this intermediate was not possible. Transmetallation with an alkynyl-boronic ester 
will yield alkynylpalladium(II) intermediate 1.86 and subsequent reductive elimination afforded 
desired pyrrole 1.87. 
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Scheme 1.25: Mechanism for Bower aminoalkynylation 
 
What is particularly striking is that the methodology provides the first “unified strategy” for a wide-
range of carboaminations. Simply by varying the nucleophile, it has been demonstrated that the 
methodology can also achieve amino-acylation, carboxylation, arylation and vinylation (Scheme 
1.26). Trapping alkylpalladium(II) intermediate 1.85 with aryl- or vinylboronic esters allows the 
synthesis of product types 1.88 and 1.89, creating a new sp3–sp2 C–C bond. The previously discussed 
strategy of CO migratory insertion, followed by nucleophilic displacement was demonstrated here, 
allowing the synthesis of a range of esters (1.90). CO migratory insertion and subsequent trapping 
with aryl-boronates was also successful, allowing the synthesis of aryl ketones (1.91). In order to 
circumvent β-hydride elimination, most examples utilise geminally-disubstituted alkenes (R1 = 
methyl). There are, however, several examples in which R1 = H, showing that the intermolecular 
trapping of alkylpalladium(II) intermediate 1.85 via transmetallation can be as rapid as β-hydride 
elimination. 
 
 
Scheme 1.26: Range of carboamination transformations 
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This methodology demonstrates an important step in the advancement of palladium-catalysed 
carboamination processes. Previously, as has been established in this report, it has been necessary to 
employ distinct methodologies to achieve small changes in product functionality. Although the group 
has demonstrated the reductive transformation of the imines to the respective pyrrolidines, further 
development of other electrophilic nitrogen-sources would allow for a wide-ranging scope of 
aminocycles. 
 
sp3–sp3 C–C bond formation 
For many years, the synthesis of preclinical drug candidates was biased towards achiral, aromatic 
molecules. High-throughput drug discovery practices tended towards compounds with higher 
synthetic tractability, or those for which analogues are more easily constructed, which often led to 
high-aromatic ring count. However, these practices have been demonstrated to have a detrimental 
effect on clinical success rate.[39] 
 
There is a demonstrated correlation between an increase in Fsp3 (defined as number of sp3-hybrised 
carbon atoms/total number of carbon atoms) and higher clinical trial success rate, suggesting that 
compounds with greater levels of saturation are more likely to succeed in clinical testing. (Figure 
1.3).[40] There is also a similar trend when comparing the number of drug-candidates with at least one 
stereocentre at each stage of development. 
 
 
Figure 1.3: Mean Fsp3 change as development proceeds 
 
At the start of this work, there was no report in the literature of a palladium-catalysed carboamination 
reaction of alkenes directly resulting in a new sp3–sp3 carbon–carbon bond. The one-pot 
aminoalkynylation-hydrogenation procedure described by Waser et al. (Eq. 1.11) demonstrates an 
indirect formation of a new sp3–sp3 bond,[36] but suffers from low functional group tolerance due to 
the hydrogenation protocol.  
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An early example of palladium-catalysed sp3–sp3 carbon–carbon bond formation was demonstrated 
in 1986 by Canty and co-workers (Scheme 1.27).[41] Treatment of dimethylpalladium(II)-bipy 
complex 1.92 with methyl iodide was found to produce ethane. It was proposed that the reaction 
proceeded via oxidative addition of methyl iodide into Pd(II) complex 1.92 yielding palladium(IV) 
intermediate 1.93. Subsequent reductive elimination resulting in palladium(II) iodide complex 1.94 
and released ethane. Importantly, this represented the first example of an sp3–sp3 carbon–carbon bond 
forming reductive elimination from a palladium(IV) intermediate. 
 
 
Scheme 1.27: Oxidative addition of Pd(II) to Pd(IV) 
 
This proposal was confirmed by concentration of the reaction mixture which yielded x-ray quality 
crystals. 1H NMR spectroscopic and crystallographic analysis of the crystals allowed the full 
characterisation of complex 1.93. The crystal structure is shown below (Figure 1.4). While 
mechanisms proceeding via organopalladium(IV) intermediates had been proposed 
previously,[42,43,44] the isolation of this palladium(IV) complex represented the first fully characterised 
example. 
 
 
Figure 1.4: X-ray crystal structure of Pd(IV) complex 1.93 
 
Previous work within the France group has developed conditions for the difunctionalisation of 
unactivated alkenes with tethered nucleophiles and external electrophiles. The reaction facilitates the 
formation of a new oxygen-containing heterocycle and a new sp3–sp3 C–C bond (Eq. 1.13).[45]  
 
31 
 
 
The reaction demonstrated a significant advance because, typically, the new C–C bond is to a sp- or 
sp2-hydrised carbon. As discussed above, the synthesis of a new sp3–sp3 C–C bond was also of 
particular importance because increasing sp3-C content has been identified as a major goal of the 
pharmaceutical industry.  
  
The optimised methodology allowed the construction of 21 oxycyclic products, with a number of 
different oxygen-containing heterocycles. The reaction also exhibits high functional group tolerance. 
A representative range of the synthesised oxycycles is displayed below (Figure 1.5). Benzofurans 
(1.94 and 1.95), isobenzofurans (1.96 and 1.97) and benzopyrans (1.98) have been efficiently 
constructed, as well as aliphatic furans 1.99 and 1.100. Bulky alkenes are tolerated by the reaction 
conditions, as demonstrated by the synthesis of tert-butyl furan 1.97. The synthesis of 
bromobenzofuran 1.95 exhibits tolerance of aryl bromides, which is an important handle for further 
transformations. Spirocyclic piperidine 1.100 demonstrates the applicability of the reaction to a 
protected-nitrogen species. That the reaction proceeds in high yield was particularly gratifying 
because nitrogen-ligands have been demonstrated to significantly retard reaction rate. Finally, the 
construction of a range of lactones (e.g. 1.101) demonstrated the applicability of carboxylic acid 
nucleophiles. 
 
 
Figure 1.5: Range of oxyallylation products 
 
Furthermore, the applicability of the methodology was demonstrated by the synthesis of citalopram, 
a widely prescribed selective serotonin reuptake inhibitor (SSRI) for the treatment of depression 
(Scheme 1.28). Oxyallylation precursor 1.103 was synthesised in two steps from commercially 
available cyanophthalide 1.102. Oxyallylation of 1.103 proceeding in good yield to afford 
isobenzofuran 1.104. A dihydroxylation/oxidative cleavage protocol, followed by reductive 
amination yielded citalopram in 5 steps.  
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Scheme 1.28: Synthesis of Citalopram 
1.1.4: C–X bond formation 
Aminocycle-forming alkene difunctionalisation reactions are not limited to the formation of a new 
carbon–carbon bond, and there are a number of established protocols for the introduction of new 
carbon–halogen, carbon–oxygen or a second carbon–nitrogen bond.  
 
Haloamination 
Palladium-catalysed haloamination reactions are an efficient method for introducing a new carbon-
halogen bonds, a moiety with large range of potential functional transformations. Vicinally 
halogenated nitrogen-containing heterocycles can represent important synthetic intermediates, and 
in some cases are included in medicinal agents.[46] 
 
In the first instance, products of a palladium-catalysed haloamination process were observed as 
undesired side-products when utilising copper halide salts as reoxidants.[27,28]  The first protocol 
optimised towards palladium-catalysed intramolecular aminobromination and aminochlorination, 
utilising copper halide salts, was described in 2004 by Chemler and co-workers (Eq. 1.14).[47] The 
reaction allowed the transformation of tosyl-protected amines 1.105 into aminohalogenation 
products in high yields. A major concern, however, was the poor regioselectivity between endo-
aminopalladation and exo-aminopalladation, in this case giving a mixture of pyrrolidine 1.106 and 
piperidine 1.107 respectively.  
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In the same year, Lu and co-workers reported their own haloamination protocol (Scheme 1.29).[48] 
The transformation of allylic alcohol with tosyl isocyanate yields carbamate intermediate 1.108. 
Subsequent treatment with a palladium(II) catalyst, a copper(II) halide and lithium halide allowed 
efficient synthesis of chlorinated/brominated oxazolidones 1.109/1.110. The methodology also 
allows the synthesis of halogenated-piperidones through the utilisation of homo-allylic alcohols. In 
contrast to the previous haloamination protocol by Chemler and co-workers, this reaction does not 
suffer from poor endo- vs exo regioselectivity. 
 
 
Scheme 1.29: One pot synthesis of halo-pyrrolidones 1.109 and 1.110 
 
The proposed mechanism is shown below (Scheme 1.30). Alkene coordination and subsequent trans-
aminopalladation gave rise to alkylpalladium(II) intermediate 1.112. Oxidative cleavage of the 
carbon–palladium bond with copper(II) bromide yields brominated pyrrolidone 1.110. An important 
factor in this mechanism was the relative rate of oxidative cleavage compared to that of β-hydride 
elimination. Alkene 1.13 was not observed, and the reaction was highly chemoselective for the 
halogenation process. It has been previously demonstrated that excess halide ions in solution can 
inhibit the β-hydride elimination process.[49] 
 
 
Scheme 1.30: Lu haloamination mechanism 
 
Vicinal aminofluorine functionality is an extensively utilised building block in biologically active 
molecules.[50] Several groups have reported selective fluorination of aromatic C–H bonds.[51,52] In 
2009, Liu and co-workers applied the concepts to aminocyclisation (Eq. 1.15).[53] The 
aminofluorination of sulfonamide 1.114 allows the efficient construction of fluorine-bearing 
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piperidine 1.115. It is important to note that, unlike the majority of aminocyclisation reactions 
discussed in this document, this reaction proceeds via a 6-endo-trig aminopalladation. 
 
 
 
Aminoacetoxylation 
Palladium-catalysed aminoacetoxylation, the introduction of a new carbon–nitrogen and a new 
carbon–oxygen bond across an olefin, allows for the synthesis of protected vicinal aminoalcohols. 
1,2-Aminoalcohols represent an important functionality in biologically active and pharmaceutical 
molecules, for example, sphingoid bases.[54,55]  
 
The seminal acyclic example of aminoacetoxylation was reported by Bäckvall and co-workers in 
1980 (Scheme 1.31).[56] Treatment of trans-butene 1.116 with a palladium(II) salt, dimethylamine 
and lead(IV) acetate yielded syn-vicinal acetoxyamine 1.117, which was subsequently reduced in 
situ to yield syn 1,2-aminoalcohol 1.118. It was also demonstrated that aminoacetoxylation of trans-
butene 1.119 allowed access to anti-1,2-aminoalcohol 1.121. 
 
 
Scheme 1.31: Bäckvall oxyamination 
 
In 2005, Sorenson et al. reported a palladium-catalysed aminoacetoxylation of tethered alkenes, 
giving access to nitrogen-containing heterocycles bearing vicinal-protected alcohol functionality 
(Eq. 1.16).[57] Treatment of carbamate 1.108 with a palladium(II) salt and bis-acetoxyiodobenzene 
(BAIB) allowed the construction of oxazolidone 1.122.  
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This aminoacetoxylation was demonstrated to be diastereoselective in a similar manner to the 
Bäckvall oxyamination described above (Scheme 1.31). Aminoacetoxylation of cis-alkene 1.23 
yielded syn-aminoacetoxy oxazolidone 1.24 and aminoacetoxylation of trans-alkene 1.25 yielded 
anti-aminoacetoxy oxazolidone 1.26 (Scheme 1.32). Both reactions are indicative of an anti-
aminopalladation process. 
 
 
Scheme 1.32: Mechanistic investigation into aminoacetoxylation reaction 
 
The full mechanism is shown below (Scheme 1.33). The reaction is initiated by trans-
aminopalladation of carbamate 1.25 to give anti-alkylpalladium(II) intermediate 1.27 in high 
diastereoselectivity. Oxidative addition with BAIB results in palladium(IV) intermediate 1.28.[58] 
Carbon–oxygen bond-forming reductive elimination yields desired oxazolidone 1.26 and recycles 
the palladium(II) catalyst.  
 
 
Scheme 1.33: Mechanism for Aminoacetoxylation 
 
Alkene Diamination 
The 1,2-diamino moiety is recognised as valuable functionality, and is exhibited in many natural and 
pharmaceutically active molecules and, as a consequence, the synthesis of 1,2-diamines has been 
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subject to significant research.[59] Early attempts towards palladium-catalysed diamination of alkenes 
were performed by Bäckvall and co-workers, in a similar manner to the oxidative-
aminoacetoxylation reactions discussed above (Scheme 1.31). Treatment of trans-butene with a 
palladium(II) salt, dimethylamine and mCPBA yielded syn-diamine 1.131 (Scheme 1.34).[60] The 
reaction proceeds via alkene-coordination of the palladium, followed by selective anti-
aminopalladation, yielding alkylpalladium(II) intermediate 1.129. Oxidation by mCPBA yields 
organopalladium(IV) intermediate 1.130. In contrast to the aminoacetoxylation examples described 
above, where the intramolecular delivery of the nucleophile results in retention of stereochemistry, 
SN2-type reductive cleavage of the Pd–C bond yields diamine 1.131 with an inversion of 
stereochemistry. 
 
 
Scheme 1.34: Bäckvall deamination reaction 
 
In 2005, Muñiz and co-workers demonstrated the applicability of tethered amine-nucleophiles to the 
diamination process (Eq. 1.17).[61] Alkenyl urea 1.132, when treated with palladium acetate and 
BAIB, undergoes a diamination process to yield imidazolidinone 1.133. The methodology efficiently 
allows for the construction of two new fused nitrogen-containing heterocycles in a single step.  
 
 
 
The full reaction mechanism is displayed below (Scheme 1.35).[62] Coordination of the palladium(II) 
salt to alkene 1.132 and subsequent selective anti-aminopalladation yields alkylpalladium(II) 
pyrrolidine intermediate 1.134. Oxidation to organopalladium(IV) intermediate 1.135 was achieved 
using BAIB. Palladium(IV) subsequently underwent nucleophilic displacement with the second ureic 
nucleophile to yield imidazolidinone 1.133 and regenerate the palladium(II) salt. Pyrrole 1.136, the 
product of β-hydride elimination from either alkylpalladium(II) intermediate 1.134 or 
alkylpalladium(IV) intermediate 1.135, was not observed, demonstrating that the relative rate of 
oxidation was faster than that of β-hydride elimination. 
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Scheme 1.35: Muñiz diamination mechanism 
 
A similar, but mechanistically distinct approach was published by Lloyd-Jones and co-workers in 
2005 (Eq. 1.18).[63] Treatment of dienes 1.137 with N,N’-diethylurea and a palladium(II) salt allowed 
the synthesis of a range of alkenyl-imidazolidinones 1.138. The reaction creates two new C–N bonds 
in a single step. 
 
 
 
The full reaction mechanism is discussed below (Scheme 1.36). Intermolecular aminopalladation of 
N,N’-diethylurea onto diene 1.139, catalysed by a palladium(II) salt, yields alkylpalladium(II) 
intermediate 1.140, which will rapidly isomerise into π-allyl palladium(II) intermediate 1.141. 
Formation of the π-allyl palladium(II) intermediate 1.141 inhibits β-hydride elimination and 
increases electrophilicity, activating the intermediate towards nucleophilic displacement, affording 
imidazolidinone 1.142. Reoxidation of the resultant Pd(0) species completes the catalytic cycle. 
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Scheme 1.36: Diene-diamination mechanism 
1.1.5 Summary 
Palladium-catalysed alkene difunctionalisation-aminocyclisation is a rich area of chemistry, allowing 
the formation of new nitrogen-containing heterocycles and the formation of a second new bond in a 
single step. This second bond formation has been demonstrated to include carbon–carbon (sp3–sp2 
and sp3–sp), carbon–heteroatom and carbon–halogen bond formation. The remaining challenge is the 
design of methodology to allow the formation of a nitrogen-containing heterocycle and a sp3–sp3 
carbon–carbon bond in a single step. 
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1.2: Insights into oxyallylation reaction mechanism 
1.2.1: Introduction and Aims 
Investigations into alkene-difunctionalisation reactions were undertaken within the France group, 
leading to the discovery of a palladium-catalysed oxyallylation of unactivated alkenes (Eq. 1.19).[45] 
The methodology constructs an oxygen-containing heterocycle via C–O bond formation and a new 
sp3–sp3 carbon–carbon bond in a single step. 
 
 
 
The reaction can be considered to proceed in two distinct processes: a) oxypalladation of an 
unactivated alkene 1.143 to yield oxacyclic alkylpalladium(II) intermediate 1.145 and b) subsequent 
trapping of alkylpalladium(II) intermediate 1.145 to yield allylated product 1.144 (Scheme 1.37). 
The first process is well established methodology for carbo- or heterocycle synthesis, and will not be 
discussed here (for a detailed discussion on this process in relation to aminocycle synthesis, see 
section 1.1).  
 
 
Scheme 1.37: Oxyallylation process 
 
While the mechanism by which alkylpalladium intermediate 1.145 is trapped by an allylic 
electrophile (process b) is not fully elucidated, the importance of the allylic halide has been 
demonstrated. A study into the scope of allyl-X was undertaken by a previous group member (Table 
1.1).[64] Utilisation of either allyl chloride or bromide (entries 1, 2) furnished desired benzofuran 
1.147 with complete consumption of phenol 1.146. The use of allyl iodide (entry 3), however, 
resulted in substantially lower conversion of phenol 1.146. Using either allyl acetate or benzoate 
(entries 4, 5) completely shut down the oxyallylation reactivity. Furthermore, no desired 
oxycyclisation product was observed when alkyl halides were utilised (not shown).[64] 
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Table 1.1: Scope of allyl electrophile 
 
Entry X Time 1.146 : 1.147 
1 Cl 6 h 0 : 1 
2 Br 16 h 0 : 1 
3 I 18 h 1 : 0.2 
4 OAc 18 h 1 : 0 
5 OBz 18 h 1 : 0 
 
The primary goal of the investigation was to elucidate a mechanism for the trapping of 
alkylpalladium(II) intermediate 1.145 by allylic halides, and, in particular, one which would provide 
an explanation for the limitation to allylic halides. It is proposed that comprehension of the operative 
reaction mechanism will allow for the extension of substrate scope and the suppression of undesired 
side-products. 
1.2.2: Mechanistic Proposals 
 
It is possible to propose several different mechanisms for the oxyallylation transformation. One 
possible mechanism is proposed to proceed via an allylpalladium(IV) intermediate (Scheme 1.38). 
The allylpalladium(IV) intermediate has potential to exist as either an η-1 intermediate,[41] or as a π-
allylpalladium(IV) intermediate.[65,66] Initial oxypalladation of hydroxyalkene 1.148 would yield 
alkylpalladium(II) intermediate 1.149. This alkylpalladium(II) intermediate would undergo oxidative 
addition with the allyl electrophile to afford η-1 palladium(IV) intermediate 1.150 which may rapidly 
undergo isomerisation to π-allylpalladium(IV) intermediate 1.151. Reductive elimination from either 
η-1 palladium(IV) intermediate 1.150 (mechanism A) or from π-allylpalladium(IV) intermediate 
1.151 (mechanism B) will yield the desired isobenzofuran 1.152 and regenerate the Pd(II) salt. 
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Scheme 1.38: Proposed mechanisms A and B 
 
The mechanistic proposals can be justified by previous organopalladium(IV) chemistry. A report by 
Waser et al. on the oxyalkynylation of hydroxyalkenes utilises a similar substrate scope to this 
oxyallylation reaction (Eq. 1.20).[33] The oxyalkynylation reaction utilises hypervalent iodide reagent 
TIPS-EBX to facilitate oxidation to Pd(IV) and, consequently, furnish a new sp3–sp C–C bond (for 
further information, see section 1.1.3). 
 
 
 
The formation of organopalladium(IV) intermediates via the oxidative addition of alkyl halides into 
alkylpalladium(II) intermediates was demonstrated by Canty and co-workers and is discussed in 
detail in Section 1.1.3. 
 
A second mechanistic proposal accounts for the similarities which have been recognised between the 
oxyallylation work undertaken within the France group and the extensive studies into palladium-
catalysed carboetherification undertaken by Wolfe and co-workers (Scheme 1.40).[31,67,68] In both 
cases, treatment of hydroxyalkenes with a palladium catalyst and an aryl/allyl halide allows the 
construction of 2-substituted tetrahydrofurans bearing a new aryl/allyl-methyl group. 
 
 
Scheme 1.40: Similarities between Wolfe Carboetherification and France Oxyallylation 
 
To this end, Pd(0) catalysed mechanism C was proposed (Scheme 1.41). The mechanism bears 
significant similarities to the previously discussed heterocyclisation-arylation research by Wolfe and 
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co-workers (Section 1.1.3). Oxidative addition of a Pd(0) catalyst to an allylic halide is proposed to 
form allylpalladium(II)-halide dimer 1.154. Complexation and oxypalladation of benzylic alcohol 
1.148 will give alkylpalladium(II) intermediate 1.155. Subsequent reductive elimination will form 
desired isobenzofuran 1.152 and Pd(0) to complete the catalytic cycle.  
 
 
Scheme 1.41: Proposed Pd(0)-catalysed mechanism 
 
Evidence against this mechanism has previously been gathered within the group.[64] In order to probe 
the proposed palladium(0)-catalysed mechanism, a palladium(0) catalyst was utilised under the 
optimised conditions (Eq. 1.21). The reaction did not proceed to the desired benzofuran 1.147, giving 
indication that the reaction is unlikely to proceed via a palladium(0) catalysed mechanism. However, 
without an exhaustive ligand screen, the mechanism cannot be ruled out based on this experiment 
alone, due to the importance of ligand environment in the optimised reaction.[64] 
 
 
 
During the extension of substrate scope for the oxyallylation reaction, aryl bromide-containing 
phenol 1.156 successfully underwent oxyallylation to yield bromobenzofuran 1.157 (Eq. 1.22). In 
the presence of palladium(0), there is a plausible side-reaction proceeding via oxidative addition into 
the aryl bromide moiety, potentially leading to allylation/proto-dehalogenation of starting 
material/product (products 1.158 and 1.159). None of these potential products were observed, thus 
giving further credence to the proposal that the reaction does not proceed via a palladium(0) 
intermediate. 
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Another possible mechanism is one in which the alkene reactivity is essential, potentially accounting 
for the lack of reactivity of non-alkenyl halides (Scheme 1.42).  Initial oxypalladation of benzylic 
alcohol 1.148 yields alkylpalladium(II) intermediate 1.149. This intermediate will undergo 
carbopalladation with the allyl halide to give a second alkylpalladium(II) intermediate 1.160. The 
reaction is terminated by β-halide elimination, affording isobenzofuran 1.152. The mechanism is 
devoid of change in palladium oxidation state change, a process known as “isohypsic”.[69] 
 
 
Scheme 1.42: Proposed isohypsic oxypalladation-carbopalladation mechanism 
 
Although there are far fewer examples of β-halide elimination in the chemical literature compared to 
β-hydride elimination, it is a phenomenon which was first observed by Heck in 1968,[70] and has 
since been proposed in numerous systems.[71] The allylation protocol described by Heck 
demonstrated selectivity for β-halide elimination over four potential β-hydride eliminations (Scheme 
1.43). 
 
 
 
Scheme 1.43: Palladium-catalysed allylation 
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It should also be recognised that the proposed β-halide elimination from alkylpalladium(II) 
intermediate 1.160 is in competition with four potential β-hydride eliminations. Alkylpalladium(II) 
intermediate 1.163, which bears significant similarity to alkylpalladium(II) intermediate 1.160, 
selectively undergoes β-halide elimination to yield allylbenzene 1.164. Furthermore, Lu and co-
workers undertook an investigation into the relative rate of β-eliminations, demonstrating that, in 
their system, β-halide elimination was significantly quicker than β-hydride elimination.[72] 
1.2.3: Elucidating the mechanism 
In order to decipher between the different mechanistic proposals, a mechanistic experiment was 
proposed. Treatment of benzylic alcohol 1.148 with Pd(II) and selectively deuterated allyl bromide 
1.165 was proposed to form either isobenzofuran 1.166 or 1.167 (or a mixture of both). The 
experiment was designed so that the observed ratio of deuterated isomers 1.166 and 1.167 will be 
different depending on the operative mechanism (Table 1.2). If there reaction is proceeding via 
mechanism A, isobenzofuran 1.166 will be observed as a single product. Conversely, if process D is 
the operative oxyallylation mechanism isobenzofuran 1.167 will be observed as a single product. In 
the case of mechanisms B or C, both of which are proposed to proceed via a π-allyl palladium 
intermediate, it is immediately clear that the position of deuteration will be scrambled upon reductive 
elimination, resulting in an equal ratio of deuterated isomers 1.166 and 1.167.  
 
Table 1.2: Predicted outcomes from deuteration study 
 
Mechanism 1.166 : 1.167 ratio 
A (η-1 allylpalladium(IV) intermediate) 1:0 
B (π-allylpalladium(IV) intermediate) 1:1 
C (π-allylpalladium(II) intermediate) 1:1 
D (Alkylpalladium(II) intermediate) 0:1 
 
A more detailed explanation of the selectivity in mechanisms A and D is shown below (Scheme 
1.44). In mechanism A, oxidative addition of alkylpalladium(II) intermediate 1.149 into the carbon–
bromine bond of allyl bromide 1.165 results in the deuterated methylene carbon directly bonded to 
the palladium in allylpalladium(IV) intermediate 1.168. Reductive elimination from this intermediate 
results in isobenzofuran 1.166, which is deuterated in the allylic position. Contrasted to this, 
mechanism D demonstrates how carbopalladation of allyl bromide 1.165 results in alkylpalladium(II) 
intermediate 1.169, which is deuterated in the palladium β-position. β-Halide elimination from 
alkylpalladium(II) intermediate 1.169 will yield dideuteroalkene 1.167. 
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Scheme 1.44: Difference in deuteration selectivity in mechanisms A and C 
 
In order to run the experiment, the substrates were synthesised. 3,3-d2-Allyl bromide was synthesised 
in two steps from acryloyl chloride by a previously reported procedure (Scheme 1.45).[73] Acryloyl 
chloride was reduced to allyl alcohol 1.170 using lithium aluminium deuteride. Subsequent SN2 
bromination yielded dideutero-allyl bromide 1.165. Importantly, isomeric dideutero-allyl bromide 
1.171, the product of SN2’ bromination, was not observed.  
 
 
Scheme 1.45: Synthesis of labelled allyl bromide 
 
Benzylic alcohol 1.148 was synthesised in three steps, following the protocol previously utilised 
within the France group (Scheme 1.46).[45] Wittig methylenation of benzaldehyde 1.172 and 
subsequent carboxylation of the resultant aryl bromide 1.173 generated benzoic acid 1.174. 
Reduction of acid 1.174 completed the synthesis of benzylic alcohol 1.148. 
 
 
 
Scheme 1.46: Synthesis of benzylic alcohol 1.148 
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With the required materials in hand, the mechanistic experiment was performed (Eq. 1.23). 
Treatment of benzylic alcohol 1.148 with Pd(II) and dideutero-allyl bromide 1.165 resulted in the 
chemoselective transformation to isobenzofuran 1.167, providing evidence that mechanism D is the 
operative oxyallylation reaction mechanism. This proposal was particularly gratifying as it explains 
the lack of reactivity of non-alkenyl halides. That isomeric dideutero-isobenzofuran 1.166 was not 
observed is strong evidence against the formation of a π-allylpalladium intermediate at any stage of 
the transformation.  
 
 
 
Further experiments were undertaken utilising methyl-allyl halides to expand the scope of the 
reaction and provide supporting mechanistic evidence. While methyl-labelling studies are non-ideal 
because the increased electron-richness and sterics can have a significant effect on reactivity, they 
are useful to back-up previous work. Treatment of benzylic alcohol 1.148 with Pd(II) and 3-chloro-
butene 1.175 resulted in the transformation to isobenzofuran 1.176 (Eq. 1.24). The new sp3–sp3 C–C 
bond of isobenzofuran 1.176 was formed to C-1, the terminal methylene carbon of the allylic 
chloride. This result was in agreement with the previous mechanistic experiments. 
 
 
 
The experiment was repeated with phenol 1.146 (Eq. 1.25). In accordance with the results obtained 
from oxyallylation of benzyl alcohol 1.148, the reaction of phenol 1.146 yielded benzofuran 1.178, 
the product with a new sp3–sp3 C–C bond to the terminal methylene carbon of the allylic chloride. 
This was in agreement with a carbopalladation–β-halide elimination mechanism.  
 
 
 
Further investigations were undertaken with disubstituted alkenes (Scheme 1.47). Treatment of 
benzylic alcohol 1.148 with 1,2-disubstituted allyl chloride 1.180 under the oxyallylation conditions 
yielded isobenzofuran 1.176 as the major product. Isobenzofuran 1.177, the predicted product based 
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on previous mechanistic evidence was observed as a minor component of the crude reaction mixture. 
It is probable that, rather than proceeding via a different mechanism, 1,2-disubstituted alkene 1.180 
was undergoing a palladium-catalysed isomerisation to mono-substituted alkene 1.175, via π-
allylpalladium(II) intermediate 1.181.[74] Monosubstituted alkene 1.175 will subsequently undergo 
carbopalladation, reflecting the reactivity shown above (Eq. 1.24). That the reaction is highly 
chemoselective for isobenzofuran 1.176 suggests that carbopalladation with 1,2-disubstituted alkene 
1.180 is a significantly slower process than isomerisation to, and carbopalladation of mono-
substituted alkene 1.175. That the substitution of the alkene has such a large effect on the reaction 
rate was indicative of a carbopalladation process, providing further evidence for mechanism D. 
 
 
Scheme 1.47: Oxyallylation utilising 1,2-disubstituted allylic halide 
 
Comprehension of the operative oxyallylation reaction mechanism allowed for the expansion of 
scope with respect to the allyl electrophile. It was proposed, for example, that utilisation of 
dibromopropene 1.182 would allow selective construction of vinyl bromide 1.183 (Eq. 1.26). Vinyl 
bromides are a useful functionality which can be utilised in further transformations, especially 
palladium-catalysed cross-coupling reactions. Treatment of benzylic alcohol 1.148 with 
dibromopropene 1.182 under oxyallylation conditions afforded vinyl bromide-isobenzofuran 1.183 
in high yield.  
 
 
 
The mechanism for the 1,2-disubstituted vinyl bromide is discussed below (Scheme 1.48). The 
reaction is proposed to proceed via oxypalladation and carbopalladation as discussed previously to 
yield dibromo-alkylpalladium(II) intermediate 1.184. The palladium can only undergo β-elimination 
with the terminal bromide, thus the secondary bromine atom remains intact.  
 
48 
 
 
Scheme 1.48: Mechanism of vinyl-bromide formation 
 
1.2.4: Conclusions 
These investigations have given evidence for the operative mechanism proceeding via 
carbopalladation followed by β-halide elimination (Scheme 1.49). The mechanism is consistent  with 
the results obtained within the scope of this project and previously published work.[64] 
 
 
Scheme 1.49: Oxyallylation reaction mechanism 
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1.3: Expansion of heteroallylation scope – synthesis of 
aminocycles 
1.3.1: Introduction and aims 
As discussed previously (section 1.1.1), nitrogen-containing heterocycles are crucial intermediates 
in organic synthesis and are a common structural motif in natural products and pharmaceutically 
active compounds (See Figures 1.1 & 1.2). As a consequence, new methodologies for 
aminocyclisation are constantly being sought after. 
 
The aim of this project was to extend the scope of the previously optimised oxyallylation 
methodology to include the construction of aminocycles (Scheme 1.50). The reaction utilises 
palladium-catalysed heterocyclisation of tethered amines onto unactivated alkenes, followed by 
allylation using an allylic halide. 
 
 
Scheme 1.50: Proposed extension of heteroallylation scope 
 
The proposed reaction would construct a new nitrogen-containing heterocycle and furnish a new sp3–
sp3 C–C bond in a single step. This would represent a significant advance as it would demonstrate 
the first example of an sp3–sp3 C–C bond forming palladium-catalysed carboamination reaction. All 
previous palladium-catalysed carboamination strategies, discussed in detail in chapter 1.1, yield 
products with a new sp3–sp2 or sp3–sp bond, most commonly via aminoarylation[29] and 
aminocarbonylation[27]. Increased Fsp3 content in drug candidates has been directly correlated to the 
chance of the candidate’s success and is, consequently, a major goal of the pharmaceutical industry 
(Figure 1.3, Section 1.1.3). 
 
The reaction mechanism for the oxyallylation process was investigated in section 1.2, and it was 
postulated that the desired aminoallylation methodology would proceed via a similar reaction 
mechanism (Scheme 1.51). Palladium(II)-catalysed aminopalladation of alkenylamine 1.185 will 
lead to alkylpalladium(II) intermediate 1.186. Carbopalladation of intermediate 1.186 with an allylic 
halide will afford alkylpalladium(II) intermediate 1.187. β-Halide elimination will yield desired 
aminocyclic product 1.188 and recycle the palladium(II) catalyst. 
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Scheme 1.51: Proposed catalytic cycle 
1.3.2: Aminoallylation reaction development 
The utilisation of sulfonyl-protected nitrogen species towards aminopalladative processes are well 
precedented and, in the first instance, was utilised to attenuate amine complexation to palladium.[75] 
Above all, N-tosyl protected amines/amides have gained significant popularity, and have been 
utilised in a wide-range of reactions.[61,76,77]  
 
In particular, the aminoalkynylation protocol reported by Waser and co-workers in 2011 
demonstrated efficacious reactivity when utilising tosylamides, and bears similarity to the desired 
aminoallylation methodology (Scheme 1.52). Alkylpalladium(II) intermediate 1.190 is a common 
intermediate in each process. Waser and co-workers demonstrated the trapping of alkylpalladium(II) 
intermediate 1.190 with hypervalent alkynyl reagent TIPS-EBX to yield alkynylpiperidone 1.191, 
but this work will attempt to trap the alkylpalladium(II) intermediate with an allyl halide, in the 
manner of the previously discussed oxyallylation methodology, to yield piperidone 1.192. 
Importantly, pyridone 1.193, the product of β-hydride elimination from alkylpalladium(II) 
intermediate 1.190, was not observed. A mechanistic study undertaken by Poli and co-workers 
demonstrated that β-hydride elimination from alkylpalladium(II) intermediates arising from 
reversible aminopalladation of tosylamides (e.g. 1.190) is impeded by palladium-sulfonyl 
coordination and, as a consequence, intermediates 1.190 either collapse to alkenyl-tosylamide or 
must undergo an alternative reaction.[78] 
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Scheme 1.52: Common reactivity between this work and Waser alkynylation 
 
As a consequence, N-tosyl amides (1.189) were selected as ideal substrates for development of 
aminoallylation reaction conditions, and were proposed to allow construction of a range of 
pyrrolidones and piperidones. Tosylamides can be efficiently constructed from the corresponding 
carboxylic acid using the commercially available tosyl isocyanate (Eq. 1.27).[79] 
 
 
 
Tosylamide 1.189 was synthesised in three steps, following a protocol published by Waser and co-
workers (Scheme 1.53).[34] Allylation of commercially available iodide 1.194 yielded alkenyl ester 
1.195. Subsequent ester hydrolysis and isocyanate mediated tosylamide synthesis yielded desired 
substrate tosylamide 1.189 in a 79% yield over three steps. 
 
 
Scheme 1.53: Synthesis of tosylamide 1.189 
 
Tosylamide 1.189 was subjected to the reaction conditions previously optimised for the oxyallylation 
methodology (Eq. 1.28). The reaction did not produce the desired isoquinolone product 1.192, 
instead yielding N-allyl tosylamide 1.196 as a single product. This was likely due to the increased 
acidity of the tosylamide proton (pKa ca. 3-5) compared to that of phenols (pKa ca. 10).[80] The 
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mechanism for the formation of N-allyl tosylamide 1.196 was postulated to proceed via formal 
deprotonation of the amide followed by substitution with allyl bromide (in absence of palladium, N-
allyl amide 1.196 was still produced). 
 
 
 
In order to prevent the formation of N-allyl amide 1.196, the reaction was attempted in the absence 
of base (Eq. 1.29). Base-free reaction conditions successfully prevented the formation of N-allyl 
amide 1.196 and the desired aminoallylation reaction proceeded, affording desired piperidone 1.192 
in high yield. The desired isoquinolone product, however, was contaminated with pyridone 1.193, a 
by-product which proved to be inseparable. At this stage, simultaneous investigations were 
undertaken to a) find a suitable base for the reaction and; b) investigate conditions which prevent β-
hydride elimination.  
 
 
 
The aminopalladation process produces a stoichiometric amount of HX. In order to allow the 
aminoallylation of acid-sensitive substrates a base must be introduced into the reaction mixture. A 
base screen was undertaken in an attempt to find an appropriate base (Table 1.3). As discussed 
previously, no base (entry 1) prevented formation of N-allyl tosylamide 1.196, and sodium 
bicarbonate (entry 2) results in complete conversion to N-allyl tosylamide 1.196. Sodium acetate 
(entry 3) also gave N-allyl tosylamide 1.196 as a single product. In an attempt to make the conditions 
homogeneous, two organic nitrogen bases were tested. Pyridine (entry 4) prevented any reactivity, 
most likely through ligation to palladium, but 2,6-di-tert-butylpyridine (entry 5), where bulky tert-
butyl substituents may prevent metal ligation, successfully formed desired isoquinolone 1.192 and 
pyridone side-product 1.193, but suffered from reduced reaction rate. Monobasic potassium 
phosphate (entry 6) resulted in complete conversion to lactams 1.192 and 1.193, and allowed the 
reaction to proceed at a good rate. Dibasic and tribasic potassium phosphate (entries 7 and 8) resulted 
in complete N-allylation of tosylamide 1.189, affording amide 1.196. Monobasic potassium 
phosphate was, consequently, selected as the optimal based for the aminoallyation process. 
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Table 1.3: Base Screen 
 
Entry Base 1.189 : 1.192 : 1.193 : 1.196 
1 - 0 : 10 : 1 : 0 
2 NaHCO3 0 : 0 : 0 : 1 
3 NaOAc 0 : 0 : 0 : 1 
4 pyridine 1 : 0 : 0 : 0 
5 2,6-(tBu)2C5H3N 1 : 9 : 1 : 0 
6 KH2PO4 0 : 9 : 1 : 0 
7 K2HPO4 0 : 0 : 0 : 1 
8 K3PO4 0 : 0 : 0 : 1 
 
In order to prevent formation of pyridone side-product 1.193, and consequently allow isolation of 
piperidone 1.192, it is important to understand how, mechanistically, pyridone 1.193 was formed 
(Scheme 1.54). Alkylpalladium(II) intermediate 1.190, the product of aminopalladation of amide 
1.189, can undergo two competing processes: carbopalladation, where subsequent β-halide 
elimination yields the desired piperidone 1.192 and; β-hydride elimination to exo-cyclic alkene 
1.197. Rapid isomerisation yields pyridone 1.193.  
 
Scheme 1.54: Postulated mechanism for pyridone 1.193 synthesis. 
 
A brief solvent screen was undertaken to test the effect of solvent polarity on the rate of β-hydride 
elimination (Table 1.4). Using dichloromethane as a solvent demonstrated slightly poorer yield and 
product ratio than that of toluene (entries 1 and 2). Ethanol, previously utilised by Waser and Co-
workers for aminoalkynylation,[34] completely shut down aminoallylation reactivity.  
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Table 1.4: Aminoallylation solvent screen 
 
Entry Solvent Yield (1.192 : 1.193) 
1 PhMe 84% (10 : 1) 
2 CH2Cl2 73% (8 : 1) 
3 EtOH -  
 
In order to prevent β-hydride elimination, attempts were made to increase the relative rate of the 
competing process: carbopalladation (Table 1.5). Results 1–3 show the effect of varying the 
concentration of allyl bromide. As expected, fewer equivalents of allyl bromide (entries 1 and 2) 
resulted in poorer chemoselectivity for piperidone 1.192. Aminoallylation reactions utilising 
dichloromethane as a solvent displayed a similar trend when varying allyl bromide equivalents 
(entries 4–6), albeit with lower selectivity for piperidone 1.192. It was expected that increasing the 
equivalents further would yield further improvements in the ratio, but in attempts to avoid waste it 
was decided that other solutions would be sought. Allyl chloride (entry 4) was utilised, and proved 
to have a pronounced effect on chemoselectivity, as undesired pyridone 1.193 was not observed 
under these conditions (see Table 1.10 for information). 
 
Table 1.5: allyl electrophile optimisation 
 
Entry Solvent Y (equiv.) X Yield (1.192 : 1.193) 
1 PhMe 2 Br 71% (5 : 1) 
2 PhMe 3 Br 68% (5 : 1) 
3 PhMe 5 Br 84% (10 : 1) 
4 CH2Cl2 2 Br 48% (3 : 1) 
5 CH2Cl2 3 Br 59% (5 : 1) 
6 CH2Cl2 5 Br 73% (8 : 1) 
7 PhMe 5 Cl 76% (>20 : 1) 
 
With optimisation conditions for base and allyl electrophile in hand, it was chosen to investigate the 
effect of palladium ligand. Initial investigations had utilised Pd(hfacac)2 because previous 
oxyallylation work has been optimised with this catalyst, but there are many cheaper commercially 
available palladium(II) salts (Table 1.6). Utilisation of either palladium trifluoroacetate or palladium 
chloride (entries 2 and 3) resulted in a retarded rate of aminoallylation. Palladium acetate allowed 
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complete conversion of tosylamide 1.189, but with a reduced yield of isolated piperidone 1.192. 
Bidentate phosphine ligand diphenylphosphinoferrocene (dppf) completely shut down 
aminoallylation reactivity. The previously optimal conditions, utilising a hexafluoroacetylacetanoate 
ligand (entry 1), proved to be ideal for the aminoallylation of amide 1.189. 
 
Table 1.6: Ligand screen 
   
Entry Ligand (X) Result 
1 hfacac 100% conversion of SM (76% yield) 
2 TFA 80% conversion of SM 
3 Cl Low conversion of SM 
4 OAc 100% conversion of SM (63% yield) 
5 dppf No reaction 
 
Lithium chloride has been previously demonstrated to increase the relative rate of β-halide 
elimination processes.[70] When utilised in the aminoallylation process (Table 1.7, entry 1) lithium 
chloride demonstrated precisely no effect, most likely due to low solubility in toluene. The reaction 
proceeded to complete conversion, and the isolated yield of 76% was identical to same conditions 
without lithium chloride (Table 1.5, entry 1). In an attempt to increase the solubility of lithium 
chloride, a 1:1 mixture of water and toluene was utilised (entry 2), but no effect was demonstrated. 
These results, however, did demonstrate the tolerance of water in the developed aminoallylation 
reaction conditions. Utilisation of lithium chloride in ethanol (entry 3), as per Waser’s 
aminoalkynylation protocol,[34] resulted in the inhibition of aminoallylation reactivity. 
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Table 1.7: Addition of lithium chloride 
 
Entry Solvent 1.189: 1.192 
 (isolated yield of 1.192) 
1 Toluene 0 : 1 (76%) 
2 Toluene/H2O (1:1) 0 : 1 (73%) 
3 EtOH 1 : 0 
 
In the course of optimisation, significant precipitation was observed on the sides of the reaction 
vessel. This precipitate was proposed to be an insoluble sodium salt of tosylamide 1.189. In 
comparison to the previously optimised conditions (Table 1.6, entry 1), an attempt under aqueous 
biphasic conditions allowed complete dissolution and, as a consequence, the isolated yield of 
isoquinolone 1.192 was further improved to 95% (Table 1.8, entry 2). In comparison to the previously 
attempted biphasic conditions with lithium chloride (Table 1.7, entry 3), this reaction was 
significantly higher yielding. Finally, it was found that the reaction conditions were still efficient and 
high-yielding when utilising a lower catalytic loading (entry 3). The optimal conditions are mild and 
high-yielding, and do not require an inert atmosphere. These conditions are similar to the 
oxyallylation reaction conditions previously discussed, with only the base (KH2PO4 rather than 
NaHCO3) and solvent (toluene/H2O rather than toluene) being altered.[45] 
 
Table 1.8: Final optimisation 
 
Entry Solvent X (mol. %) Yield 
1 Toluene 10 76% 
2 Toluene/H2O (1:1, v/v) 10 95% 
3 Toluene/H2O (1:1, v/v) 5 84% 
 
The aminocyclisation process creates a new stereocentre, adjacent to the nitrogen atom. Chiral 
amines are important synthetic intermediates and are common structural motifs in pharmaceutically 
active molecules.[10] As a consequence, the development of enantioselective reaction conditions was 
a key objective. Attempts towards the control of stereochemistry using chiral ligands are detailed 
below (Table 1.9). In 2012, Zhang and co-workers demonstrated an asymmetric aza-Wacker protocol 
utilising a pyrox (pyridyl-oxazoline) ligand.[81] Pyrox (entry 1) and iPr-Quinox (entry 2) resulted in 
57 
 
complete shutdown of aminoallylation reactivity. Bisoxazoline 1.198 (entry 3) demonstrated the 
same effect. Pyridine was previously demonstrated to have a negative effect on reactivity, so the 
results were expected. In 2010, Wolfe and co-workers demonstrated that a range of arylphosphines 
can control the stereochemistry in aminoarylation reactions.[32] T-Binap (entry 4) prevented the 
aminoallylation from proceeding. Furthermore, triphenylphosphine was discovered to have the same 
effect (entry 5). The results demonstrate that two major classes of asymmetric palladium ligands 
inhibit aminoallylation reactivity. As a consequence, no further chiral ligands were utilised. 
 
Table 1.9: Utilisation of chiral ligands 
 
Entry Ligand 1.189 : 1.192 
1 Pyrox 1 : 0 
2 iPr-Quinox 1 : 0 
3 Bisoxazaline 1.198 1 : 0 
4 (S)-T-Binap 1 : 0 
5 PPh3 1 : 0 
 
Mechanistic Considerations 
As discussed previously (Section 1.2.1), utilising different allylic halides can have a profound effect 
on the reactivity. One possible explanation is that this was due to the palladium halide species formed 
by β-halide elimination. In an attempt to further understand the effect, the aminoallylation reaction 
conversion was compared for a variety of halides (Table 1.10). In 1 h, aminoallylation with allyl 
chloride (entry 1) proceeded to 66% conversion of amide 1.189 to piperidone 1.192. Aminoallylation 
with allyl bromide (entry 2) proceeded to 25% conversion, but with allyl iodide (entry 3) formation 
of the desired piperidone was not observed. Addition of lithium chloride (entries 4 and 5) had no 
significant effect on reactivity, although this was proposed to be due to low solubility of lithium 
chloride in toluene. Addition of soluble chloride salt tetrabutylammonium chloride (entries 6 and 7) 
resulted in no conversion of tosylamide 1.189. The investigation demonstrated that the reaction rate 
when utilising allyl chloride is faster for tosylamide 1.192. Previous work has demonstrated that, in 
many cases, utilisation of allyl bromide results in more efficient heteroallylation. There is, as yet, no 
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demonstrable trend to which substrates react more efficiently with either allyl bromide or allyl 
chloride. 
 
Table 1.10: Halide investigation 
 
Entry Allyl-X Additive 1.189 : 1.192 
1 Chloride - 1 : 2 
2 Bromide - 3 : 1 
3 Iodide - 1 : 0 
4 Bromide Lithium Chloride (2 equiv.) 4 : 1 
5 Iodide Lithium Chloride (2 equiv.) 1 : 0 
6 Bromide TBACl (2 equiv.) 1 : 0 
7 Iodide TBACl (2 equiv.) 1 : 0 
 
As discussed in section 1.2.3, alkene substitution of the allylic halide will have a significant effect 
on the rate of carbopalladation, if the reaction is proceeding via the proposed aminopalladation–
carbopalladation mechanism. Gem-disubstituted allyl chloride was utilised in the aminoallylation of 
tosylamide 1.189 (Scheme 1.55). While desired isoquinolone 1.199 was observed, the reaction 
resulted in significant conversion to pyridone 1.193, the product of β-hydride elimination from 
alkylpalladium(II) intermediate 1.190. Pyridone 1.193 was not observed when utilising allyl chloride 
under the same reaction conditions (Table 1.4). 
 
 
Scheme 1.55: Utilisation of gem-disubstituted allyl halide 
 
That the alkene substitution has a major effect on the carbon–carbon bond forming event supports 
the proposal of carbopalladation–β-halide elimination. In order to increase the relative rate of the 
intermolecular carbopalladation process, the reaction concentration was increased (Eq. 1.30). When 
tosylamide 1.189 was treated with methylallyl chloride under aminoallylation reaction conditions at 
a concentration of 0.5 M (as opposed to 0.25 M in Scheme 1.55) pyridone by-product 1.193 was only 
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observed as 10% of the crude material. Desired isoquinolone product 1.199 was isolated in a 71% 
yield. 
 
 
 
1.3.3: Substrate scope – Tosyl-protected Amides 
With optimised conditions having been discovered for tosylamide 1.189, the next goal was increase 
the substrate scope, and to test the limitations of the methodology. It was proposed that pyrrole-
containing tosylamides (e.g. 1.202) would allow access to piperazine derivatives, a common motif 
in biologically active compounds.[82,83] Pyrrole 1.202 was synthesised in three steps from methyl 
pyrrole-2-carboxylate following a known protocol (Scheme 1.56).[34] Pyrrole 1.200 was subjected to 
base-promoted allylation conditions to yield N-allyl pyrrole 1.201. The substrate synthesis was 
completed by ester hydrolysis and formation of tosylamide 1.202 using tosyl isocyanate. 
 
 
Scheme 1.56: Synthesis of pyrrole 1.202 
 
N-Tosyl pyrrole 1.202 was subjected to the previously optimised conditions (Scheme 1.57). 
Although desired piperazine 1.204 was observed, the reaction rate was slow and the overall 
conversion of tosylamide 1.202 was less than 10%. Pyrazine 1.205, the product of β-hydride 
elimination from alkylpalladium(II) intermediate 1.203 followed by isomerisation, was not observed. 
Consequently, it was proposed that the slow reaction rate was due to a retarded rate of 
aminopalladation.  
 
 
Scheme 1.57: Synthesis of piperazine 1.204 
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In order to increase the conversion of tosylamide 1.202, increasing the rate of aminopalladation was 
targeted (Table 1.11). When subjected to the previously optimised conditions (entry 1), the reaction 
was slow and the conversion of tosylamide 1.202 low (<10%). Increased concentration (entry 2) led 
to an increase in the conversion of tosylamide 1.202 to 50%. It was found that there was no further 
catalyst turnover at 50% conversion, so an increase of catalyst loading (entry 3) demonstrated an 
expected improvement in conversion to 66%, although the isolated yield of piperazine 1.204 was low 
(30%). Increasing the reaction temperature to 80 °C (entry 4), further increase in the conversion of 
pyrrole 1.202 was demonstrated (90%), and allowed isolation of piperazine 1.204 in a 61% yield.  
 
Table 1.11: aminoallylation of pyrrole 1.202 
 
 
 
Indole tosyl amides (e.g. 1.208) were proposed to give access to indolo-piperazines, a motif which 
has been incorporated in pharmaceutically-active compounds.[84,85] Tosylamide 1.208 was 
synthesised via the same protocol as described for pyrrole 1.202 (Scheme 1.58). Allylation of indole 
1.206, followed by ester hydrolysis and tosyl-amide formation yielded desired indole 1.208 in 52% 
yield over three steps.  
 
 
Scheme 1.58: Synthesis of indole 1.208 
 
Indole 1.208 was subjected to the aminoallylation conditions found optimal for pyrrole 1.202 (table 
1.12, entry 1). Desired piperazine 1.209 was observed, but the conversation of the starting tosylamide 
was poorer than for pyrrole 1.202 (50% vs 90%). A significant volume of precipitate was observed, 
which was previously resolved through the use of aqueous reaction conditions. In this case, addition 
of water (entry 2) allowed an increase of conversion to 75%, although precipitation was still 
observed. Increasing solvent volume (entry 3) allowed complete dissolution and allowed 90% 
Entry Temperature 
(°C) 
Solvent Concentration 
(M) 
X  
(mol. %) 
1.202 : 1.204 
(isolated yield) 
1 50 PhMe 0.25 M 5 > 10 : 1 
2 50 PhMe 0.50 M 5 1 : 1 
3 50 PhMe/H2O 0.50 M 10 1 : 2 (30%) 
4 80 PhMe/H2O 0.50 M 10 1 : 9 (61%) 
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conversion of indole 1.209, with a 54% isolated yield of piperazine 1.209. Entry 4 demonstrates 
reproducibility and scalability of the reaction conditions. 
 
Table 1.12: Indole optimisation 
 
Entry Solvent Concentration (M) Scale (mmol) 1.208 : 1.209 (isolated yield) 
1 PhMe 0.50  0.16 1 : 1 
2 PhMe/H2O 0.50 0.16 1 : 3 
3 PhMe/H2O 0.25 0.06 1 : 9 (54%) 
4 PhMe/H2O 0.25 0.42 1 : 9 (60%) 
 
Having demonstrated the synthesis of piperidones and piperazines, subsequent efforts focussed on 
the synthesis of pyrrolidones. Tosylamide 1.212, a vinyl analogue of allyl tosylamide 1.189 used 
previously, was chosen for initial trials, and was synthesised in two steps (Scheme 1.59). Wittig 
methylenation of aldehyde 1.210 yielded 2-vinyl benzoic acid 1.211. Subsequent tosyl amide 
formation yielded amide 1.212. 
 
 
Scheme 1.59: Synthesis of vinyl-benzamide 1.212 
 
Tosylamide 1.212 was subjected to the aminoallylation conditions (Scheme 1.60). Rather than 
yielding desired aminoallylation product isoindolinone 1.214, which was not observed in the crude 
material, the attempted aminoallyation of tosylamide 1.212 instead produced a high yield of exo-
cyclic methylene pyrrolidone 1.215. Pyrrolidone 1.215 was formed as a result of β-hydride 
elimination from alkylpalladium(II) intermediate 1.213 (vide infra). It was also demonstrated that an 
increase in reaction concentration had no effect on reactivity. 
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Scheme 1.60: Aminoallylation of tosylamide 1.212 
 
The reaction demonstrates a catalytic aza-Wacker reaction without a traditional stoichiometric 
reoxidant (Scheme 1.61). β-Hydride elimination from alkylpalladium(II) intermediate 1.213 would 
result in pyrrolidone 1.215 and palladium(0), which would ordinarily be reoxidised by oxygen or a 
copper salt. The reaction was run in atmospheric conditions, so oxygen was a potential reoxidant, 
but it is also possible that the high concentration of allyl chloride was facilitating reoxidation via 
oxidative addition to an allylpalladium chloride species. 
 
 
Scheme 1.61: Proposed mechanism for catalytic aza-Wacker cyclisation of tosylamide 2.212 
 
In an attempt to suppress β-hydride elimination, diphenylphosphinoferrocene(dppf)-palladium 
chloride was utilised. It was demonstrated by Hartwig and co-workers that larger ligands on 
arylpalladium(II) intermediates accelerated the relative rate of reductive elimination over β-hydride 
elimination.[86] It was further demonstrated that dppf favoured reductive elimination over β-hydride 
elimination due to chelation and a large bite angle.[87] Upon utilisation of PdCl2(dppf) in the 
aminoallylation reaction (Eq. 1.31), there was no conversion of tosylamide 1.212 and no product of 
aminoallylation was observed. It has been previously demonstrated that phosphine ligands have a 
detrimental effect on aminoallylation reactivity (Table 1.9).  
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Previous reports have demonstrated that an increase in halide ion concentration, especially chloride 
ion concentration, can decrease the relative rate of β-hydride elimination.[88,89] The 
aminoalkynylation report by Waser and co-workers demonstrated the utilisation of lithium chloride 
to inhibit the formation of β-hydride elimination products.[34] In the case of the aminoallylation of 
tosylamide 1.212, addition of lithium chloride had no effect on reactivity and desired isoindolinone 
1.214 was not observed (Eq. 1.32). 
 
 
 
The addition of acetic acid has previously been demonstrated to attenuate β-hydride elimination from 
alkylpalladium(II) intermediates in certain systems.[78] This approach was not viable for the 
aminoallylation protocol, however, because treatment of tosylamide 1.212 with acetic acid under the 
aminoallylation reaction conditions proved to prevent conversion of tosylamide 1.212. Neither 
pyrrolidone 1.214 or 1.215 were observed (Eq. 1.33). 
 
 
 
Clearly, in the case of tosylamide 1.212, the aminoallylation reaction conditions are highly 
chemoselective for β-hydride elimination product 1.215 (Scheme 1.62). This was in contrast to the 
reactivity of tosylamide 1.189, which successfully underwent aminoallylation to yield isoquinolone 
1.192 with high chemoselectivity. Alkylpalladium(II) intermediates 1.213 and 1.190 are functionally 
similar, but undergo different termination processes. It is probable that the rate of carbopalladation 
with allyl chloride is not significantly different in either case. It was thus proposed that β-hydride 
elimination from alkylpalladium(II) intermediate 1.213 was significantly faster. Three possible 
explanations for this are: a) increased rate of β-hydride elimination of a benzylic hydrogen atom; b) 
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alignment of the palladium atom and the β-hydrogen are more closely coplanar in alkylpalladium 
intermediate 1.213; or c) the external C–C bond angle of isoindoline intermediate 1.213 destabilises 
palladium-sulfonyl coordination. To the author’s best knowledge this difference in reactivity has not 
been previously remarked upon. 
 
 
Scheme 1.62: Contrasting alkylpalladium(II) intermediates 1.213 and 1.190 
 
Having concluded that tosylamide 1.212 is highly chemoselective for the β-hydride elimination, it 
was decided to investigate whether the increased rate of β-hydride elimination was accelerated by 
the presence of a benzylic hydride. Towards this goal, tosylamide 1.218 was synthesised via a 2 step 
protocol (Scheme 1.63). Suzuki-coupling of arylbromide 1.216 with a vinylboronate proceeded in 
excellent yield. Subsequent tosylamide formation gave tosylamide 1.218 in a 54% yield.  
 
 
Scheme 1.63: Synthesis of tosylamide 1.218 
 
When treated with Pd(II) under aminoallylation conditions, tosylamide 1.218 was found to be 
completely unreactive. Neither desired piperidone 1.219 nor piperidone 1.220, the product of β-
hydride elimination, were observed. That the aminopalladation did not occur does not provide any 
conclusive results about the reactivity of conjugated alkenes to aminoallylation. Attempts to force 
conversion of tosylamide 1.218 through increased temperature, increased concentration and 
increased catalyst loading were all unsuccessful.  
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In an attempt to increase the substrate scope, it was decided to move away from aromatic-ring 
containing tosylamides, which is important from the perspective of increasing Fsp3. Tosylamide 1.68 
was synthesised in a single step from commercially available pentenoic acid 1.221 (Eq. 1.35). 
Tosylamide formation proceeded efficiently under the previously used isocyanate-mediated protocol. 
 
 
 
Treatment of tosylamide 1.68 with Pd(II) and allyl chloride under the aminoallylation protocol did 
not yield either desired pyrrolidone 1.222 or pyrrolidone 1.223 – the product of β-hydride elimination 
and isomerisation.  
 
 
 
Attempts to increase the rate of aminopalladation are summarised below (Table 1.13). The optimal 
aminoallylation conditions utilised above (Eq. 1.36) are shown in entry 1. Increasing the reaction 
temperature (entry 2), increasing the reaction concentration (entry 3) and use of allyl bromide (entry 
4) all had no effect on the reactivity. Pyrrolidones 1.222 and 1.223 were not observed under any 
conditions. 
 
Table 1.13: Aminoallylation attempts towards pyrrolidone 1.222 
 
Entry Temperature (°C) Concentration (M) Allyl-X 1.68 : 1.222 : 1.223 
1 50 0.25 Cl 1 : 0 : 0 
2 80 0.25 Cl 1 : 0 : 0 
3 50 0.50 Cl 1 : 0 : 0 
4 50 0.25 Br 1 : 0 : 0 
 
Concurrently, the analogous hexenamide substrate 1.225 was synthesised from commercially 
available hexenoic acid 1.224 in a single step using the previously discussed isocyanate-mediated 
protocol (Scheme 1.64). With the substrate in hand, it was subjected to the optimal aminoallylation 
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conditions. As with pentenamide 1.68 above, there was no conversion of tosylamide 1.225 and 
desired piperidone 1.226 was not observed. Piperidone 1.227, the product of β-hydride elimination, 
was also not observed. 
 
 
Scheme 1.64: Synthesis and attempted aminoallylation of tosylamide 1.225 
 
In the case of tosylamides 1.68 and 1.225, no product of an aminopalladative process was observed. 
The lack of products arising from β-hydride elimination, which has been demonstrated to be a rapid 
process, suggests that neither tosylamide is undergoing aminopalladation. This was in contradiction 
to Waser’s aminoalkynylation report however, which demonstrated that both tosylamides 1.68 and 
1.225 successfully undergo aminopalladation (Eq. 1.37).[34] As a consequence, the reason for a lack 
of aminoallylation of either 1.68 or 1.225 is currently unknown.   
 
 
 
It was proposed that taking advantage of the gem-disubstituent effect would allow the 
aminoallylation reaction to proceed, either by lowering the energy of the aminopalladation reactive-
rotamer or through stabilisation of the resultant alkylpalladium(II) intermediate.[90] By introducing 
gem-dimethyl functionality to the α-amide position, the rotamer population will be shifted in favour 
of the reactive rotamer, potentially increasing the rate of aminopalladation. Tosylamide 1.230 was 
proposed to test this theory (Scheme 1.65). Double deprotonation of isobutyric acid 1.228, followed 
by allylation of the resultant dianion yielded dimethylpentenoic acid 1.229. Tosylamide formation 
under the tosylisocyanate-mediated conditions yielded tosylamide 1.230. 
 
 
Scheme 1.65: Synthesis of tosylamide 1.230 
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With the tosylamide 1.230 in hand, the substrate was subjected to the aminoallylation reaction 
conditions (Scheme 1.66). The substrate successfully underwent aminopalladation, but desired 
pyrrolidone 1.232 was not observed. Pyrrolidone 1.233, a product of β-hydride elimination from 
alkylpalladium(II) intermediate 1.231, was observed as a single product. 
 
 
Scheme 1.66: Attempted cyclisation of gem-dimethyl tosylamide 1.230 
 
Attempts made towards increasing the rate of carbopalladation are summarised below (Table 1.14). 
The previously optimal conditions are detailed in entry 1. Change of palladium ligand to acetate, 
which previously allowed rapid aminoallylation (Table 1.6), did not result in the synthesis of 
pyrrolidone 1.232. Attempts to prevent β-hydride elimination by utilising the 
diphenylphosphinoferrocene ligand (entry 3) completely prevented aminopalladation, corroborating 
the previously demonstrated non-reactivity with phosphine ligands. Increase in concentration (entry 
4) did not increase the relative rate of carbopalladation enough to overcome β-hydride elimination. 
Utilisation of allyl bromide (entry 5) had a profoundly negative effect on aminopalladation, and the 
only observed reactivity was alkene isomerisation, yielding alkene 1.234. 
 
Table 1.14: Attempts towards the synthesis of pyrrolidone 1.232 
 
Entry Pd(X)2 Concentration (M) Allyl-Y 1.230 : 1.232 : 1.233 : 1.234 
1 Pd(hfacac)2 0.25 Cl 0 : 0 : 1 : 0 
2 Pd(OAc)2 0.25 Cl 0 : 0 : 1 : 0 
3 PdCl2(dppf) 0.25 Cl 1 : 0 : 0 : 0 
4 Pd(hfacac)2 0.50 Cl 0 : 0 : 1 : 0 
5 Pd(hfacac)2  0.25 Br 1 : 0 : 0 : 2 (E/Z = 5 : 1) 
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Concurrently, cyclohexyl-tosylamide 1.237 was proposed in an attempt to increase the population of 
the reactive rotamer, similarly to gem-dimethyl tosylamide 1.230. Tosylamide 1.237 was synthesised 
in 2 steps, starting from cyclohexylcarboxylic acid 1.235, via the same protocol as gem-dimethyl 
substrate 2.30 (Scheme 1.67).  
 
 
Scheme 1.67: Synthesis of cyclohexyl-tosylamide 1.237 
 
Cyclohexyl-tosylamide 1.237 was subjected to the optimal aminoallylation conditions (Scheme 
1.68). In a similar manner to tosylamide 1.230, desired pyrrolidone 1.239 was not observed. 
Pyrrolidone 1.240 was observed as a single product, which would indicate that cyclohexyl-
tosylamide 1.237 successfully undergoes aminopalladation to yield alkylpalladium(II) intermediate 
1.238, but subsequently undergoes β-hydride elimination and isomerisation. 
 
 
Scheme 1.68: Attempted aminoallylation of cyclohexyl-tosylamide 1.237 
 
Similar attempts towards the synthesis of cyclohexyl-pyrrolidone 1.237 were made to those shown 
for gem-dimethyl tosylamide 1.230 (Table 1.15). Changing the catalyst from Pd(hfacac)2 (entry 1) 
to palladium acetate (entry 2) or palladium acetylacetanoate (entry 3) demonstrated no change in 
reactivity. Addition of lithium chloride (entry 4) completely inhibited aminopalladation of 
tosylamide 1.237. 
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Table 1.15: Attempts towards aminoallylation of cyclohexylamide 1.237 
 
Entry Pd(X)2 Additive 1.237 : 1.239 : 1.240 
1 Pd(hfacac)2 - 0 : 0 : 1 
2 Pd(OAc)2 - 0 : 0 : 1 
3 Pd(acac)2 - 0 : 0 : 1 
4 Pd(hfacac)2 LiCl (3 equiv.) 1 : 0 : 0 
 
While attempts towards pyrrolidone synthesis have been, thus far, unsuccessful, previous attempts 
towards the synthesis of piperidones have shown chemoselectivity for allylation over β-hydride 
elimination (Scheme 1.60). Gem-dimethyl tosylamide 1.242 was designed to give access to saturated 
piperidones. The substrate was synthesised by a similar protocol to tosylamide 1.230 above (Scheme 
1.69). C-Alkylation of isobutyric acid with homoallylic bromide yielded dimethylhexenoic acid 
1.241, in a 58% yield. Formation of the tosylamide proceeded in good yield to garner tosylamide 
1.242.  
 
 
Scheme 1.69: Synthesis of tosylamide 1.242 
 
Tosylamide 1.242 was subjected to the optimal aminoallylation reaction conditions (Eq. 1.38). 
Piperidone 1.243 was not observed. Furthermore, no other product of an aminopalladative process 
was observed. Tosylamide 1.242 was recovered. 
 
 
 
In order to increase the rate of aminopalladation, the catalyst loading was increased. After 48 h, the 
only observed reaction of tosylamide 1.242 was N-allylation to N-allyl tosylamide 1.244 (Eq. 1.39). 
No further attempts were made towards the synthesis of piperidine 1.243. 
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Previous straight-chained tosylamides suffered either from β-hydride elimination or from a lack of 
aminopalladation. Malonamide 1.248 was prepared in an attempt to combat the latter by increasing 
the number of potential reactive rotamers (Scheme 1.70). It may also, if successful, assess whether 
the reaction can tolerate an amide which is not involved in the cyclisation. Dimethylmalonate 1.245 
was allylated under basic conditions to yield 2-allyl-dimethylmalonate 1.246. Subsequent ester 
hydrolysis furnished allyl malonic acid 1.247. Isocyanate mediated amide formation yielded the 
desired tosylmalonamide 1.248. 
 
 
Scheme 1.70: Synthesis of tosylmalonamide 1.248 
 
The substrate was subjected to the optimal aminoallylation reaction conditions (Eq. 1.40). Desired 
product 1.249 was not observed in the crude material and malonamide 1.248 was recovered. Despite 
having two possible reactive-rotamers, malonamide 1.248 did not undergo aminopalladation (neither 
desired pyrrolidone 1.249 nor pyrrolidone 1.250, the product of β-hydride elimination and 
isomerisation were observed), highlighting the slow rate of aminopalladation in aliphatic 
tosylamides. 
 
 
 
In their 2011 aminoalkynylation report, Waser and co-workers demonstrated the applicability of the 
aminoalkynylation reaction conditions to a range of carbamates and ureas.[34] Carbamate 1.253 was 
proposed to test the applicability of carbamates to the aminoallylation methodology (Scheme 1.71). 
Benzaldehyde underwent Grignard addition with allylmagnesium bromide to yield benzylic alcohol 
1.252. Subsequent carbamate formation yielded the desired tosylcarbamate 1.253. 
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Scheme 1.71: Synthesis of tosyl-carbamate 1.253 
 
Carbamate 1.253 was submitted to the optimal aminoallylation conditions, but there was no reactivity 
(Eq. 1.41). That oxazinone 1.254, nor any product of β-hydride elimination, was observed, suggests 
that tosylcarbamate 1.253 was not undergoing aminopalladation. 
 
 
 
Attempts to increase the rate of aminopalladation by increasing reaction temperature only resulted in 
N-allylation (Eq. 1.42). That the substrate preferentially yields N-allyl carbamate 1.255, rather than 
undergoing aminoallylation demonstrates that the current aminoallylation conditions are not suitable 
for the synthesis of aminocycle 1.254.  
 
 
1.3.4: Overcoming β-hydride elimination 
A significant number of the attempted aminoallylation reactions attempted thus far have suffered 
from β-hydride elimination, rather than undergoing allylation. As previously discussed in section 
1.1.3, many carboamination protocols relied on rapid trapping of the alkylpalladium(II) intermediate 
to prevent β-hydride elimination. In attempts towards aminoallylation, it has been demonstrated that, 
for many substrates, the rate of carbopalladation with allyl halides is slower than the rate of β-hydride 
elimination. Towards the goal of generalised aminoallylation conditions which would allow the 
synthesis of a range of nitrogen-containing heterocycles, a method to reliably prevent β-hydride 
elimination was sought. 
 
The oxyallylation methodology demonstrated that heteropalladation onto a disubstituted alkene was 
an efficient way to prevent β-hydride elimination (Scheme 1.72). Initial oxypalladation of alkene 
1.148 resulted in alkylpalladium(II) intermediate 1.149. β-Hydride elimination from this 
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intermediate is impossible, and thus must either collapse back to starting material 1.148, or undergo 
carbopalladation to the isobenzofuran 1.152. For the application to aminoallylation, disubstituted 
alkene 1.256 was proposed. 
 
 
Scheme 1.72: Oxyallylation intermediate 
 
The proposed contrast in reactivity between disubstituted alkene 1.256 and mono-substituted alkene 
1.212 is summarised in Scheme 1.73. Aminopalladation onto a mono-substituted alkene 1.212 results 
in alkylpalladium(II) intermediate 1.213. Rapid β-hydride elimination yields isoindolinone 1.215. 
Carbopalladation to isoindolinone 1.214 was not observed. Aminopalladation onto a gem-
disubstituted alkene 1.256 is proposed to yield alkylpalladium(II) intermediate 1.257. β-Hydride 
elimination is not possible from this intermediate. Alkylpalladium(II) intermediate must, therefore, 
either collapse back to the starting material 1.256, undergo carbopalladation to isoindolinone 1.258 
or undergo another, undesired, termination process. 
 
 
Scheme 1.73: Proposed aminoallylation reactivity of disubstituted alkenes 
 
Previous examples of aminopalladation by protected-amides onto gem-disubstituted alkenes are 
relatively uncommon. The previously discussed report on aminoalkynylation from Waser and co-
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workers reported a single example of a gem-disubstituted alkene (Eq. 1.43).[34] Aminoalkynylation 
of the disubstituted alkene proceeded in good yield when compared to the mono-substituted, albeit 
under slightly altered conditions and an extended reaction time. Further examples have been 
demonstrated by Zhang[81] and Yoshida.[27] 
 
 
 
Model disubstituted alkene substrate 1.256 was synthesised in a single step from previously utilised 
2-isopropenyl benzoic acid 1.174 using the isocyanate-mediated tosylamide formation protocol (Eq. 
1.44). 
 
 
 
Tosylamide 1.256 was subjected to the optimised aminoallylation conditions (Scheme 1.74). 
However, no conversion to pyrrolidone 1.257 was observed, and the starting material was recovered. 
At this stage, it was unknown whether the lack of reactivity was due to a slow rate of 
aminopalladation leading to alkylpalladium(II) intermediate 1.257, or a slow rate of carbopalladation 
of intermediate 1.257 with allyl chloride. 
 
 
Scheme 1.74: Attempted synthesis of isoindolinone 1.258 
 
Attempts made at increasing the rate of both processes are summarised in Table 1.16. Increased 
reaction temperature (entries 1, 2 and 3) did not allow conversion of 1.256 to pyrrolidone 1.258. An 
increase in reaction concentration (entries 4 and 5) also failed to yield pyrrolidone 1.258. 
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Table 1.16: Variation of concentration and temperature 
 
Entry Temperature (°C) Concentration (M) 1.256 : 1.258 
1 50 0.25 1 : 0 
2 80 0.25 1 : 0 
3 110 0.25 1 : 0 
4 50 0.50 1 : 0 
5 50  1.0 1 : 0 
 
It was next proposed that the bulky bidentate hexafluoroacetyl acetate ligand was preventing 
aminopalladation onto the bulkier gem-disubstituted alkene. The results of the catalyst screen are 
summarised in (Table 1.17). Palladium acetate, which previously showed good conversion in mono-
substituted alkenes (Table 1.6), showed no improvement, either at 0.25 M (entry 1) or at the increased 
concentration of 0.5 M (entry 2). Palladium chloride (entry 3), a significantly smaller ligand than 
hfacac, also showed no improvement in reactivity. 
 
Table 1.17: Catalyst screen 
 
Entry Catalyst Concentration (M) 1.256 : 1.258 
1 Pd(OAc)2 0.25 1 : 0 
2 Pd(OAc)2 0.50 1 : 0 
3 PdCl2 0.25 1 : 0 
 
Attempts towards aminoallylation of geminally-disubstituted alkenes were also, concurrently, 
undertaken on tosylamide 1.260, the disubstituted alkene analogue of model substrate 1.189. The 
substrate was synthesised in 3-steps following a modification to the procedure used for the synthesis 
of tosylamide 1.189 (Scheme 1.75). Allylation of aryl iodide 1.194 with 2-methallyl chloride yielded 
methallylbenzyl ester 1.259. Subsequent ester hydrolysis and tosylamide-formation yielded 
tosylamide 1.260 in 3 steps. 
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Scheme 1.75: Synthesis of disubstituted alkene 1.260 
 
Initial attempts towards the aminoallylation of tosylamide 1.260 were made using the then optimal 
aminoallylation reaction conditions (Scheme 1.76). Desired isoquinolone product 1.262 was 
observed as part of the crude material, but the conversion of tosylamide 1.260 was low.  
 
 
Scheme 1.76: Aminoallylation of tosylamide 1.260 
 
It is unknown if slow aminopalladation to alkylpalladium(II) intermediate 1.261 or slow 
carbopalladation of intermediate 1.261 with allyl chloride was the cause of low reactivity. Both 
processes are palladium catalysed, so the catalytic loading of palladium was increased (Eq. 1.45). 
The increased catalytic loading allowed for increased conversion of tosylamide 1.260 and desired 
isoquinolone 1.262 was isolated in a 33% yield. 
 
 
 
Attempts to increase the rate of aminoallylation are summarised in Table 1.18. Increased temperature 
to 80 °C (entry 2) resulted in lower conversion of alkene 1.260 due to rapid catalyst deactiviation. 
Further increase of temperature to 110 °C (entry 3) prevented aminoallylation altogether, and the 
only reactivity was isomerisation of alkene 1.260 to tri-substituted alkene 1.263. Increased 
concentration (entry 4) also resulted in rapid catalyst deactivation. 
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Table 1.18: Attempts towards high-yielding reaction conditions for the aminoallylation of 
tosylamide 1.260 
 
Entry Temperature (°C) Concentration (M) 1.260 : 1.262 : 1.263 
1 50 0.5  2 : 1 (33%) : 0 
2 80 0.5 9 : 1 : 0 
3 110 0.5  1 : 0 : 1 
4 50 1.0 9 : 1 : 0 
 
In the case of Waser and co-workers’ aminoalkynylation, the single example of a gem-disubstituted 
alkene required different conditions, including the use of 4-chlorosalicylic acid.[34] Addition of 4-
chlorosalicylic acid (Table 1.19, entry 2) completely inhibited aminoallylation reactivity. This was 
potentially caused by the viscosity of the reaction mixture due to the low solubility of 4-
chlorosalicylic acid. Increased solvent volume (entry 3) allowed dissolution, but aminoallylation did 
not proceed. It is unknown whether this was due to the significantly lowered concentration or the 4-
chlorosalicylic acid. Utilisation of dichloromethane (entry 4), the solvent utilised by Waser et al. had 
no improvement on reactivity. Addition of lithium chloride and utilisation of ethanol as the solvent 
(entry 5), the conditions utilised by Waser et al. for mono-substituted alkenes, resulted in gem-
dimethyl piperidone product 1.264. Piperidone 1.264 is proposed to be either a product of proto-
depalladation from alkylpalladium(II) intermediate 1.261 or of direct hydroamination of alkene 
1.260 with HCl, an acidic by-product of the desired aminoallylation process. In order to prevent this 
process, mono potassium phosphate was added (entry 6), which successfully prevented formation of 
piperidone 1.264 but also prevented formation of desired isoquinolone 1.262. Utilisation of lithium 
chloride with the previously optimised conditions also failed to demonstrate conversion of alkene 
1.260. 
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Table 1.19: Utilisation of Waser’s conditions 
 
Entry Solvent Additive (2 equiv.) Concentration (M) 1.260 : 1.262 : 1.264 
1 PhMe - 0.50 2 : 1 (33%) : 0 
2 PhMe 4-Chlorosalicylic acid 0.50 1 : 0 : 0 
3 PhMe 4-Chlorosalicylic acid 0.05 1 : 0 : 0 
4 CH2Cl2 4-Chlorosalicylic acid 0.05 1 : 0 : 0 
5 EtOH LiCl 0.50 0 : 0 : 1 
6 EtOH LiCl + KH2PO4 0.50 1 : 0 : 0 
7 PhMe LiCl + KH2PO4 0.50  1 : 0 : 0 
 
Waser also gave a single example of the aminoalkynylation of a disubstituted alkene in his 2010 
oxyalkynylation report.[33] The optimised conditions were tested with the addition of allyl chloride, 
but no conversion of alkene 1.260 to either desired piperidone 1.262 or piperidone by-product 1.264 
was observed (Eq. 1.45). 
 
 
1.3.5: Substrate Scope – Boc-protected amides 
It was proposed that tuning the reactivity of the nitrogen through variation of the protecting group 
would have a significant effect on aminoallylation, and hence allow the expansion of substrate scope. 
tert-Butyl carbamate groups (Boc-amines) are a common nitrogen protecting group used regularly 
in palladium-catalysed aminocyclisation, but there are currently no examples of aminopalladation 
reactions with Boc-protected amides in the chemical literature, though they have been utilised for 
other aminocyclisation strategies.[7] The model Boc-amide substrate 1.265 was synthesised in a single 
step from previously synthesised benzoic acid 1.174, by treatment with tert-butyl carbamate and 
phenylsilane (Eq. 1.47). 
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The model substrate was subjected to the previously optimised conditions aminoallylation conditions 
(Scheme 1.77). There was no observed conversion to desired isoindolinone 1.267, and Boc-amide 
1.265 was recovered. 
 
 
Scheme 1.77: Attempted aminoallylation of amide 1.267 
 
It was proposed that aminoallylation reactivity was inhibited by either a slow rate of 
aminopalladation of Boc-amide 1.265 or a slow rate of carbopalladation of alkylpalladium(II) 
intermediate 1.266 with allyl chloride. Attempts to increase the rate of both processes are detailed 
below (Table 1.20). Increased concentration (entry 2) had no effect. Change of catalyst to palladium 
acetate (entry 3), a less bulky ligand than hexafluoroacetylacetanoate, also had no effect. An increase 
in temperature to 80 °C demonstrated no conversion of Boc-amide 1.265. Further increase of 
temperature to 110 °C demonstrated complete conversion of the starting material, but did not yield 
desired isoindolinone 1.267 (see Scheme 1.78). 
 
Table 1.20: Attempted cyclisation of 1.265 
 
Entry Temperature (°C) Pd(X)2 Concentration (M) 1.265 : 1.267 
1 50 Pd(hfacac)2 0.25  1 : 0 
2 50 Pd(hfacac)2 0.50 1 : 0 
3 50 Pd(OAc)2 0.50 1 : 0 
4 80 Pd(OAc)2 0.50 1 : 0 
5 110 Pd(OAc)2 0.50 0 : 0 
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At 110 °C, full conversion of Boc-amide 1.265 was observed, but rather than forming desired 
pyrrolidone 1.267, the reaction proceeded to form lactone 1.268 (Scheme 1.78). The formation of 
lactone 1.268 is proposed to proceed via initial carbamate hydrolysis of Boc-amide 1.265 by 
adventitious water to yield isopropenyl benzoic acid 1.174. The acid subsequently undergoes 
efficient oxyallylation to yield lactone 1.268.[45] 
 
 
Scheme 1.78: Proposed mechanism for formation of lactone 1.268 
 
The optimised aminoallylation protocol allows the reaction to proceed under non-inert conditions. In 
this case however, it was predicted that water-free reaction conditions would inhibit the hydrolysis 
of Boc-amide 1.265 and, consequently, the formation of lactone 1.268 (Eq. 1.48). The reaction 
successfully prevented formation of lactone 1.268, but there was also no observed aminoallylation 
to pyrrolidone 1.268 and Boc-amide 1.265 was recovered. 
 
 
As a consequence, it was proposed that di-substituted alkenyl Boc-amides are not suitable 
aminoallylation substrates under the current optimal reaction conditions. Mono-substituted alkenyl 
Boc-amide 1.270 was utilised to test the applicability of Boc-amides to the aminoallylation of mono-
substituted alkenes (Eq. 1.49). Boc-amide 1.270 was synthesised in a single step from allyl benzoic 
acid 1.269 via the same protocol as for Boc-amide 1.265 (Eq. 1.47). 
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Aminoallylation of monosubstituted alkene 1.270 was attempted under the conditions optimised for 
the tosylamide 1.189 (Eq. 1.50). Piperidone 1.271 (R = Boc) was not observed, and Boc-amide 1.270 
was recovered. In comparison to the aminoallylation of tosylamide 1.189, which yields desired 
piperidone 1.192 in high yield, this result suggests that Boc-amide substrates are not suitable for 
aminoallylation. It is possible that the lack of reactivity was a result on the increased bulk of the tert-
butyl moiety slowing the rate of aminopalladation. Another possible explanation is that the lack of a 
sulfonyl-moiety prevents the formation of a stable alkylpalladium(II) intermediate.[78] 
 
 
1.3.6: Mesyl-protected amides 
The only nitrogen species to have thus far successfully undergone aminoallylation is the tosylamide. 
It was proposed that the toluene-sulfonyl moiety was too bulky to allow aminoallylation onto gem-
disubstituted alkenes, so attempts were made towards a less bulky sulfonyl-protected amide. 
Mesylamides have not been previously utilised for palladium-catalysed aminocyclisations, but there 
are examples of mesyl-protected amines successfully undergoing aminopalladative processes.[91] 
 
Mesylisocyanate is not commercially available and requires a multi-step synthesis,[92] so it was 
decided to seek a different protocol than the one utilised for tosylamides. Chemler and co-workers 
demonstrated the synthesis of sulfonylamides from the respective carboxylic acids and a sulfonamide 
under peptide-coupling conditions.[47] The protocol utilised coupling reagent EDC to promote the 
coupling with toluenesulfonamide to yield a range of tosylamides (Eq. 1.51). In 2011, Waser and co-
workers demonstrated the applicability of the EDC protocol to aromatic carboxylic acids.[34] 
 
 
 
Mesylamide 1.272 was proposed as the model substrate for the investigations into the 
aminoallylation of methanesulfonyl amides. Attempts to synthesise it from benzoic acid 1.174 are 
detailed below (Table 1.21). Utilisation of the Chemler protocol detailed above (entry 1) 
demonstrated no conversion of benzoic acid 1.174. Utilising CDI (entry 2) as the amide coupling 
reagent also provided no conversion.[93] Attempted synthesis of mesylamide 1.272 via the acyl 
chloride resulted in degradation of the material (entry 3). 
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Table 1.21: Attempted methylsulfonamide couplings 
 
Entry Conditions Results 
1 1.273, EDC, DMAP, CH2Cl2, 0 °C to RT, 24 h No reaction 
2 1.273, CDI, DMAP, CH2Cl2, RT, 24 h No reaction 
3 1) (COCl)2, DMF, Et2O, 0 °C 18 h 
2) 1.273, NEt3, Et2O 0 °C to 40 °C, 3 h 
Degradation 
 
Attempts to synthesise mesylamide 1.272 then centred on sulfonyl-protection of amide 1.274, which 
was synthesised in a single step from 2-isopropenyl benzoic acid 1.174 (Scheme 1.79).[94] The 
protocol for the formation of benzamide 1.274 was low yielding. Substitution of benzamide 1.274 
with mesyl chloride successful allowed the synthesis of mesylamide 1.272 in a 25% yield over two 
steps. 
 
 
Scheme 1.79: Synthesis of mesylamide 1.272 
 
With mesylamide 1.272 in hand, it was subjected to the optimised aminoallylation reaction 
conditions (Eq. 1.52). Gratifyingly, desired isoindolinone 1.275 was observed as part of the crude 
material. The major observed product was pyridone 1.276.  
 
 
 
The proposed mechanism for the formation of piperidone 1.276 is detailed below (Scheme 1.80). 6-
endo aminopalladation yields alkylpalladium(II) intermediate 1.278. Subsequent β-hydride 
elimination will yield exo-cyclic methylene piperidone 1.279, which rapidly isomerises to yield 
vinylic-amide 1.276. This pathway is in competition with 5-exo aminopalladation to 
alkylpalladium(II) intermediate 1.277, from which subsequent carbopalladation and β-halide 
elimination yield desired isoquinolone 1.275. 
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Scheme 1.80: Competitive pathways for the synthesis of 1.275 and 1.276 
 
Attempts to increase the yield of desired isoindolinone 1.275 were aimed at increasing the relative 
rate of carbopalladation of alkylpalladium(II) intermediate 1.277 with the allyl electrophile (Table 
1.22). Utilisation of allyl bromide (entry 2) increased the ratio of desired isoindolinone 1.275 over 
piperidone 1.276, but with significantly lower conversion. Increase of temperature (entry 3) allowed 
improved conversion, and the desired aminocycle was observed as 60% of the crude material. The 
most promising conditions, however, were observed by cooling the aminoallylation reaction with 
allyl chloride to room temperature (entry 4), which resulted in complete conversion with no observed 
6-endo product 1.272, however there was a significant yield of an side-product 1.280. 
 
Table 1.22: Optimisation of isoquinolone 1.275 synthesis 
 
 
 
The side product of the aminoallylation conditions discussed above (Table 1.22, entry 4) is proposed 
to be pseudo-dimeric pyrrolidone 1.280 (Scheme 1.81). The formation of product 1.280 is proposed 
to arise from carbopalladation of alkylpalladium(II) intermediate 1.277 with desired product 1.275. 
A similar side-product was encountered during the optimisation of the oxyallylation reaction.[64] It 
was predicted that increased concentration of allyl electrophile would decrease the yield of pseudo-
dimeric aminocycle 1.280. Subsequent research utilising mesylamides demonstrated difficulty in 
Entry X Temperature 
(°C) 
Time 
(h) 
Cat. Loading 
(mol. %) 
1.272 : 1.275 : 1.276 
1 Cl 50 24 5 0 : 1 : 1.2 
2 Br 50 72 5 1.2 : 1 : 0.3 
3 Br 80 20 10 0.2 : 1 : 0.2 
4 Cl RT 80 10 0 : >20 : 0 
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substrate synthesis (see below) and as a consequence, no further work was attempted with 
mesylamide 1.272, despite the promising results obtained. 
 
 
Scheme 1.81: Proposed formation of pseudo-dimeric pyrrolidone 1.280 
 
Previous investigations with non-substituted aliphatic tosylamides demonstrated a total lack of 
aminopalladation. It was proposed that the less bulky mesylamide may lower the energy of the 
reactive rotamer and transition state of aminopalladation (Scheme 1.82). Mesylamide 1.282 was 
synthesised from hexenoic acid 1.224 via amide 1.281.  
 
 
Scheme 1.82: Synthesis of mesylamide 1.224 
 
When subjected to the aminoallylation conditions, mesylamide 1.282 failed to undergo 
aminopalladation, and neither desired piperidone 1.283 nor dihydropyridone 1.284, were observed 
(Eq. 1.53). Attempts at increasing the rate of aminoallylation through increased temperature also 
demonstrated a lack of aminopalladation.  
 
 
 
N-Mesyl allylbenzamides 1.288 and 1.289 were proposed because the tosyl analogues had previously 
successfully undergone aminoallylation. First attempts focussed on the synthesis of intermediate 
benzamides 1.286 and 1.287, following the same protocol utilised for the synthesis of mesylamide 
1.272. Mono- and di-substituted alkenyl benzoic acids 1.269 and 1.285 were subjected to the 
conditions previously used for non-protected benzamide synthesis (entries 1 and 2), but no 
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conversion of the starting material was observed. Attempts to synthesise the amides via acyl chlorides 
(entries 3 and 4) resulted in degradation of reaction material. 
 
Table 1.23: Attempted allylbenzamide synthesis 
 
Entry R Conditions Result (1.286 : 1.287) 
1 H CDI, DMF, 60 °C, 2 h then NH4Cl, RT, 2 h 1 : 0 
2 Me CDI, DMF, 60 °C, 2 h then NH4Cl, RT, 2 h 1 : 0 
3 H SOCl2, CH2Cl2, 50 °C then NH4Cl, 0 °C, 2 h degradation 
4 Me SOCl2, CH2Cl2, 50 °C then NH4Cl, 0 °C, 2 h degradation 
 
The synthesis of N-mesyl allylbenzamides 1.288 and 1.289 was then attempted using the direct 
amide-coupling protocol previously used by Chemler and co-workers (Table 1.24, entries 1 and 2).[47] 
The conditions failed to yield either desired product and the starting material was recovered. When 
attempting the coupling via the acyl chloride (entries 3 and 4), the reaction material degraded. 
 
Table 1.24: Attempts towards the synthesis N-mesyl allylbenzamides 1.288 and 1.289 
 
Entry R Conditions Result (1.288 : 1.289) 
1 H 1.273, EDC, DMAP, CH2Cl2, 0 °C to RT, 24 h 1 : 0 
2 Me 1.273, EDC, DMAP, CH2Cl2, 0 °C to RT, 24 h 1 : 0 
3 H 1) (COCl)2, DMF, Et2O, 0 °C 18 h 
2) 1.273, NEt3, Et2O, 0 °C to 40 °C, 3 h 
Degradation 
4 Me 1) (COCl)2, DMF, Et2O, 0 °C 18 h 
2) 1.273, NEt3, Et2O, 0 °C to 40 °C, 3 h 
Degradation 
 
The preliminary results into the utilisation of mesylamides were encouraging, despite difficulties in 
synthesising certain substrates. These attempts were by no means exhaustive, and further 
experimentation could conceivably allow for a wider scope of mesylamides. More promising results 
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were, however, obtained from other research directions. Consequently, the research into 
aminoallylation of mesylamides was discontinued. 
1.3.7: Substrate Scope – Hydroxamates 
Attempted aminocyclisations of geminally-disubstituted alkenes thus far have utilised strongly 
electron-withdrawing nitrogen protecting groups. O-Functionalised hydroxamic acids have 
demonstrated the potential to undergo efficient aminopalladation, but have thus far been under-
utilised. It is proposed that the hydroxamates will exhibit increased nucleophilicity as a result of the 
alpha effect,[95] potentially increasing the rate of aminopalladation. 
 
For example, a single instance in the oxyalkynylation report by Waser and co-workers utilised 
benzyloxyamide 1.65 (Eq. 1.54). The gem-disubstituted alkene successfully underwent 
aminoalkynylation but suffered from poor N vs O heterocyclisation chemoselectivity, yielding a 
mixture of lactam 1.66 and imidate 1.67.[33] 
 
 
 
In 2012, Zhang et al. reported an enantioselective palladium-catalysed aza-Wacker cyclisation of 
trisubstituted alkenes with tethered hydroxamate functionality (Eq. 1.55).[81] The methodology 
demonstrated high chemoselectivity for aminopalladation (no oxypalladation products were 
observed) with either benzyloxy- or methoxy amides. 
 
 
 
Methoxyamide 1.292 was chosen as a model substrate for reaction optimisation, and was synthesised 
in a single step by treating previously synthesised benzoic acid 1.174 with O-methylhydroxylamine 
hydrochloride under peptide coupling conditions (Eq. 1.56). 
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With methoxyamide 1.292 in hand, it was subjected to the reaction conditions previously optimised 
for oxyallylation (Table 1.25). Gratifyingly, the desired product of aminoallylation, pyrrolidone 
1.293, was observed when utilising either allyl bromide or chloride. There was, however, two 
significant side-products: Pseudo-dimeric product 1.295 and brominated product 1.296. In the case 
of allyl chloride, there was no observed chlorination, but there was significant isomerisation of the 
product alkene (1.294). 
 
Table 1.25: Aminoallylation of methoxyamide 1.292 
 
Entry X 1.292 : 1.293 : 1.294 : 1.295 : 1.296 Isolated yield of 1.293 
1 Cl 0 : 1.0 : > 1.0 : 0.8 : 0 18% 
2 Br 0 : 1.0 : 0 : 0.5 : 0.7 - 
 
Mechanistic considerations:  
In order to design conditions which limit the formation of undesired side-products 1.295 and 1.196, 
it is important to understand the mechanisms for their formation. Desired product pyrrolidone 1.293 
was formed via the aminocyclisation–carbopalladation–β-halide elimination sequence discussed in 
the previous chapters (Scheme 1.83). Intramolecular aminopalladation of methoxyamide 1.292 
proceeds to garner alkylpalladium(II) intermediate 1.297. Carbopalladation with allyl 
chloride/bromide produces alkylpalladium(II) intermediate 1.298. Subsequent β-halide elimination 
yields the desired pyrrolidone 1.293 and releases the active palladium(II) salt. 
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Scheme 1.83: Mechanism for the formation of desired isoindolinone 1.293 
 
Pseudo-dimeric isoindolinone 1.295 is proposed to be formed by an aminopalladation–β-hydride 
elimination sequence (Scheme 1.84). Aminopalladation of alkene 1.292 with a palladium(II) salt 
yields alkylpalladium(II) intermediate 1.297. Carbopalladation with a second molecule of alkene 
1.292, as opposed to the allylic halide, leads to alkylpalladium(II) intermediate 1.298, which will 
rapidly undergo β-hydride elimination, yielding 1.299. Alkene 1.299 will then undergo 
aminopalladation with the now-tethered methoxyamide to yield alkylpalladium(II) intermediate 
1.300. β-Hydride elimination will yield the pseudo-dimerised product 1.295.  
 
 
Scheme 1.84: Proposed mechanism for pseudo-dimer 1.295 formation 
 
One criticism for the mechanism is the proposal that alkylpalladium(II) intermediate 1.297 will 
undergo carbopalladation more rapidly with disubstituted alkene 1.292 than with the mono-
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substituted allylic halide, despite the concentration of the allylic halide considerably higher. Previous 
evidence in this thesis highlighted that the carbopalladation of gem-disubstituted alkene in the 
aminoallylation reaction has a significant retarding effect on the reaction rate (Scheme 1.85). As a 
consequence, it was expected that carbopalladation with allyl chloride would be significantly more 
rapid than with hydroxamate 1.292.  
 
 
Scheme 1.85: Comparison in carbopalladation of mono- and di-substituted allylic chlorides in the 
aminoallylation of tosylamide 1.189 
 
One possible explanation for the formation of pseudo-dimer 1.295 is the metal-chelation exhibited 
by hydroxamic acids. Hydroxamic acids have previously demonstrated strong chelation with a range 
of metals[96] and, in particular, have been demonstrated to form labile complexes with palladium(II) 
species.[97] It was proposed that chelation of alkylpalladium(II) intermediate 1.297 by hydroxamate 
1.292 will act to accelerate carbopalladation onto gem-disubstituted alkene 1.292 (Figure 1.6). 
Tosylamide 1.189 lacks the ability to ligate palladium in the same manner and, as a consequence, no 
dimeric products were observed. 
 
 
Figure 1.6: Proposed complexation of alkylpalladium(II) intermediate 1.297 with hydroxamate 
1.292 
 
Brominated isoindolinone 1.296 was observed from aminoallylation reactions utilising allyl bromide. 
Two potential mechanisms for formation of brominated isoindolinone 1.296 are shown below 
(Scheme 1.86). Proposal 1 is a palladium-catalysed mechanism wherein alkylpalladium(II) 
intermediate 1.297 will undergo a carbon–bromine bond forming reductive elimination. Proposal 2 
is non-palladium catalysed and involves an electrophilic bromine source. Attempts were made 
towards preventing the formation of a bromonium species by removing potential oxidants (e.g. O2) 
from the reaction mixture, thus preventing formation of benzylic cation 1.301. These attempts, 
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however, had no effect on the reaction. As a consequence, efforts were focussed on the palladium-
catalysed proposal. 
 
 
Scheme 1.86: Potential mechanisms for bromo-isoindolinone 1.296 formation 
 
The full mechanism for proposal 1 is shown below (Scheme 1.87). Aminopalladation of hydroxamate 
1.292 leads to alkylpalladium(II) intermediate 1.297. Where X = Br, alkylpalladium(II) intermediate 
1.297 may undergo C–Br bond-forming reductive elimination to yield brominated pyrrolidone 1.296. 
Although this is not possible on the first catalyst turnover (where X = hfacac), β-halide elimination 
from alkylpalladium(II) intermediate 1.302 will yield a palladium(II) bromide salt. Lautens and co-
workers have demonstrated that carbon–halogen bond-forming reductive elimination from a 
palladium(II) intermediate can allow the formation of new sp3 carbon–iodine bonds,[98] but the 
analogous carbon–bromine and carbon–chlorine bond forming reactions are highly inefficient.[99] 
 
 
Scheme 1.87: Proposed palladium(II) catalysed formation of bromo-isoindolinone 1.296 
 
Alternatively, there are a number of reports of palladium-catalysed carbon–bromine bond forming 
processes in which reductive elimination from a palladium(IV) intermediate is implicated.[47,48] It 
was proposed that alkylpalladium(II) intermediate 1.297 can undergo an oxidation event to yield 
alkylpalladium(IV) intermediate, from which reductive elimination will yield pyrrolidone 1.296 
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(Scheme 1.88). As above, the catalytic cycle which forms pyrrolidone 1.296 is not possible on the 
first catalytic turnover. 
 
Scheme 1.88: Proposed palladium(IV) catalysed formation of bromo-isoindolinone 1.296  
 
Previous mechanistic experiments demonstrated that the desired heteroallylation process does not 
proceed via a palladium(IV) intermediate and no oxidative addition of alkylpalladium(II) 
intermediates with allyl halides was been observed (section 1.2.3). There are, however, examples of 
alkylhalide mediated oxidation of organopalladium(II) intermediates.[41] The aminoallylation 
reactions are run under atmospheric conditions, so another possible mechanism for the formation of 
proposed alkylpalladium(IV) intermediate 1.303 is oxidation by atmospheric oxygen. In order to 
probe the potential for oxidation, non-ambient reaction conditions were utilised (Table 1.26). 
Treatment of hydroxamate 1.292 under air-free aminoallylation conditions (entry 2) had little effect 
on the ratio of desired pyrrolidone 1.293 to brominated pyrrolidone 1.296 compared to ambient 
reaction (entry 1). Undertaking the aminoallylation reaction in the absence of air and water (entry 3) 
also results in a similar proportional formation of brominated pyrrolidone 1.296. The results confirm 
that atmospheric oxygen was not involved in the formation of brominated isoindolinone 1.296. 
 
Table 1.26: Probing palladium oxidation 
 
Entry Probe 1.293 : 1.295 : 1.296 
1 Ambient 1.0 : 0.3 : 0.9 
2 Air-free 1.0 : 0.2 : 1.5 
3 Air and water-free 1.0 : 0.2 : 0.7 
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Furthermore, it can be proposed that brominated product 1.296 is a reactive intermediate towards 
desired pyrrolidone 1.293 and pseudo-dimerised product 1.295 (Scheme 1.89). Oxidative addition of 
a palladium(0) species into the carbon–bromine bond would produce alkylpalladium(II) intermediate 
1.297.  
 
Scheme 1.89: Proposed transformation from brominated isoindolinone 1.296 to desired 
isoindolinone 1.293 and by-product 1.295 
 
In order to probe the possibility that brominated isoindolinone 1.296 is an intermediate towards the 
synthesis of desired isoindolinone 1.293, the isolated brominated product 1.296 was resubmitted to 
the reaction conditions (Eq. 1.57). Under these conditions, neither desired pyrrolidone 1.293 nor 
pseudo-dimerised product 1.295 were observed and bromo-pyrrolidone 1.296 was recovered. 
 
 
 
There is potential that the active catalytic species for the carbopalladation process was generated by 
aminopalladation of amide 1.292. In order to probe this, a spiking experiment, in which 5 mol. % of 
amide 1.292 was added to the reaction mixture, was performed (Eq. 1.58). The experiment failed to 
yield either pyrrolidone 1.293 or pseudo-dimerised product 1.295. Consequently, it is proposed that 
brominated aminocycle 1.296 is not an intermediate towards products 1.293 and 1.295, and is simply 
an undesired by-product.  
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Reaction optimisation: 
Based on the mechanistic proposals above, a direct comparison can be drawn between the pathways 
towards the three major products (Scheme 1.90). Alkylpalladium(II) intermediate 1.297 is the 
common intermediate in pathways 1, 2 and 3. Pathway 1, the desired pathway, relies on an 
intermolecular carbopalladation of alkylpalladium(II) intermediate 1.297 with allyl bromide. 
Pathway 2 involves intermolecular carbopalladation of alkylpalladium(II) intermediate 1.297 with 
hydroxamate 1.292. Pathway 3 is proposed to involve a C–Br bond forming elimination event from 
alkylpalladium(II) intermediate 1.297. 
 
 
 
Scheme 1.90: Common intermediate towards desired isoindolinone 1.296 and by-products 1.295 
and 1.296 
 
Consequently, it was hypothesised that increased relative concentration of allyl bromide would 
increase the relative yield of desired pyrrolidone 1.293 (Table 1.27). In the case of both allyl chloride 
(entries 1 & 2) and allyl bromide (entries 3 & 4), increased equivalents of the allylic halide improved 
the relative ratio of desired product 1.293 to side products 1.295 and 1.296. In the case of allyl 
chloride, there was no observed chlorinated product, but there was significant isomerisation of the 
desired alkene 1.293. As a result of the isomerisation of the desired product, it was decided that 
further investigations would utilise allyl bromide. 
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Table 1.27: Variation of allylic halide 
 
Entry X Y (Equiv.) 1.293 : 1.295 : 1.296 
1 Cl 5 1.0 : 0.8 : 0 
2 Cl 10 1.0 : 0.5 : 0 
3 Br 5 1.0 : 0.5 : 0.7 
4 Br 10 1.0 : 0.3 : 0.4 
 
One factor that has a major effect on the fate of alkylpalladium(II) intermediate 1.297 was the identity 
of the X ligand on palladium (Scheme 1.90). To probe this, a range of palladium(II) salts were tested 
(Table 1.28). The previous results using Pd(hfacac)2 are shown in entry 1. Pd(acac)2 (entry 2) and 
PdCl2(dppf) (entry 3) gave zero or very poor conversion of the starting material. 
Bis(benzonitrile)palladium chloride (entry 4) allowed complete conversion of the starting material, 
but with a poorer ratio of desired pyrrolidone 1.293 to pseudo-dimer 1.295 in comparison to 
Pd(hfacac)2, while palladium chloride (entry 5) gave similarly efficient conversion, but an even 
poorer ratio of 1.293 and 1.295. Utilising palladium acetate and palladium trifluoroacetate salts gave 
the best ratio, both allowing complete conversion of starting material. 
 
Table 1.28: Screen of palladium catalysts 
 
Entry Pd(X)2 1.292 : 1.293 : 1.295 
1 Pd(hfacac)2 0 : 1.0 : 0.4 
2 Pd(acac)2 1.0 : 0 : 0.2 
3 Pd(dppf)(Cl)2 1.0 : 0 : 0 
4 Pd(C6H5CN)2Cl2 0 : 1.0 : 0.5 
5 Pd(Cl)2 0 : 1.0 : 0.8 
6 Pd(OCOCF3)2 0 : 1.0 : 0.2 
7 Pd(OAc)2 0 : 1.0 : 0.2 
 
An investigation into the effect of reaction temperature was undertaken in toluene (Table 1.29). At 
room temperature (entry 1), aminoallylation did not proceed and hydroxamate 1.292 was recovered. 
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At 80 °C (entry 3), there was an improvement in desired pyrrolidone 1.293 to side products 1.295 
and 1.296 ratio compared to 50  °C (entry 2). 
 
Table 1.29: Temperature Screen 
 
Entry Temperature (°C) 1.292 : 1.293 : 1.295 : 1.296 
1 RT 1 : 0 : 0 : 0 
2 50 0 : 1.0 : 0.3 : 0.7 
3 80 0 : 1.0 : 0.1 : 0.8 
 
It has been hypothesised that the formation of brominated side-product 1.296 may involve a halide 
salt. Hence, solvent polarity can have a major effect on the solubility of a potential intermediate. 
Solvent polarity will also have an effect on nitrogen-nucleophilicity due to the alpha effect.[95] 
Toluene (Table 1.30, entry 1) gave a roughly 1:1 ratio of desired product 1.293 to undesired side-
products 1.295 and 1.296, with full conversion of starting material 1.292. Utilisation of a 1:1 biphasic 
mixture of toluene and water prevented aminoallylation reactivity. A study of increasingly polar 
solvents demonstrated that dichloromethane (entry 3) gave near-identical results to toluene, but 
ethereal solvents THF, diethyl ether and 2-methyl-THF prevented aminoallylation. Acetonitrile, 
known to be a weakly coordinating ligand for palladium, and thus proposed to potentially break-up 
hydroxamate chelation, resulted in poor conversion of amide 1.292. Finally DME, previously utilised 
for palladium-catalysed carboallylation reactions in the France group,[64] demonstrated excellent 
conversion and a reduced relative yield of pseudo-dimerised side-product 1.295. DME, however, 
demonstrated increased conversion to brominated product 1.296. It was decided to continue 
optimisation with DME and PhMe, because each solvent had its relative merits. 
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Table 1.30: Solvent screen 
 
Entry Solvent 1.292 : 1.293 : 1.295 : 1.296 
1 Toluene 0 : 1.0 : 0.3 : 0.7 
2 Toluene/H2O (1:1) <10% conversion of 1.292 
3 CH2Cl2 0 : 1.0 : 0.3 : 0.7 
4 THF <10% conversion of 1.292 
5 Et2O <10% conversion of 1.292 
6 2-methyl THF <10% conversion of 1.292 
7 MeCN 50% conversion of 1.292 
8 DME 0 : 1.0 : 0.1 : 1.6 
 
It was proposed that, because the desired carbopalladation is an intermolecular process, increased 
reaction concentration will increase the relative rate of carbopalladation compared to any 
intramolecular process (Table 1.31). Decreased reaction concentration of either 0.1 M (entry 1) or 
0.25 M (entry 2) demonstrate a reduced relative yield of desired pyrrolidone 1.293 compared to 
previously utilised conditions (0.5 M, entry 3). Increased concentration to 0.8 M (entry 4) and 1.0 M 
(entry 5) show similar results to 0.5 M (entry 3), but the high concentration also resulted in significant 
precipitation. Increased reaction concentration in toluene from 0.25 M (entry 6) to 0.5 M (entry 7) 
showed a similar trend, as the relative ratio of both side-products 1.295 and 1.296 decreased. 
 
Table 1.31: Variation in concentration in an attempt to prevent bromination 
 
Entry Solvent Concentration (M) 1.293 : 1.295 : 1.296 
1 DME 0.10 1.0 : 0.3 : 1.8 
2 DME 0.25 1.0 : 0.2 : 1.6  
3 DME 0.50 1.0 : 0.1 : 1.0 
4 DME 0.80 1.0 : 0.2 : 1.1 
5 DME 1.0 1.0 : 0.2 : 0.7 
6 PhMe 0.25 1.0 : 0.3 : 0.7 
7 PhMe 0.50 1.0 : 0.2 : 0.6 
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In order to further optimise the aminoallylation reaction, the range of bases tolerated by the reaction 
conditions was investigated. Initially, the reaction was attempted in the absence of base (Eq. 1.59), 
but only yielded dimethyl isoindolinone 1.304. Isoindolinone 1.304 was proposed to be a product of 
hydroamination, catalysed by excess HX in solution. A similar product (1.264) was seen for the 
aminoallylation of tosylamide 1.260 (Eq. 1.46). 
 
 
 
With the necessity of base addition demonstrated, a range of bases were tested in the aminoallylation 
reaction (Table 1.32). Mono potassium phosphate (entry 2) demonstrated poorer conversion than 
sodium bicarbonate (entry 1), although pseudo-dimer 1.295 was not observed. As has been 
demonstrated previously, weak amine bases have a detrimental effect on aminoallylation reactivity. 
No conversion of hydroxamate 1.292 was observed when utilising pyridine (entry 3) or DBU (entry 
4). Employment of potassium acetate (entry 5), a stronger heterogeneous base than sodium 
bicarbonate, resulted in no observed aminoallylation. There was also no observed conversion to N-
allylated products. 
 
Table 1.32: Base Screen 
 
Entry Base 1.292 : 1.293 : 1.295 : 1.296 
1 NaHCO3 0 : 1.0 : 0.1 : 1.0 
2 KH2PO4 0.4 : 1.0 : 0 : 0.9 
3 Pyridine 1.0 : 0 : 0 : 0  
4 DBU 1.0 : 0 : 0 : 0 
5 KOAc 1.0 : 0 : 0 : 0 
 
Further attempts to inhibit the formation of brominated aminocycle 1.296 are summarised below 
(Table 1.33). Addition of silver salts (entries 2–4), commonly used to sequester halide ions, resulted 
in a number of products arising from N-allylation of amide 1.292 (the products of N-allylation were 
not isolated). This was most likely a consequence of increased electrophilicity of allyl bromide. 
Potassium hexafluorophosphate (entry 5), a potassium salt with a soluble counter-ion, was added in 
an attempt to precipitate potassium bromide and thus, decrease conversion to brominated 
97 
 
isoindolinone 1.1296. The additive, however, proved to have no observed effect on the reaction. 
Aminoallylation reactions with halide salts lithium chloride (entry 6) and sodium iodide (entry 7) 
were attempted to see if either chlorinated/iodinated analogue of 1.296 was observed, which would 
potentially give mechanistic insight. Aminoallylation did not proceed in either case. 
 
Table 1.33: Additives to limit bromination 
 
Entry Additive 1.292 : 1.293 : 1.295 : 1.296 
1 - 0 : 1.0 : 0.2 : 0.6 
2 AgTFA N-allylation 
3 AgOAc N-allylation 
4 Ag2CO3 N-allylation 
5 KPF6 0 : 1.0 : 0.1 : 0.7 
6 LiCl 1.0 : 0 : 0 : 0 
7 NaI 1.0 : 0 : 0 : 0 
 
It was proposed that, if brominated product 1.296 is formed by alkylpalladium(II) halide reductive 
elimination (Scheme 1.87), introduction of an electron rich phosphine ligand may inhibit the 
elimination process (Table 1.34). Previous utilisation of phosphine ligands in heteroallylation 
research in the France group has demonstrated complete inhibition of reactivity (Table 1.9) but 
addition of triphenylphosphine (entry 2) in the aminoallylation of hydroxamate 1.292 decreased the 
yield of brominated product 1.296 while retaining complete conversion of starting material. XPhos 
(entry 3) and BrettPhos (entry 4) demonstrated similar reactivity. SPhos (entry 5) gave the most 
impressive product ratio thus far, in which the crude material was relatively pure isoindolinone 1.293, 
although it was only isolated in a 40% yield. Utilising SPhos in the reaction with DME (entry 6) 
produced a significant amount of brominated pyrrolidone 1.296, thus ending attempts towards 
aminoallylation in DME. Attempts towards an enantioselective aminoallylation were undertaken 
with (S)-Binap (entry 7), but no aminoallylation reactivity was observed under these conditions. 
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Table 1.34: Phosphine ligand trials 
 
Entry Solvent PR3 1.292 : 1.293 : 1.295 : 1.296 
1 PhMe - 0 : 1.0 : 0.1 : 1.0 
2 PhMe PPh3 0 : 1.0 : 0.2 : <0.2 
3 PhMe XPhos 0 : 1.0 : 0.1 : <0.2 
4 PhMe BrettPhos 0 : 1.0 : 0.3 : <0.2 
5 PhMe SPhos 0 : 1.0 (40%) : 0.1 : <0.2 
6 DME SPhos 0 : 1.0 : 0.2 : 0.8 
7 PhMe (S)-Binap 1 : 0 : 0 : 0 
 
The current optimal conditions for the aminoallylation of O-substituted hydroxamates is shown 
below (Eq. 1.60). The low yield is due, in part, to instability of isoindolinone 1.293 to silica 
chromatography, with a 20% mass loss observed on repeated subjection to purification. 
Reproducibility of the reaction has been demonstrated with near-identical isolated yield.  
 
 
 
The remainder of the reaction mass balance is, as yet, unaccounted for. Analysis of the crude material 
shows trace amounts of several alkene products which have been tentatively assigned to alkenes 
1.305 and 1.306, different elimination products of the pseudo-dimerisation pathway (Figure 1.7). 
 
 
Figure 1.7: Proposed unidentified by-products 
 
Due to the instability of N-methoxyisoindolone 1.293 to column chromatography, utilisation of a 
different hydroxamate was proposed. Benzyloxyamides, for example 1.65, were previously utilised 
for aminoalkynylation by Waser and co-workers.[33] The substrate was synthesised in a single step 
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under amide coupling conditions from previously utilised benzoic acid 1.174 and O-benzyl 
hydroxylamine (Eq. 1.61). 
 
 
 
Benzyloxyamides and methoxyamides allow access to different functionality after deprotection 
protocols (Scheme 1.91). Treatment of methoxyamides with samarium diiodide results in de-
methoxylation to yield the respective amide. Hydrogenation of benzyloxyamides yields the 
respective hydroxamic acid. Aminoallylation reaction conditions which can tolerate the application 
of either methoxy- or benzyloxy-amides is desirable for synthetic applicability. 
 
 
Scheme 1.91: Altered deprotection strategies for O-methyl and O-benzyl hydroxamates 
 
Benzyloxyamide 1.65 was subjected to the optimal hydroxamate-aminoallylation reaction conditions 
(Eq. 1.62). The reaction proceeded to full conversion of benzyloxyamide 1.65 and successfully 
allowed isolation of the desired isoindolinone 1.307 in a 41% yield. There was no observed 
bromination or pseudo-dimerisation products under the reaction conditions. The reaction also 
produced protocyclised product 1.308 in a low (<2%) yield. 
 
 
 
Towards the synthesis of isoquinolones, methoxyamide 1.309 was proposed. It was synthesised in a 
single step from previously utilised benzoic acid 1.285 in a single step using amide-coupling reagent 
propylphosphonic anhydride (T3P) and O-methyl hydroxylamine (Eq. 1.63). 
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N-Methoxyamide 1.285 was subjected to the optimal hydroxamate-aminoallylation conditions (Eq. 
1.64). The reaction allowed complete conversion of amide 1.309 and the desired isoquinolone 
product 1.310 was isolated in a 33% yield. No products of bromination or pseudo-dimerisation were 
observed under these conditions.  
 
 
 
Furthermore, attempts were made towards the synthesis of saturated heterocycles. Gem-dimethyl 
amide 1.312 was synthesised in a single step from the respective carboxylic acid 1.311 in a single 
step (Eq. 1.65). 
 
 
 
N-Methoxyamide 1.312 was subsequently submitted to the optimal hydroxamate-aminoallylation 
reaction conditions (Eq. 1.66). Amide 1.312, however, did not undergo aminoallylation and 
pyrrolidone 1.313 was not observed. That no products of bromination or pseudo-dimerisation were 
observed implies that the lack of reactivity was due to slow aminopalladation. 
 
 
 
In conclusion, O-methyl, and O-benzyl hydroxamates have been observed to undergo 
aminoallylation onto gem-disubstituted alkenes. The applicability to gem-disubstituted alkenes is 
tantamount to the goal of generalised aminoallylation reaction conditions which reliably avoid β-
hydride elimination. The yields, however, are currently sub-optimal. 
1.3.8: Substrate Scope – Amines and Anilines 
The aminoallylation using N-sulfonylamines was proposed as a method for further increasing 
substrate scope. It was envisaged to have the potential to synthesise a series of piperidine/pyrrolidine 
containing alkaloids, for example, tropane alkaloids (Scheme 1.92). 
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Scheme 1.92: Potential access to tropane alkaloids 
 
Benzylic amine 1.316 was synthesised by a known protocol (Scheme 1.93).[100] Allylation of 
bromobenzonitrile 1.314 yielded allylbenzonitrile 1.315 in a 56% yield. Subsequent nitrile reduction 
yielded benzylamine 1.316. 
 
 
Scheme 1.93: Synthesis of benzylic amine 1.316 
 
While the eventual goal was to tune the reactivity through amine protection, unprotected 
benzylamine 1.316 was subjected to the aminoallylation conditions (Eq. 1.67). The desired 
isoquinoline product 1.317 was not observed and the starting material was recovered. Furthermore, 
no product of amine allylation/diallylation was observed in the crude reaction material. 
 
 
 
Due to the significantly different pKa of benzylic amines compared to tosylamides (ca. 35 vs 4), it 
was decided to test the effect of varying the base (Table 1.35). Utilisation of sodium bicarbonate 
(entry 1), Hünig’s base (entry 2), dimethylaniline (entry 3) and di-tert-butyl pyridine (entry 4) did 
not allow for the aminoallylation of amine 1.316. Neither desired isoquinoline 1.317 nor isoquinoline 
1.318, the product of β-hydride elimination and alkene isomerisation, were observed under any 
conditions. One explanation is that unprotected amine 1.316 was not undergoing aminopalladation, 
due to strong ligation to palladium. 
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Table 1.35: Base screen for aminoallylation of benzylic amine 1.316 
 
Entry Base 1.316 : 1.317 : 1.318 
1 NaHCO3 1 : 0 : 0 
2 EtN(iPr)2 1 : 0 : 0 
3 PhN(CH3)2 1 : 0 : 0 
4 2,6-(tBu)C6H3N 1 : 0 : 0 
 
Sulfonamides have been utilised in a number of aminopalladative processes to tune amine reactivity, 
primarily due to weaker ligation to palladium.[75,77] Tosyl-protection of benzylic amine 1.316 
successfully allowed the synthesis of sulfonamide 1.319. 
 
 
 
Sulfonamide 1.319 was submitted to the optimised aminoallylation conditions at 50 °C and 80 °C 
but desired isoquinolone 1.321 was not observed and isoquinoline 1.322 was yielded as a single 
product (Scheme 1.94). Isoquinoline 1.322 was a product of β-hydride elimination from 
alkylpalladium(II) intermediate 1.320, which confirms that tosylamine 1.319 does undergo 
aminopalladation. Under the previously optimised conditions, however, the reaction was highly 
chemoselective for β-hydride elimination.  
 
 
Scheme 1.94: Attempted aminoallylation of sulfonamide 1.319 
 
In an attempt to tailor the reaction conditions towards allylation, amine ligands were utilised (Table 
1.36). In 2005, Lu demonstrated that the use of pyridine and 2,2-bipyridine (bipy) can effectively 
inhibit β-hydride elimination in favour of other processes.[89] Treatment of sulfonamide 1.319 under 
aminoallylation reaction conditions with pyridine (entry 1) and bipy (entry 2) as ligands results in 
complete inhibition of aminopalladation. The use of pyridine as a base (entry 3) had the same result. 
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In the absence of amine ligands, the reaction was so highly chemoselective for isoquinoline 1.322 
that further attempts towards aminocycle 1.321 were not made. 
 
Table 1.36: Ligand screen for aminoallylation of sulfonamide 1.319 
 
Entry Base Ligand 1.319 : 1.321 : 1.322 
1 NaHCO3 Pyridine (20 mol. %) 1 : 0 : 0 
2 NaHCO3 Bipy (20 mol. %) 1 : 0 : 0 
3 - Pyridine (2 equiv.) 1 : 0 : 0 
 
In an attempt to differently tune the reactivity, amine 1.316 was protected as a carbamate. Boc-
protected amines have been previously demonstrated to undergo aminopalladation.[101] Carbamate 
1.323 was synthesised in a single step from amine 1.316 in an 86% yield (Eq. 1.68).  
 
 
 
With carbamate 1.323 in-hand, it was subjected to aminoallylation conditions (Scheme 1.95). As 
with sulfonamide 1.319, carbamate 1.323 selectively underwent aminopalladation to 
alkylpalladium(II) intermediate 1.324 and subsequently terminated via β-hydride elimination and 
isomerisation to yield isoquinoline 1.326. Desired isoquinoline 1.325 was not observed under the 
reaction conditions.  
 
 
Scheme 1.95: Attempted aminoallylation of Carbamate 1.323 
 
Previous investigations into heteroallylation processes have demonstrated that the allyl halide has a 
large effect on reaction rate.[45] In an attempt to increase the relative rate of allylation, allyl bromide 
was utilised (Eq. 1.69). The aminoallylation of carbamate 1.323 with allyl bromide proceeded as 
before and desired isoquinoline 1.325 was not observed in the crude material.  
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In an effort to improve the rate of carbopalladation, allylpalladium chloride dimer was utilised as a 
catalyst. It was proposed that, by intra-molecularly delivering the alkene via ligation to palladium, 
the rate of carbopalladation could be increased (Scheme 1.96). The aminopalladation of carbamate 
1.323 with allylpalladium chloride dimer was proposed to result in alkylpalladium(II) intermediate 
1.327, thus allowing intramolecular delivery of the allyl moiety. The reaction, however, was 
unsuccessful, and neither isoquinoline 1.325 nor 1.326 was observed.  
 
 
Scheme 1.96: Proposal aminoallylation of Boc-amine 1.323 
 
In an attempt to prevent β-hydride elimination, utilisation of a gem-disubstituted alkene was 
proposed. Carbamates[101,102] and sulfonamides [27] have both been demonstrated to undergo efficient 
aminopalladation onto gem-disubstituted alkenes, and the examples are more wide-ranging than for 
protected-amide species. Disubstituted alkene 1.329 was proposed as a model substrate for the study 
(Scheme 1.97). The same protocol was followed as for the monosubstituted alkene (Scheme 1.93), 
but utilised methylallyl bromide in the allylation reaction. Both allylation and reduction proceeded 
in high yields to afford benzylic amine 1.329. 
 
 
Scheme 1.97: Synthesis of disubstituted-alkene 1.329 
 
Previous investigations demonstrated aminopalladation of the non-protected amine was unsuccessful 
(Eq. 1.67). As a consequence, no attempts were made towards the aminoallylation of benzylic amine 
1.329, which was instead protected as a sulfonamide (1.330) and a carbamate (1.331) (Scheme 1.98).  
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Scheme 1.98: Amine-protection of disubstituted alkene 1.329 
 
Methyl-sulfonamide 1.330 and carbamate 1.331 were subjected to the optimised aminoallylation 
reaction conditions (Eq. 1.70). Neither amine demonstrated conversion to the desired isoquinoline 
product.  
 
 
 
It was decided to undertake optimisation attempts with methyl sulfonamide 1.330 due to the 
significant volume of previous reactions undertaken with sulfonamides, in this thesis (Scheme 1.94) 
and in the literature. [75,77]  Changing the base to either sodium acetate or sodium bicarbonate had no 
effect on reactivity and methyl sulfonamide 1.330 was recovered (Eq. 1.71).  
 
 
 
Subsequent investigations were undertaken to test the effect of varying the palladium salt (table 
1.37). Neither palladium chloride (entry 2) nor palladium acetate (entry 3) successfully catalysed the 
aminoallylation of sulfonamide 1.330. Palladium trifluoroacetate (entry 4), previously utilised in aza-
Wacker cyclisations of tosylamides,[21] also demonstrated no conversion. Finally, aminoallylation 
with palladium acetylacetonoate failed to provide isoquinoline 1.332.   
 
 
 
 
 
 
 
 
 
 
106 
 
Table 1.37: Catalyst screen for aminoallylation of mesylamine 1.330 
 
Entry X 1.330 : 1.332 
1 hfacac 1 : 0 
2 Cl 1 : 0 
3 OAc 1 : 0 
4 TFA 1 : 0 
5 acac 1 : 0 
 
Anilines have been used extensively for aminocyclisation reactions in the past. For example, allyl-
aniline 1.333 was utilised in the seminal aminocyclisation research of Hegedus and co-workers in 
the 1970s (Eq. 1.72).[17] It was proposed that the utilisation of aniline substrates will give access to a 
range of 2-substituted indoles. 
 
 
 
It was decided to utilise aniline 1.333, the same substrate as utilised by Hegedus and co-workers, as 
a model substrate for investigation into aniline aminoallylation. 2-Allyl aniline 1.333 was synthesised 
from N-allylaniline 1.335 via microwave-induced aza-Claisen. The desired aniline substrate was 
isolated in a 75% yield (Eq. 1.73). 
 
 
 
Aniline 1.333 was subjected to the aminoallylation reaction conditions with a range of bases (Table 
1.38). The use of sodium bicarbonate (entry 1), as per the optimised conditions for oxyallylation, did 
not yield desired indole 1.336. The crude reaction mixture contained only aniline 1.333. This non-
reactivity was matched by the use of homogenous nitrogen-bases (entries 2–4). That 2-methylindole 
1.334, the product of β-hydride elimination and isomerisation, was not observed led to the conclusion 
that allylaniline 1.333 was not undergoing aminopalladation under the aminoallylation reaction 
conditions. 
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Table 1.38: Variation of base in aniline aminoallylation reaction 
 
Entry Base 1.333 : 1.336 : 1.334 
1 NaHCO3 1 : 0 : 0 
2 EtN(iPr)2 1 : 0 : 0 
3 PhN(CH3)2 1 : 0 : 0 
4 (tBu)2C5H3N 1 : 0 : 0 
 
Previously, efforts towards the palladium-catalysed aminocyclisation of aniline-substrates have 
demonstrated the applicability of carbamates.[103] Carbamate protection was achieved using di-tert-
butyl-dicarbonate under basic conditions, successfully affording carbamate 1.337. 
 
 
 
Carbamate 1.337 was subjected to the conditions optimised for tosylamide aminoallylation (Scheme 
1.99). Desired indole 1.339 was not observed under the aminoallylation conditions, with only 
methylindole 1.340 being produced. 2-methylindole is a result of β-hydride elimination from 
alkylpalladium(II) intermediate 1.338, followed by isomerisation. This result suggest that, unlike the 
non-protected aniline substrate 1.333, the carbamate-protected aniline was undergoing 
aminopalladation. However, the reaction is highly chemoselective for β-hydride elimination that no 
efforts were made towards conditions to chemically favour allylation. 
 
 
Scheme 1.99: Attempted aminoallylation of aniline 1.337 
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1.3.9: Conclusions and Future Work 
Over the course of this research, methodology has been developed to synthesise nitrogen-containing 
heterocycles substituted in the 2-position, constructing a new C−N and C−C sp3–sp3 bond in a single 
step from aromatic tosylamides. Four new isoquinolones were synthesised in yields of 33–84% 
(Scheme 1.100).  
 
 
Scheme 1.100: Summary of tosylamide aminoallylation 
 
The reactions are operationally simple. Technical grade solvents were utilised, and the reactions were 
carried out under air. Other than the change of base from sodium bicarbonate to monopotassium 
phosphate, necessitated by the lower pKa of the tosylamides, the conditions are in-line with those 
utilised for the previously optimised oxyallylation reaction. 
 
The current conditions, however, have significant limitations (Figure 1.8). It is clear that the 
developed aminoallylation reaction is sensitive to nitrogen pKa (successful examples have a pka of 
approximately 4). Attempts towards pyrroles, pyrrolidines, piperidines, aliphatic piperidones, and 
any Boc-functionalised aminocycles were unsuccessful.  
 
 
Figure 1.8: Summary of substrates which did not undergo aminoallylation 
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The most recent results utilising methyl substituted hydroxamates have demonstrated the potential 
for efficient aminoallylation of geminally-disubstituted alkenes. Utilisation of gem-disubstituted 
alkenes is a common method for avoiding β-hydride elimination (Scheme 1.101). 
 
 
Scheme 1.101: Optimal conditions for the aminoallylation of hydroxamates 
 
While examples of isoquinolone-containing alkaloid natural products are known,[104] they are less 
common than other nitrogen heterocycles. Consequently, aminoallylation conditions which are 
broadly applicable to the construction of a range of aminocycles are still being sought.  
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1.4: Supporting Information 
1.4.1: General Methods 
Reactions involving air-sensitive agents and dry solvents were performed in glassware that had been 
dried in an oven (150 °C) or flame-dried prior to use. These reactions were carried out with the 
exclusion of air using an argon atmosphere. All microwave reactions were carried out using a Biotage 
Initiator system. NMR spectra were recorded on a Bruker DPX-400 spectrometer (1H NMR at 400 
MHz and 13C NMR at 100 MHz) or a Bruker DPX-500 spectrometer (1H NMR at 500 MHz and 13C 
NMR at 125 MHz). Chemical shifts are reported in ppm. 1H NMR spectra were recorded with CDCl3, 
using residual CHCl3 (δ = 7.26) as internal standard, and for 13C NMR spectra the chemical shifts 
are reported relative to the central resonance of CDCl3 (δ = 77.16) and with d6-DMSO, using the 
central resonance of residual DMSO (δ = 2.50) as internal standard, and for 13C NMR spectra the 
chemical shifts are reported relative to the central resonance of d6-DMSO (δ = 39.51).  Signals in 
NMR spectra are described as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), septet 
(sept), multiplet (m), broad (br) or combination of these, which refers to the spinspin coupling 
pattern observed. Spinspin coupling constants reported are uncorrected. Two-dimensional (COSY, 
HSQC, HMBC, NOESY) NMR spectroscopy was used where appropriate to assist the assignment 
of signals in the 1H and 13C NMR spectra. IR spectra were obtained employing a Shimadzu FTIR-
8400 instrument with a Golden Gate™ attachment that uses a type IIa diamond as a single reflection 
element so that the IR spectrum of the compound (solid or liquid) could be detected directly (thin 
layer). High resolution mass spectra were recorded under FAB, ESI and CI conditions by the 
analytical services at the University of Glasgow. Flash column chromatography was performed using 
forced flow of the indicated solvent system on EMD Geduran Silica Gel 60 as solid support and 
HPLC graded solvents as eluent. Reactions were monitored by thin layer chromatography (TLC) on 
Merck silica gel 60 covered aluminium sheets. TLC plates were developed under UV-light and/or 
with an acidic ethanolic anisaldehyde solution or a KMnO4 solution. Liquid reagents were distilled 
prior to use where stated. All reagents were purchased from commercial suppliers and used without 
further purification unless otherwise stated. 
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1.4.2: Mechanistic experiments 
 
 
2-isopropenylbromobenzene 1.173 
To a stirred suspension of methyl triphenylphosphonium bromide (7.2 g, 20 mmol) in 
THF (51 mL) was added a solution of potassium tert-butoxide (2.3 g, 20 mmol) in THF 
(21 mL). The resulting bright yellow suspension was stirred at room temperature for 15 
minutes then a solution of o-bromoacetophenone 1.172 (3.4 g, 17 mmol) in THF (34 mL) added 
dropwise. The resulting suspension was stirred at room temperature for 3 h then quenched with sat. 
aq. NH4Cl (100 mL). The mixture was extracted with Et2O (3 x 50 mL) and the combined organic 
extracts dried (MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography 
(petroleum ether) afforded title compound 1.173 as a colourless oil (2.6 g, 77%). Analytical data 
observed were in accordance with literature values.[105] 
 
2-isopropenylbenzoic acid 1.174 
To a cooled (0 °C) solution of 1-bromo-2-(prop-1-en-2-yl) benzene 1.173 (2.6 g, 13 
mmol) in Et2O (26 mL) was added dropwise a solution of n-butyllithium (1.7 M in 
hexanes, 7.8 mL, 13 mmol). The resulting yellow suspension was stirred for 15 minutes, 
before CO2 was bubbled through. The mixture was allowed to warm to room temperature over 2 h 
then quenched with sat. aq. NaHCO3 (100 mL). The mixture was extracted with Et2O (2 x 50 mL) 
and the aqueous phase adjusted to pH 1 with 1 M aq. HCl. The aqueous phase was then extracted 
with Et2O (3 x 100 mL) and the combined organic extracts dried (Na2SO4), filtered and concentrated 
in vacuo to title compound 1.174 as a sticky white solid (1.7 g, 99%). Analytical data observed were 
in accordance with literature values.[33] 
 
2-(2-isopropenylphenyl)methanol 1.148 
To a stirred suspension of lithium aluminium hydride (0.49 g, 13 mmol) in Et2O (25 
mL) was added a solution of 2-isopropenylbenzoic acid 1.174 (0.80 g, 4.9 mmol) in 
Et2O (5 mL) at 0 °C. The solution was stirred for 20 h, before quenching by addition of 
sat. aq. potassium sodium tartrate (30 mL). After a further 4 h of stirring, the organic phase was 
extracted with Et2O (3 x 30 mL). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo to yield title compound 1.148 as a colourless oil (0.63 g, 87%). No further 
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purification was required. Analytical data observed were in accordance with those previously 
observed within the group.[64] 
 
1-(4’,4’-d2-but-3’-enyl)-1,3-dihydro-1-methylisobenzofuran 1.167 
A 4 mL glass screw-top vial was charged with (2-(prop-1-en-2-yl)phenyl) 
methanol 1.148 (51 mg, 0.34 mmol), freshly prepared deuterated allyl bromide 
1.165[73] (0.21 mg, 1.7 mmol), toluene (1.3 mL), NaHCO3 (37 mg, 0.68 mmol) 
and Pd(hfacac)2 (8.5 mg, 0.017 mmol). The mixture was heated at 50 °C for 4 h then additional 
Pd(hfacac)2 (8.5 mg, 0.017 mmol) added. Heating was continued for a further 2 h, then the mixture 
was allowed to cool to room temperature and subjected directly to flash chromatography (petroleum 
ether:EtOAc, 9:1) to afford title compound 1.167 as a yellow oil (53 mg, 82%). 1H NMR (400 MHz, 
CDCl3) δ 7.28 – 7.24 (2H, m, Ar-H), 7.20 – 7.18 (1H, m, Ar-H), 7.10 – 7.08 (1H, m, Ar-H), 5.80 – 
5.73 (1H, m, 3’-CH), 5.10 (1H, d, J = 12.3 Hz, 3-CH), 5.06 (1H, d, J = 12.3 Hz, 3-CH), 2.17 – 2.08 
(1H, m, 2’-CH), 1.96 – 1.87 (3H, m, 1’-CH2 & 2’-CH), 1.49 (3H, s, C1-CH3). 13C NMR (100 MHz, 
CDCl3) δ 145.3 (C), 139.2 (C), 138.6 (CH), 127.5 (CH), 127.4 (CH), 121.1 (CH), 121.0 (CH), 113.6 
(1J (C-D) = 24.0 Hz, CD2), 88.3 (C), 71.8 (CH2), 41.0 (CH2), 28.5 (CH2), 27.6 (CH3); IR (thin film) 
1765, 1451, 1358, 1030. HRMS (CI/Isobutane) exact mass calculated for C13H15D2O [M+H]+ m/z 
191.1405, found m/z 191.1413. 
 
 
(E/Z)-1-methyl-1-(pent-3’-enyl)-1,3-dihydroisobenzofuran 1.176 
 A 4 mL glass screw-top vial was charged with (2-(prop-1-en-2-yl)phenyl) 
methanol 1.148 (51 mg, 0.34 mmol), 3-chloro-1-butene 1.175 (0.17 mL, 1.7 
mmol), toluene (1.3 mL), NaHCO3 (57 mg, 0.68 mmol) and Pd(hfacac)2 (8.5 mg, 
0.017 mmol). The mixture was heated at 50 °C for 6 h. The mixture was allowed to cool to room 
temperature and subjected directly to flash chromatography (petroleum ether:EtOAc, 9:1) to afford 
title compound 1.176 as a yellow oil (53 mg, 82%, E/Z = 3:1). 1H NMR (500 MHz, CDCl3) δ 7.28 – 
7.07 (4H, m, Ar-H), 5.38 – 5.30 (2H, m, 3’-CH & 4’-CH), 5.12 – 5.04 (2H, m, 3-CH2), 2.03 – 2.02 
(1H, m, 2’-CH), 1.91 – 1.71 (3H, m, 1’-CH2 & 2’-CH), 1.59 – 1.47 (6H, m, C1-CH3 & C4’-CH3); 
13C NMR (125 MHz, CDCl3) δ 145.4 (C), 139.2 (C), 130.4/131.2 (major/minor isomer) (CH), 127.40 
(CH), 127.35 (CH), 123.9/124.5 (CH), 121.0 (CH), 120.9 (CH), 88.4 (C), 71.8 (CH2), 41.6 (CH2), 
27.6 (CH2), 21.9 (CH3), 12.7/18.1 (CH3); IR (thin film) 1767, 1452, 1358, 1030; HRMS 
(CI/Isobutane) exact mass calculated for C14H19O [M+H]+ m/z 203.1436, found m/z 203.1451. 
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(E/Z)-2-methyl-2-(pent-3’-en-1’-yl)-2,3-dihydrobenzofuran 1.178 
A 4 mL glass screw-top vial was charged with 2-(2-methyl)allylphenol 1.146[106] (51 
mg, 0.34 mmol), 3-chloro-1-butene 1.175 (0.17 mmol, 1.7 mmol), toluene (1.3 mL), 
NaHCO3 (37 mg, 0.68 mmol) and Pd(hfacac)2 (8.5 mg, 0.017 mmol). The mixture 
was heated at 50 °C for 36 h then additional Pd(hfacac)2 (8.5 mg, 0.017 mmol) added. Heating was 
continued for a further 36 h, then the mixture was allowed to cool to room temperature and subjected 
directly to flash chromatography (petroleum ether:EtOAc, 9:1) to afford title compound 1.178 as a 
yellow oil (51 mg, 74%, E/Z = 3:1). 1H NMR (400 MHz, CDCl3) δ 7.15 – 7.08 (2H, m, Ar-H), 6.83 
– 6.72 (2H, m, Ar-H), 5.48 – 5.35 (2H, m, 3’-CH & 4’-CH), 3.13 – 2.90 (2H, m. 3-CH2), 2.19 – 2.08 
(2H, m, 2’-CH2), 1.80 – 1.75 (2H, m, 1’-CH2), 1.64 – 1.55 (3H, m, C4’-CH3), 1.45 – 1.42 (3H, m, 
C2-CH3); 13C NMR (125 MHz, CDCl3) δ; 159.1 (C), 130.0 (CH), 128.08/128.05 (major/minor 
isomer) (CH), 127.0 (C), 125.20/125.17 (CH), 124.3 (CH), 120.0 (CH), 109.5 (CH), 88.6 (C), 
41.28/41.27 (CH2), 41.03/41.16 (CH2), 26.5/26.6 (CH3), 21.8 (CH2), 12.8 (CH3); IR (thin film) 1699, 
1439, 1346, 1084; LRMS (CI/Isobutane) mass calculated for C14H19O [M+H]+ m/z 203.1, found m/z 
203.2.  
 
 
1-(3’-bromobut-3’-en-1’-yl)-1-methyl-1,3-dihydroisobenzofuran 1.183 
A 4 mL glass screw-top vial was charged with (2-(prop-1-en-2-yl)phenyl) 
methanol 1.148 (51 mg, 0.34 mmol), 2,3-dibromopropene 1.182 (0.18 mL, 1.7 
mmol), toluene (1.3 mL), NaHCO3 (57 mg, 0.68 mmol) and Pd(hfacac)2 (8.5 mg, 
0.017 mmol). The mixture was heated at 50 °C for 16 h. The mixture was allowed to cool to room 
temperature and subjected directly to flash chromatography (petroleum ether:EtOAc, 9:1) to afford 
title compound 1.183 as a yellow oil (69 mg, 74%). 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.25 (2H, 
m, Ar-H), 7.22 – 7.18 (1H, m, Ar-H), 7.14 – 7.09 (1H, m, Ar-H), 5.50 – 5.48 (1H, m, 4’-CH), 5.32 
(1H, d, J = 1.6 Hz, 4’-CH), 5.08 (2H, dd, J = 20.7, 12.4 Hz, 3-CH2), 2.58 – 2.46 (1H, m, 2’-CH), 
2.19 – 2.01 (3H, m, 2’-CH & 1’-CH2), 1.49 (3H, s, C1-CH3); 13C NMR (100 MHz, CDCl3) 144.8 
(C), 139.1 (C), 134.8 (C), 127.7 (2 x CH), 121.1 (CH), 121.0 (CH), 116.2 (CH2), 87.7 (C), 71.8 
(CH2), 40.3 (CH2), 36.6 (CH2), 27.7 (CH3); IR (thin film); HRMS (ESI positive) exact mass 
calculated for C13H15OBrNa [M+Na]+ m/z 289.0198, found m/z 289.0199. 
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1.4.3: Aminoallylation - preparation of Substrates 
 
 
Methyl-2-allyl benzoate 1.195 
 Following a modification of a reported procedure,[34] to a suspension of magnesium 
turnings (2.0 g, 67 mmol) and a crystal of iodine in THF (30 mL) was added dropwise 
1-bromo-n-butane (7.2 mL, 67 mmol). The mixture was stirred for 15 minutes then 
cooled to –40 °C before dropwise addition of methyl-2-iodobenzoate 1.196 (5.0 mL, 
34 mmol). The mixture was stirred at –40 °C for 1.5 h. A freshly prepared solution of LiCl (3.4 g, 80 
mmol) and CuCN (3.4 g, 40 mmol) in THF (60 mL) was added and the mixture was stirred for a 
further 15 min, followed by the addition of allyl bromide (12 mL, 140 mmol). The mixture was 
stirred at –40 °C for a further 10 min, then warmed to room temperature. The mixture was diluted 
with EtOAc (200 mL) and filtered over Celite®. The filtrate was washed with 25% aq. NH4OH (200 
mL). The aqueous layer was further extracted with EtOAc (2 x 200 mL), and the combined organic 
extracts washed with brine (200 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification 
by flash chromatography (petroleum ether:EtOAc, 9:1), afforded title compound 1.195 as a 
colourless oil (5.3 g, 90%). Analytical data observed were in accordance with literature values.[107] 
 
2-allyl benzoic acid 1.269 
 Methyl-2-allyl benzoate 1.195 (2.7 g, 17 mmol) was dissolved in EtOH (250 mL), and 
2 M aq. NaOH (200 mL) added. The mixture was stirred for at room temperature for 4 
h then EtOH was removed in vacuo. The residue was extracted with Et2O (2 x 150 mL), 
acidified to pH 3 with 2 M aq. HCl and extracted with EtOAc (3 x 150 mL). The 
combined organics were dried (Na2SO4), filtered and concentrated in vacuo to afford title compound 
1.269 as a colourless solid (2.7 g, quant.), which was used directly without further purification.  
 
2-allyl-N-tosylbenzamide 1.189 
 To a solution of 2-allyl benzoic acid 1.269 (2.7 g, 17 mmol) in THF (50 mL) was 
added p-tosyl isocyanate (3.3 g, 17 mmol). The resulting solution was stirred for 10 
min then triethylamine (2.3 mL, 17 mmol) added dropwise. Gas evolution was 
observed on addition. After 1 h, the mixture was diluted with EtOAc (50 mL) and 
washed with 2 M aq. HCl (50 mL) and brine (50 mL). The organic extracts were dried (Na2SO4), 
filtered and concentrated in vacuo. The crude product was purified by column chromatography 
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(CH2Cl2) to afford title compound 1.189 as a colourless solid (4.6 g, 88%). Analytical data observed 
were in accordance with literature values.[34] 
 
 
Methyl-1-allyl-pyrrole-2-carboxylate 1.201 
 Following a modification of a reported procedure,[34]  to a cooled (0 °C) suspension of 
NaH (60% dispersion in mineral oil, 0.48 g, 12 mmol) in DMF (10 mL) was added a 
solution of methyl-2-pyrrole-carboxylate 1.200 (1.0 g, 8.0 mmol) in DMF (2.0 mL). The 
resulting mixture was stirred for 20 min at 0 °C, then allyl bromide (1.2 mL, 14 mmol) added 
dropwise. The mixture was allowed to warm to room temperature, and stirred for 2 h, then quenched 
by pouring onto ice (30 g). The mixture was extracted with Et2O (3 x 15 mL) and the combined 
organic extracts were washed with water (4 x 15 mL), brine (1 x 15 mL), dried (Na2SO4), filtered 
and concentrated in vacuo to afford title compound 1.201 as a colourless oil (1.3 g, 95%). Analytical 
data observed were in accordance with literature values.[108] 
 
1-allyl-pyrrole-2-carboxylic acid 1.341 
 To a solution of methyl-1-allyl-pyrrole-2-carboxylate 1.201 (1.3 g, 7.6 mmol) in EtOH 
(18 mL) was added 1 M aq. NaOH (21 mL). The mixture was refluxed for 1.5 h, then 
EtOH was removed in vacuo. The aqueous phase was washed with EtOAc (3 x 25 mL) 
then acidified to pH 2 with 4 M aq. HCl and extracted with EtOAc (3 x 25 mL). The 
combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo, to afford title 
compound 1.341 as a colourless solid (1.0 g, 89%) which was used directly without further 
purification.  
 
1-allyl-N-tosyl-pyrrole-2-carboxamide 1.202 
 To a flask charged with 1-allyl-pyrrole-2-carboxylic acid 1.341 (0.50 g, 3.3 mmol) in 
THF (10 mL) was added p-tosyl isocyanate (0.77 g, 6.6 mmol). The resulting solution 
was stirred for 10 min then triethylamine (0.50 mL, 3.6 mmol) added dropwise. Gas 
evolution was observed on addition. After 1 h, the mixture was diluted with EtOAc (50 mL) and 
washed with 2 M aq. HCl (50 mL) and brine (50 mL). The organic extracts were dried (Na2SO4), 
filtered and concentrated in vacuo. The crude product was purified by column chromatography 
(CH2Cl2) to afford title compound 1.202 as a colourless solid (0.71 g, 61%). Analytical data observed 
were in accordance with literature values.[34] 
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Ethyl-1-allyl-indole-2-carboxylate 1.207 
 Following a reported procedure,[34] to a cooled (0 °C) suspension of NaH (60% 
dispersion in mineral oil, 0.32 g, 8.0 mmol) in DMF (10 mL) was added a solution 
of methyl-2-indole-carboxylate 1.206 (1.0 g, 5.3 mmol) in DMF (4.0 mL). The 
resulting mixture was stirred for 20 min at 0 °C, then allyl bromide (0.78 mL, 9.0 
mmol) added dropwise. The mixture was heated at 100 °C for 2 h, then cooled and quenched by 
pouring onto ice (30 g). The mixture was extracted with Et2O (3 x 15 mL) and the combined organic 
extracts were washed with water (4 x 15 mL), brine (1 x 15 mL), dried (Na2SO4), filtered and 
concentrated in vacuo to afford title compound 1.207 as a colourless oil. Material was used directly 
without further purification. 
 
1-allyl-indole-2-carboxylic acid 1.342 
 To a solution of methyl-1-allyl-indole-2-carboxylate 1.207 (1.3 g, 5.8 mmol) in 
EtOH (15 mL) was added 1 M aq. NaOH (18 mL). The mixture was refluxed for 1.5 
h, then EtOH was removed in vacuo. The aqueous phase was washed with EtOAc (3 
x 25 mL) then acidified to pH 2 with 4 M aq. HCl and extracted with EtOAc (3 x 25 mL). The 
combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo, to title compound 
1.342 as a colourless solid (0.73 g, 68% over 2 steps) which was used directly without further 
purification.  
 
1-allyl-N-tosyl-1H-indole-2-carboxamide 1.208 
 To a flask charged with 1-allyl-indole-2-carboxylic acid 1.342 (0.20 g, 1.0 mmol) 
in THF (4.0 mL) was added p-tosyl isocyanate (0.16 mL, 1.0 mmol). The resulting 
solution was stirred for 10 min then triethylamine (0.14 mL, 1.0 mmol) added 
dropwise. Gas evolution was observed on addition. After 1 h, the mixture was diluted with EtOAc 
(20 mL) and washed with 2 M aq. HCl (20 mL) and brine (20 mL). The organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (CH2Cl2) to afford title compound 1.208 as a colourless solid (0.28 g, 78%). 
Analytical data observed were in accordance with literature values.[34] 
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2-vinyl benzoic acid 1.211 
To a stirred suspension of methyltriphenylphosphonium bromide (19 g, 53 mmol) in 
THF (80 mL) was added dropwise a solution of potassium tert-butoxide (8.8 g, 79 
mmol) in THF (40 mL). The resultant yellow solution was stirred for 1.5 h, before the 
addition of a solution of 2-carboxybenzaldehyde 1.210 (5.0 g, 33 mmol) in THF (20 mL). The 
solution was warmed to 60 °C and stirred overnight, before cooling and the addition of acetic acid 
(5.0 mL) and the solution was filtered over Celite®. The filtrate was concentrated in vacuo, before 
being washed with sat. aq. NaHCO3 (3 x 50 mL). The combined aqueous extracts were acidified to 
pH 1 with 1 M aq. HCl, and the aqueous phase was extracted with Et2O (3 x 50 mL). The organic 
extracts were dried (Na2SO4), filtered and concentrated in vacuo to afford title compound 1.211 (3.7 
g, 74%). No further purification was required. Analytical data observed were in accordance with 
literature values.[109] 
 
N-tosyl-2-vinyl benzamide 1.212 
To a solution of 2-vinyl benzoic acid 1.211 (1.6 g, 11 mmol) and p-tosyl isocyanate 
(3.4 mL, 22 mmol) in THF (25 mL) was added triethylamine (3.0 mL, 22 mmol) at 
room temperature, with the release of gas. The solution was stirred for 4 h, before the 
reaction was diluted with EtOAc (20 mL). The organic phase was washed with 1 M 
aq. HCl (40 mL), and the aqueous extracted with EtOAc (3 x 20 mL). The organic extracts were 
dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by column 
chromatography (CH2Cl2) to yield the title compound 1.212 (0.93 g, 28%). 1H NMR (400 MHz, 
CDCl3) δ 8.47 (1H, brs, NH), 8.02 (2H, d, J = 8.3 Hz, Ts-H), 7.52–7.27 (6H, m, Ar-H & Ts-H), 6.87 
(1H, dd, J = 17.4, 11.0 Hz, ArCHCH2), 5.64 (1H, d, J = 17.4 Hz, CH2-Ha), 5.36 (1H, d, J = 11.0 Hz, 
CH2-Hb), 2.45 (3H, s, Ts-CH3); 13C NMR (125 MHz, CDCl3) δ 165.8 (C), 145.5 (C), 137.2 (C), 135.5 
(C), 134.0 (CH), 132.2 (CH), 131.4 (C), 129.8 (CH), 128.8 (CH), 128.12 (CH), 128.09 (CH), 127.5 
(CH), 119.0 (CH2), 21.9 (CH3); IR (thin film); 3217, 1724, 1342; HRMS (EI+) exact mass calculated 
for C16H15NO3S [M]+ m/z 301.0773; found m/z 301.0769. 
 
 
2-(2-vinylphenyl)acetic acid 1.217 
 To a 2.0 mL microwave vial, equipped with stirrer, was added 2-(2-
bromophenyl)acetic acid 1.216 (0.050 g, 0.23 mmol), potassium vinyltrifluoroborate 
(0.027 g, 0.23 mmol), isopropanol (0.90 mL) triethylamine (0.11 mL, 0.81 mmol) and 
118 
 
Pd(dppf)Cl2 (9.0 mg, 0.011 mmol). The vial was sealed and the reaction was stirred at room 
temperature until homogeneous. The reaction mixture was subsequently heated to 130 °C for 5 
minutes. The resultant mixture was diluted with H2O (1.0 mL) and Et2O (1.0 mL). The organic phase 
was extracted with Et2O (3 x 1.0 mL). The aqueous phase was acidified to pH 1 with 1 M aq. HCl, 
followed by extraction of the organic phase by Et2O (3 x 2.0 mL). The combined organic extracts 
were dried (Na2SO4), filtered and concentrated in vacuo to afford title compound 1.217. The crude 
material was used directly in the following step. 
 
N-tosyl-2-(2-vinylphenyl)acetamide 1.218 
 To a solution of 2-(2-vinylphenyl)acetic acid 1.217 (0.050 g, 0.31 mmol) in THF 
(3.0 mL) was added p-tosyl isocyanate (0.063 mL, 0.34 mmol). The resultant 
solution was stirred at room temperature for 10 min, before the addition of 
triethylamine (0.050 mL, 0.34 mmol), with the release of gas. The solution was 
stirred for 4 h, before quenching with 2 M aq. HCl (5.0 mL). The aqueous mixture was extracted 
with EtOAc (3 x 5.0 mL). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography (CH2Cl2) to afford 
title compound 1.218 as a colourless oil (0.058 g, 56%). 1H NMR (500 MHz, CDCl3) δ 8.22 (1H, 
brs, NH), 7.92 – 7.80 (3H, m, Ts-H & Ar-H), 7.49 (1H, d, J = 7.6 Hz, Ar-H), 7.33 – 7.22 (3H, m, Ts-
H & Ar-H), 7.11 (1H, d, J = 7.6 Hz, Ar-H), 6.63 (1H, dd, J = 17.2, 11.0 Hz, CH=CH2), 5.58 (1H, dd, 
J = 17.2, 1.2 Hz, CH=CHa), 5.21 (1H, dd, J = 11.0, 1.2 Hz, CH=CHb), 3.64 (2H, s, ArCH2), 2.43 
(3H, s, Ts-CH3); 13C NMR (100 MHz, CDCl3) δ 168.4 (C), 145.3 (C), 137.8 (C), 135.3 (C), 133.4 
(CH), 131.0 (CH), 129.8 (C), 129.6 (CH), 128.9 (CH), 128.8 (CH), 127.0 (CH), 126.6 (CH), 118.1 
(CH2), 41.9 (CH2), 21.8 (CH3); IR (thin film) 1703, 1439, 1169; HRMS (EI+) exact mass calculated 
for C17H17NO3S [M]+ m/z 315.0929; found m/z 315.0931. 
 
 
N-tosyl-pent-4-enamide 1.68 
Following a reported procedure,[34] to a solution of 4-pentenoic acid 1.221 (0.20 mL, 2.1 
mmol) and p-tosyl isocyanate (0.31 mL, 2.1 mmol) in THF (6.0 mL) was added dropwise 
triethylamine (0.29 mL, 2.1 mmol), with the release of gas. After 1 h, the mixture was 
diluted with EtOAc (10 mL) and washed with 2 M aq. HCl (10 mL) and brine (10 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. The crude product was dissolved in Et2O to obtain 
a saturated solution and petroleum ether was added to precipitate the title product 1.68 (0.36 g, 70%) 
as a colourless crystalline solid. Analytical data observed were in accordance with literature 
values.[34] 
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N-tosyl-hex-5-enamide 1.225 
Following a reported procedure,[34] to a solution of 5-hexenoic acid 1.224 (0.11 mL, 1.0 
mmol) and p-tosyl isocyanate (0.25 mL, 1.0 mmol) in THF (5.0 mL) was added dropwise 
triethylamine (0.074 mL, 1.0 mmol), with the release of gas. After 1 h, the mixture was 
diluted with EtOAc (10 mL) and washed with 2 M aq. HCl (5 mL) and brine (5 mL), dried (Na2SO4), 
filtered and concentrated in vacuo. The crude product was dissolved in Et2O to obtain a saturated 
solution and petroleum ether was added to precipitate title compound 1.225 (89 mg, 35%) as a 
colourless crystalline solid. Analytical data observed were in accordance with literature values.[34] 
 
 
2,2-dimethylpent-4-enoic acid 1.229 
Following a reported procedure,[34] to a suspension of NaH (0.15 g, 6.2 mmol) and 
diisopropylamine (0.93 mL, 6.6 mmol) in THF (10 mL) was added dropwise isobutyric 
acid 1.228 (0.50 mL, 5.5 mmol) The resulting suspension was heated at reflux for 1 h, 
then cooled to 0 °C, followed by dropwise addition n-butyllithium (2.2 M solution in 
hexanes, 2.8 mL, 6.1 mmol). The resulting solution was stirred at 0 °C for 15 min, and at room 
temperature for 1 h, before being re-cooled to 0 °C and allyl bromide (0.48 mL, 5.5 mmol) was added 
dropwise to give an off-white suspension which was stirred at 0 °C for 1 h and at room temperature 
overnight. The suspension was quenched with water (20 mL) at 0 °C and the organic layer washed 
with 1 M aq. NaOH (3 x 20 mL). The combined aqueous extracts were acidified to pH 1 with 1M 
aq. HCl and extracted with Et2O (3 x 20 mL). The organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc/AcOH 95:5:0.5) to afford title compound 1.229 (0.33 g, 47 %) as a colourless oil. 
Material was used directly in the following step. 
 
2,2-dimethyl-N-tosylpent-4-enamide 1.230 
To a solution of 2,2-dimethylpent-4-enoic acid 1.229 (0.33 g, 2.6 mmol) and p-tosyl 
isocyanate (0.81 mL, 5.2 mmol) in THF (6.0 mL) was added dropwise triethylamine 
(0.40 mL, 2.9  mmol) with the release of gas. The mixture was stirred at room 
temperature for 4 hours, before dilution with EtOAc (20 mL). The organic phase was 
washed with 2 M aq. HCl (20 mL) and brine (20 mL), dried (Na2SO4), filtered and concentrated in 
vacuo. The crude product was purified by flash chromatography (CH2Cl2/AcOH 100/0.5) to afford 
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title compound 1.230 (0.19 g, 27%) as a colourless solid. Analytical data observed were in 
accordance with literature values.[34]  
 
 
1-allylcyclohexanecarboxylic acid 1.236 
Following a reported procedure,[34] to a solution of diisopropylamine (1.4 mL, 9.8 
mmol) in THF (6.0 mL) was added dropwise a solution of n-butyllithium in hexanes 
(2.2 M, 4.5 mL, 9.8 mmol) at –78 °C. The mixture was warmed to 0 °C and stirred for 
10 min, before the dropwise addition of a solution of cyclohexanecarboxylic acid 1.235 
(0.50 g, 3.9 mmol) in THF (4.0 mL). The resulting mixture was stirred at room temperature for 40 
min, warmed to reflux for 50 min, before cooling to 0 °C and dropwise addition of allyl bromide 
(0.84 mL, 9.8 mmol). The resulting pale yellow solution was stirred overnight at room temperature. 
The reaction was quenched by addition of sat. aq. NH4Cl (30 mL). The aqueous layer was separated, 
acidified to pH 1 with 2 M aq. HCl and extracted with Et2O (3 x 20 mL). The organic extracts were 
dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (CH2Cl2/EtOAc/AcOH 95:4.5:0.5 to 90:9.5:0.5) to afford title compound 1.236 
(0.19 g, 30%) as a colourless oil. 
 
1-allyl-N-tosylcyclohexanecarboxamide 1.237 
To a solution of 1-allylcyclohexanecarboxylic acid 1.236 (0.19 g, 1.2 mmol) and p-
tosyl isocyanate (0.35 mL, 2.3 mmol) in THF (2.5 mL) was added dropwise 
triethylamine (0.18 mL, 1.3 mmol) with the release of gas. The mixture was stirred at 
room temperature for 4 hours, before dilution with EtOAc (10 mL). The organic phase 
was washed with 2 M aq. HCl (10 mL) and brine (10 mL), dried (Na2SO4), filtered and concentrated 
in vacuo. The crude product was purified by flash chromatography (CH2Cl2/EtOAc/AcOH 99.5:0:0.5 
to 95:4.5:0.5) to afford title compound 1.237 (0.27 g, 72%) as a colourless solid. Analytical data 
observed were in accordance with literature values.[34]  
 
 
2,2-dimethylhex-5-enoic acid 1.241 
 To a suspension of NaH (0.15 g, 6.2 mmol) and diisopropylamine (0.93 mL, 6.6 mmol) 
in THF (10 mL) was added dropwise isobutyric acid 1.228 (0.50 mL, 5.5 mmol) The 
resulting suspension was heated at reflux for 1 h, then cooled to 0 °C, followed by 
dropwise addition of a solution of n-butyllithium in hexanes (2.3 M, 2.6 mL, 6.1 mmol). The resulting 
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solution was stirred at 0 °C for 15 min, and at room temperature for 1 h, before being re-cooled to 0 
°C and homoallyl bromide (0.56 mL, 5.5 mmol) was added dropwise to give an off-white suspension 
which was stirred at 0 °C for 1 h and at room temperature overnight. The suspension was quenched 
with water (20 mL) at 0 °C and the organic layer washed with 1 M aq. NaOH (3 x 20 mL). The 
combined aqueous extracts were acidified to pH 1 with 1 M aq. HCl and extracted with Et2O (3 x 20 
mL). The organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The crude 
product was purified by flash chromatography (petroleum ether/EtOAc/AcOH 95:4.5:0.5) to afford 
title compound 1.241 (0.45 g, 58%) as a colourless oil. Analytical data observed were in accordance 
with literature values.[110] 
 
2,2-dimethyl-N-tosylhex-5-enamide 1.242 
To a solution of 2,2-dimethylhex-5-enoic acid 1.241 (0.12 g, 0.86 mmol) and p-tosyl 
isocyanate (0.15 mL, 0.95 mmol) in THF (4.0 mL) was added dropwise triethylamine 
(0.13 mL, 0.95 mmol) with the release of gas. The mixture was stirred at room 
temperature for 4 h, before dilution with EtOAc (10 mL) and sat. aq. NH4Cl (10 mL). 
The aqueous phase was extracted with EtOAc (2 x 10 mL), and the combined organics were basified 
with sat. aq. K2CO3 (30 mL). The aqueous was extracted with EtOAc (2 x 10 mL), and acidified to 
pH 1 with 1 M aq. HCl. The aqueous phase was extracted with EtOAc (3 x 10 mL), and the organic 
extracts were dried ((Na2SO4), filtered and concentrated in vacuo to afford title compound 1.242 
(0.18 g, 71%) as a colourless solid. 1H NMR (500 MHz, CDCl3) δ 8.77 (1H, brs, NH), 7.94 (2H, d, 
J = 8.3 Hz, Ts-H), 7.34 (2H, d, J = 8.1 Hz, Ts-H), 5.63 (1H, ddt, J = 17.0, 10.2, 6.5 Hz, 5-CH), 4.90 
– 4.84 (2H, m, 6-CH2), 2.44 (3H, s, Ts-CH3), 1.80 – 1.77 (2H, m, 4-CH2), 1.55 – 1.51 (2H, m, 3-
CH2), 1.13 (6H, s, (CH3)2); 13C NMR (125 MHz, CDCl3) δ 175.5 (C), 145.2 (C), 137.7 (CH), 135.6 
(C), 129.7 (CH), 128.5 (CH), 115.0 (CH2), 43.4 (C), 39.8 (CH2), 28.9 (CH2), 24.7 (CH3), 21.8 (CH3); 
IR (thin film) 3263, 1717, 1410; HRMS (CI/Isobutane) exact mass calculated for C15H22NO3S 
[M+H]+ m/z 296.1320; found m/z 296.1316. 
 
 
2-allyl-dimethylmalonate 1.246 
 To a suspension of sodium hydride (60% dispersion in mineral oil, 0.26 g, 6.5 
mmol) in THF (70 mL) was added dropwise dimethylmalonate 1.245 (1.0 mL, 8.7 
mmol) at 0 °C. Once effervescence had ceased, allyl chloride (0.40 mL, 4.8 mmol) 
was added dropwise. The mixture was warmed to room temperature and stirred for 2 h, before 
warming to reflux for 18 h. The reaction mixture was subsequently cooled to room temperature and 
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quenched by the addition of H2O (50 mL). The mixture was extracted with Et2O (3 x 50 mL). The 
combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The crude 
material was used directly in the following step.  
 
2-allyl-dimethylmalonic acid 1.247 
To a solution of 2-allyldimethylmalonate 1.246 (4.8 mmol) in ethanol (15 mL) was 
added 1 M aq. NaOH (15 mL). The mixture was stirred at room temperature for 24 h. 
The ethanol was subsequently removed in vacuo, and the resultant aqueous solution 
was extracted with Et2O (3 x 15 mL). The aqueous solution was subsequently acidified to pH1 with 
1 M aq. HCl and was extracted with Et2O (3 x 15 mL). The combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo to yield the title compound 1.247 as a white powdered 
solid (0.17 g, 25% over 2 steps). Analytical data observed were in accordance with literature 
values.[111] 
 
2-allyl-N,N’-di-tosyl-malonamide 1.248 
To a solution of 2-allyl malonic acid 1.247 (0.17 g, 1.1 mmol) in THF (10 mL) was 
added p-tosyl isocyanate (0.38 mL, 2.5 mmol). The resultant solution was stirred 
at room temperature for 10 min, before the addition of triethylamine (0.35 mL, 2.5 
mmol), with the release of gas. The solution was stirred for 16 h, before quenching 
with 2 M aq. HCl (10 mL). The aqueous mixture was extracted with EtOAc (3 x 10 mL). The 
combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The crude 
product was purified by flash chromatography (petroleum ether:EtOAc, 4:1) to yield title compound 
1.248 as a colourless oil (0.35 g, 70%). 1H NMR (400 MHz, CDCl3) 7.87 (4H, d, J = 8.3 Hz, Ts-H), 
7.28 (4H, d, J = 8.2 Hz, Ts-H), 5.40 (1H, ddt, J = 17.1, 10.0, 7.1 Hz, 2’-CH), 4.78 (1H, d, J = 10.1 
Hz, 3’-CHb), 4.73 (1H, d, J = 17.1 Hz, 3’-CHa), 3.26 (1H, t, J = 7.0 Hz, 2-CH), 2.45-2.40 (8H, m, 
Ts-CH3 & 1’-CH2); 13C NMR (100 MHz, CDCl3) δ 167.9 (C), 145.5 (C), 135.2 (C), 131.7 (CH), 
129.8 (CH), 128.6 (CH), 119.6 (CH2), 53.7 (CH), 35.7 (CH2), 21.8 (CH3); IR (thin film) 1713, 1437, 
1155; HRMS (ESI positive) exact mass calculated for C20H22N2O6S2Na [M+Na]+ m/z 473.0811; 
found m/z 473.0810. 
 
 
1-phenyl-3-butenol 1.252 
To a stirred solution of benzaldehyde 1.251 (1.0 mL, 9.8 mmol) in Et2O (10 mL) at 
0 °C was added allyl magnesium bromide (1.0 M solution in hexanes, 15 mL, 15 
mmol). The reaction was warmed to room temperature over 1 h, and subsequently 
stirred at room temperature for 20 h. The reaction mixture was quenched by the addition of 2% aq. 
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NH4Cl (60 mL). The mixture was extracted with Et2O (3 x 50 mL). The combined organic extracted 
were dried (Na2SO4), filtered and concentrated in vacuo. The crude material was purified by column 
chromatography (petroleum ether:EtOAc, 19:1) to afford title compound 1.252 as a colourless oil 
(1.2 g, 85%). Analytical data observed were in accordance with literature values.[112] 
 
1-phenyl-3-butenyltosylcarbamate 1.253 
To a solution of 1-phenyl-3-butenol 1.252 (0.50 g, 3.4 mmol) in CH2Cl2 (7.0 mL) 
was added dropwise p-tosyl isocyanate (0.53 mL, 3.4 mmol) at 0 °C. The reaction 
mixture was warmed to room temperature, and stirred for 1.5 h. The reaction mixture 
was concentrated in vacuo, and the subsequent oil was diluted with EtOAc (20 mL) 
and H2O (20 mL). The organic phase was extracted with EtOAc (3 x 20 mL). The combined organic 
extracts were dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (CH2Cl2/AcOH, 99.5:0.5) to afford title compound 1.253 as a colourless oil 
(0.54 g, 46%). Analytical data observed were in accordance with literature values.[113] 
 
 
2-isopropenyl-N-tosyl benzamide 1.256 
To a solution of 2-isopropenylbenzoic acid 1.174 (0.50 g, 4.1 mmol) in THF (13 mL) 
was added p-tosyl isocyanate (0.63 mL, 4.1 mmol). The solution was stirred at room 
temperature for 10 min, before the dropwise addition of triethylamine (0.57 mL, 4.1 
mmol), with the release of gas. The resulting solution was stirred at room temperature 
for 2 h, and quenched with 1 M aq. HCl (15 mL). The aqueous phase was extracted with EtOAc (3 
x 15 mL) and the combined organic extracts dried (Na2SO4), filtered and concentrated in vacuo. The 
crude material was purified by flash chromatography (petroleum ether/CH2Cl2 1:1) to afford title 
compound 1.256 (0.66 g, 51%) as a white amorphous solid. 1H NMR (500 MHz, CDCl3) δ 8.79 (1H, 
brs, NH), 8.02 (2H, d, J = 8.3 Hz, Ts-H), 7.70 (1H, d, J = 7.7 Hz, Ar-H), 7.46 (1H, td, J = 7.5, 1.3 
Hz, Ar-H), 7.37 – 7.32 (3H, m, Ar-H), 7.21 (1H, dd, J = 7.6, 0.8 Hz, Ar-H), 5.32 (1H, s, ArCCH2-
H), 5.08 (1H, s, ArCCH2-H), 2.45 (3H, s, Ts-CH3), 1.97 (3H, s, ArCCH3); 13C NMR (125 MHz, 
CDCl3) δ 166.2 (C), 146.0 (C), 145.0 (C), 142.7 (C), 136.1 (C), 132.1 (CH), 129.6 (C), 129.5 (CH), 
129.2 (CH), 128.78 (CH), 128.76 (CH), 127.9 (CH), 117.4 (CH2), 24.6 (CH3), 21.7 (CH3); IR (thin 
film) 3217, 1722, 1342; HRMS (CI/Isobutane) exact mass calculated for C17H17NO3S [M]+ m/z 
315.0929; found m/z 315.0930.  
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Methyl-2-(2-methylallyl) Benzoate 1.259 
Following a modification of a reported procedure,[34] to a mixture of magnesium 
turnings (0.22 g, 9.2 mmol) and a crystal of iodine in THF (15 mL) was added dropwise 
1-bromo-n-butane (0.82 mL, 7.6 mmol). The mixture was stirred for 15 minutes then 
cooled to –40 °C before dropwise addition of a solution of methyl-2-iodobenzoate 
1.194 (1.0 g, 3.8 mmol) in THF (30 mL). The mixture was stirred at –40 °C for 1.5 h. A freshly 
prepared solution of LiCl (0.39 g, 9.1 mmol) and CuCN (0.39 g, 4.5 mmol) in THF (20 mL) was 
added and the mixture was stirred for a further 15 min, followed by the addition of 3-chloro-2-
methyl-1-propene (1.5 mL, 15 mmol). The mixture was stirrer at –40 °C for a further 10 min, then 
warmed to room temperature. The mixture was diluted with EtOAc (20 mL) and filtered over 
Celite®. The filtrate was washed with 25% aq. NH4OH (20 mL). The aqueous layer was further 
extracted with EtOAc (2 x 20 mL), and the combined organic extracts washed with brine (20 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (petroleum 
ether/EtOAc, 9:1), afforded title compound 1.259 as a colourless oil (0.65 g, 89 %). Material was 
used directly in the subsequent step. 
 
2-(2-methylallyl) benzoic acid 1.285 
Methyl-2-(2-methylallyl) benzoate 1.259 (0.65 g, 3.4 mmol) was dissolved in EtOH 
(7.5 mL), and 2 M aq. NaOH (5.0 mL) added. The mixture was heated to reflux for 4 h, 
cooled to room temperature, and EtOH was removed in vacuo. The residue was 
extracted with Et2O (2 x 20 mL), acidified to pH 3 with 2M aq. HCl and extracted with 
EtOAc (3 x 20 mL). The combined organics were dried (Na2SO4), filtered and concentrated in vacuo 
to afford title compound 1.285 as a colourless solid (0.48 g, 80%), which was used directly without 
further purification. 
 
2-(2-methylallyl)-N-tosyl-benzamide 1.260 
To a solution of 2-(2-methylallyl)-benzoic acid 1.285 (0.48 g, 2.7 mmol) in THF (30 
mL) was added p-tosyl isocyanate (0.96 mL, 6.3 mmol). The resulting solution was 
stirred for 10 min then triethylamine (0.81 mL, 6.3 mmol) added dropwise. Gas 
evolution was observed on addition. After 4 h, the mixture was diluted with EtOAc 
(30 mL) and washed with 2 M aq. HCl (30 mL) and brine (30 mL). The organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. The crude product was purified by column 
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chromatography (CH2Cl2) to afford title compound 1.260 as a colourless solid (0.83 g, 93%). 1H 
NMR (500 MHz, CDCl3) δ 8.54 (1H, brs, NH), 8.00 (2H, d, J = 8.3 Hz, Ts-H), 7.49–7.48 (1H, m, 
Ar-H), 7.44–7.41 (1H, m, Ar-H), 7.36 (2H, d, J = 8.3 Hz, Ts-H), 7.30–7.27 (1H, m, Ar-H), 7.20–
7.19 (1H, m, Ar-H), 4.80 (1H, s, 4-CH), 4.28 (1H, s, 4-CH), 3.39 (2H, s, 1-CH2), 2.46 (3H, s, Ts-
CH3), 1.72 (3H, s, 3-CH3); 13C NMR (125 MHz, CDCl3) δ 166.2 (C), 146.5 (C), 145.3 (C), 137.9 
(C), 135.6 (C), 133.4 (C), 131.92 (CH), 131.90 (CH), 129.7 (CH), 128.8 (CH), 128.6 (CH), 127.1 
(CH), 112.9 (CH2), 41.4 (CH2), 23.1 (CH3), 21.8 (CH3); IR (thin film) 3217, 2922, 1724, 1595; 
HRMS (CI/Isobutane) exact mass calculated for C18H20NO3S [M+H]+ m/z 330.1164; found m/z 
330.1158. 
 
 
N-Boc-2-isopropenylbenzamide 1.265 
To a solution of 2-isopropenyl benzoic acid 1.174 (0.20 g, 1.2 mmol) and tert-
butylcarbamate (0.15 g, 1.2 mmol) in DMF (10 mL) was added dropwise 
phenylsilane (0.72 mL, 3.7 mmol). The solution was stirred for 5 h, and quenched 
with water and diluted with EtOAc (15 mL). The organic phase was washed with 
water (4 x 10 mL) and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude 
product was purified by flash chromatography (CH2Cl2) to yield title compound 1.265 (0.23 g, 71%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 7.94 (1H, dd, J = 7.8, 1.1 Hz, Ar-H), 7.49 (1H, td, 
J = 7.6, 1.4 Hz, Ar-H), 7.35 (1H, td, J = 7.7, 1.4 Hz, Ar-H), 7.26 (1H, dd, J = 7.6, 1.2 Hz, Ar-H) 5.13 
(1H, s, C=CH), 4.90 (1H, s, C=CH), 4.77 (1H, brs, NH), 2.12 (3H, s, CH3), 1.46 (9H, s, Boc-(CH3)3); 
13C NMR (125 MHz, CDCl3) δ 172.7 (C), 157.8 (C), 146.8 (C), 146.2 (C), 132.5 (CH), 130.8 (CH), 
129.8 (CH), 128.5 (C), 127.1 (CH), 114.0 (CH2), 80.4 (C), 28.4 (CH3), 24.4 (CH3); IR (thin film) 
3219, 1722, 1595; HRMS (ESI positive) exact mass calculated for C10H10O2Na (hydrolysis product) 
[M(hydrolysis) + Na]+ m/z 185.0578; found m/z 185.0582 
 
 
2-allyl-N-Boc-benzamide 1.270 
To a solution of 2-allyl benzoic acid 1.269 (0.20 g, 1.2 mmol) and tert-butyl 
carbamate (0.15 g, 1.2 mmol) in DMF (10 mL) was added dropwise phenylsilane 
(0.46 mL, 3.7 mmol). The mixture was stirred at room temperature for 5 h, before 
addition of water (20 mL) and EtOAc (30 mL). The organic phase was extracted with water (4 x 20 
mL) and brine (1 x 20 mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude product 
126 
 
was purified by column chromatography (CH2Cl2) to afford title compound 1.270 as a colourless oil 
(0.27 g, 83%). 1H NMR (400 MHz, CDCl3) δ 11.46 (1H, brs, NH), 8.06 – 8.03 (1H, m, Ar-H), 7.48 
(1H, td, J = 7.5 Hz, 1.5 Hz, Ar-H), 7.32 – 7.28 (2H, m, Ar-H), 6.06 (1H, ddt, J = 17.7, 9.4, 6.5 Hz, 
ArCH2CHCH2), 5.08 – 5.03 (2H, m, ArCH2CHCH2), 5.84 (2H, d, J = 6.6 Hz, ArCH2CHCH2), 1.48 
(9H, s, Boc-(CH3)3); 13C NMR (100 MHz, CDCl3) δ 172.3 (C), 158.0 (C), 142.5 (C), 137.5 (CH), 
132.7 (CH), 131.5 (CH), 131.1 (CH), 129.2 (C), 126.3 (CH), 115.7 (CH2), 80.4 (C), 38.5 (CH2), 28.4 
(CH3); IR (thin film) 2926, 1695, 1394; LRMS (EI+) mass calculated for C10H12NO [M–C5H8O2]+ 
[114] m/z 161.1; found m/z 161.1. 
 
 
2-isopropenylbenzamide 1.274 
To a solution of isopropenylbenzoic acid 1.174 (0.10 g, 0.62 mmol) in DMF (2.0 mL) 
was added CDI (0.11 g, 0.68 mmol) at room temperature. The mixture was heated to 
60 °C and stirred for 2 h, before addition to a stirred solution of sat. aq. NH4Cl (2.0 
mL). The resultant mixture was stirred for a further 30 mins, before dilution with CHCl3 
(5 mL). The reaction mixture was washed with water (5 x 2 mL) and brine (2 mL). The organic phase 
was dried (Na2SO4), filtered and concentrated in vacuo. The crude material was used directly in the 
subsequent reactions. 
 
2-isopropenyl-N-mesylbenzamide 1.272 
To a solution of 2-isopropenylbenzamide 1.274 (0.20 g, 1.2 mmol) in THF (15 mL) 
was added LiHMDS (1.0 M in THF, 3.7 mL, 3.7 mmol). The mixture was stirred at 
room temperature for 15 min before the addition of mesyl chloride (0.20 mL, 2.5 
mmol) The resultant mixture was stirred at room temperature for 3 h, before quenching 
by addition of H2O (15 mL). The aqueous mixture was acidified to pH 3 with 1 M aq. HCl, and 
extracted by Et2O (3 x 15 mL). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. The crude mixture was purified by flash chromatography (CH2Cl2 + 0.5% 
AcOH) to yield title compound 1.272 as a colourless oil (0.22 g, 72%). 1H NMR (500 MHz, CDCl3) 
δ 8.69 (1H, brs, NH) 7.82 (1H, dd, J = 7.5, 1.0 Hz, Ar-H), 7.52 (1H, td, J = 7.5, 1.0 Hz, Ar-H), 7.41 
(1H, td, 7.5, 1.0 Hz, Ar-H), 7.28 – 7.26 (1H, m, Ar-H), 5.42 (1H, s, Ar-C(CH3)CH2), 5.28 (1H, s, Ar-
C(CH3)CH2), 3.38 (3H, s, Ms-CH3), 2.16 (3H, s, Ar-C(CH3)CH2); 13C NMR (125 MHz, CDCl3) δ 
166.7 (C), 146.2 (C), 142.9 (C), 132.8 (CH), 130.0 (C), 129.8 (CH), 129.5 (CH), 128.2 (CH), 118.0 
(CH2), 41.8 (CH3), 25.0 (CH3); IR (thin film) 3192, 2539, 1695, 1340; HRMS (EI+) exact mass 
calculated for C11H14NO3S [M+H]+ m/z 240.0694; found m/z 240.0693.  
 
127 
 
 
5-hexenamide 1.281 
To a solution of 5-hexenoic acid 1.224 (1.0 mL, 8.4 mmol) in CHCl3 (20 mL) was added 
thionyl chloride (0.73 mL, 10 mmol). The reaction mixture was heated to reflux for 2 h, 
before quenching by addition to a stirred solution of sat. aq. NH4Cl (20 mL) at 0 °C. The 
organic phase was extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo to yield title compound 1.281 as a colourless oil. The 
crude material was used directly in the following step. 
 
N-mesyl-hex-5-enamide 1.282 
5-hexenamide 1.281 (0.26 g, 2.3 mmol) was dissolved in THF (30 mL) and a LiHMDS 
(1.0 M solution in THF, 6.9 mL, 6.9 mmol) was added dropwise. The solution was stirred 
for 15 min, before the addition of mesyl chloride (0.36 mL, 4.6 mmol). The solution was 
stirred at room temperature for 5 h, before quenching with water (20 mL). The aqueous 
phase was acidified to pH 3 with 1 M aq. HCl, and extracted with Et2O (3 x 30 mL). The organic 
extracts were dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (CH2Cl2:Acetic acid 99/1) to afford title compound 1.282 (90 mg, 16%) as 
a white powdered solid. 1H NMR (500 MHz, CDCl3) δ 8.14 (1H, brs, NH), 5.76 (1H, ddt, J = 17.1, 
10.2, 6.8 Hz, 5-CH), 5.07 – 5.01 (2H, m, 6-CH2), 3.31 (3H, s, Ms-CH3), 2.34 (2H, t, J = 7.4 Hz, 2-
CH2), 2.12 (2H, td, J = 14.4,  6.9 Hz, 4-CH2), 1.78 (2H, tt, J = 14.7, 7.4 Hz, 3-CH2); 13C NMR (125 
MHz, CDCl3) δ 171.7 (C), 137.3 (CH), 116.2 (CH2), 41.8 (CH3), 35.7 (CH2), 32.8 (CH2), 23.4 (CH2); 
IR (thin film) 3218, 1716, 1442; HRMS (EI+) exact mass calculated for C7H13NO3S [M]+ m/z 
191.0616; found m/z 191.0616. 
 
 
 
2-isopropenyl-N-methoxybenzamide 1.292 
To a solution of 2-isopropenylbenzoic acid 1.174 (0.20 g, 1.2 mmol) in THF (5.0 
mL) was added HOBT (0.20 g, 1.5 mmol), EDC (0.29 g, 1.5 mmol), and O-
methylhydroxylamine hydrochloride (0.13 g, 1.5 mmol). The reaction was stirred at 
room temperature for 5 min, before addition of iPr2NEt (0.26 mL, 1.5 mmol). The 
reaction was stirred at room temperature for 16 h. The resultant mixture was diluted with H2O (10 
mL), and the aqueous mixture was extracted with Et2O (3 x 10 mL). The combined organic extracts 
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were dried (Na2SO4), filtered and concentrated in vacuo. The crude mixture was purified by flash 
chromatography (Petroleum ether/EtOAc, 1:1) to afford title compound 1.292 as an amorphous solid 
(0.22 g, 92%). 1H NMR (500 MHz, CDCl3) δ 8.71 (1H, s, NH), 7.60 (1H, d, J = 7.6 Hz, Ar-H), 7.41 
(1H, td, J = 7.6, 1.4 Hz, Ar-H), 7.32 (1H, td, J = 7.6, 1.3 Hz, Ar-H), 7.23 (1H, d, J = 7.6 Hz, Ar-H), 
5.25 (1H, s, C=CH), 5.09 (1H, s, C=CH), 3.85 (3H, s, NOCH3), 2.10 (3H, s, CCH3); 13C NMR (125 
MHz, CDCl3) δ 167.6 (C), 145.8 (C), 142.1 (C), 131.0 (CH & C), 129.0 (CH), 128.8 (CH), 127.7 
(CH), 116.7 (CH2), 64.4 (CH3), 24.4 (CH3); IR (thin film) 1640, 1508, 1300; HRMS (ESI positive) 
exact mass calculated for C11H13NO2Na [M+Na]+ m/z 214.0838; found m/z 214.0848. 
 
 
N-(benzyloxy)-2-isopropenyl benzoic acid 1.65 
To a solution of 2-isopropenyl benzoic acid 1.174 (0.16 g, 1.0 mmol) and O-benzyl 
hydroxylamine hydrochloride (0.16 g, 1.0 mmol) in CH2Cl2 (5.0 mL) was added 
triethylamine (0.15 mL, 1.1 mmol) and DCC (0.25 g, 1.2 mmol). The mixture was 
stirred at room temperature for 16 h, before concentration in vacuo. The filtrate was 
washed with sat. aq. NH4Cl (10 mL), and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). 
The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (Petroleum ether/EtOAc, 3:2) to afford title 
compound 1.65 as an amorphous solid (0.083 g, 30%). 1H NMR (500 MHz, CDCl3) 8.63 (1H, brs, 
NH), 7.55 (1H, d, J = 7.3 Hz, Ar-H), 7.42 – 7.28 (7H, m, Ar-H), 7.19 (1H, d, J = 7.5 Hz, Ar-H), 5.12 
(1H, s, C=CHa), 5.02 (2H, s, OCH2Ph), 4.99 (1H, s, C=CHb), 2.01 (3H, s, CCH3); 13C NMR (125 
MHz, CDCl3) δ 167.3 (C), 145.6 (C), 142.2 (C), 135.5 (C), 131.1 (C), 130.9 (CH), 129.1 (CH), 128.9 
(CH), 128.8 (CH), 128.6 (2 x CH), 127.5 (CH), 116.5 (CH2), 78.2 (CH2), 24.3 (CH3); IR (thin film) 
3221, 1646, 1497; HRMS (ESI positive) exact mass calculated for C17H17NO2Na [M+Na]+ m/z 
290.1151; found m/z 290.1159. Analytical data observed were in accordance with literature values.[33] 
 
 
2-(2-methylallyl)-N-methoxy-benzamide 1.309 
To a solution of 2-(2-methylallyl)benzoic acid 1.285 (0.65 g, 3.7 mmol) in CH2Cl2 
(10 mL) was added T3P (50% w/v in EtOAc, 6.6 mL, 11 mmol). The mixture was 
stirred at room temperature for 1 h, before the addition of O-methylhydroxylamine 
hydrochloride (0.50 g, 7.4 mmol) and iPr2NEt (1.3 mL, 7.4 mmol). The mixture was 
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stirred at room temperature for 24 h, before being concentrated in vacuo. The crude product was 
purified by flash chromatography (Petroleum Ether:EtOAc 7:3) to afford title compound 1.309 as a 
white powdered solid (0.51 g, 67%). 1H NMR (500 MHz, CDCl3) δ 8.82 (1H, brs, NH), 7.38 – 7.34 
(2H, m, Ar-H), 7.23 – 7.20 (2H, m, Ar-H), 4.84 (1H, s, C=CHa), 4.49 (1H, s, C=CHb), 3.81 (3H, s, 
NOCH3), 3.46 (2H, s, ArCH2), 1.73 (3H, s, CCH3); 13C NMR (125 MHz, CDCl3) δ 167.8 (C), 145.8 
(C), 137.9 (C), 133.2 (C), 131.1 (CH), 130.7 (CH), 128.1 (CH), 126.5 (CH), 112.5 (CH2), 64.5 (CH3), 
41.2 (CH2), 22.9 (CH3); IR (thin film) 2363, 1637, 1040; HRMS (ESI positive) exact mass calculated 
for C12H15NO2Na [M+Na]+ m/z 228.0995; found m/z 228.1002. 
 
 
N-methoxy-4-methyl-2,2-dimethylpent-4-enamide 1.312 
To a solution of 2,2-dimethyl-4-methyl-hexenoic acid 1.311[115] (0.12 g, 0.84 
mmol) and O-methyl hydroxylamine hydrochloride (0.060 g, 0.84 mmol) in 
CH2Cl2 (5.0 mL) was added triethylamine (0.14 mL, 1.0 mmol), HOBT (0.14 g, 
1.0 mmol) and DCC (0.21 g, 1.0 mmol). The mixture was stirred at room temperature for 16 h, before 
concentration in vacuo. The filtrate was washed with sat. aq. NH4Cl (10 mL), and the aqueous layer 
was extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (Na2SO4), filtered 
and concentrated in vacuo. The crude material was purified by flash chromatography (Petroleum 
ether:EtOAc, 3:2) to afford title compound 1.312 as an amorphous solid (0.069 g, 49%). 1H NMR 
(400 MHz, CDCl3) δ 8.94 (1H, brs, NH), 4.79 (1H, s, 5-CH), 4.65 (1H, s, 5-CH), 3.70 (3H, s, 
NOCH3), 2.27 (2H, s, 3-CH2), 1.67 (3H, s, 4-CCH3), 1.15 (6H, s, (CH3)2); 13C NMR (100 MHz, 
CDCl3) δ 175.5 (C), 142.4 (C), 114.6 (CH2), 64.0 (CH3), 48.4 (CH2), 41.2 (C), 25.4 (CH3), 23.9 
(CH3); IR (thin film) 1643, 1473, 1054; HRMS (ESI positive) exact mass calculated for C9H17NO2Na 
[M+Na]+ m/z 194.1151; found m/z 194.1155. 
 
 
2-allylbenzonitrile 1.315 
Following a modification of a literature procedure,[100] to a mixture of magnesium 
turnings (20 mg, 0.80 mmol) and a crystal of iodine in THF (0.50 mL) was added 
dropwise 1-bromo-n-butane (0.059 mL, 0.55 mmol). To the resulting mixture was 
added a solution of n-butyllithium (1.8 M in hexanes, 0.60 mL, 1.1 mmol) at 0 °C. The solution was 
stirred for 10 min, before addition of a solution of 2-bromobenzonitrile 1.314 (0.20 g, 1.1 mmol) in 
THF (2.0 mL) at –40 °C and stirring for 30 min, followed by addition of a solution of copper (I) 
cyanide (28 mg, 0.33 mmol) and lithium chloride (28 mg, 0.66 mmol) in THF (0.20 mL), then 
addition of allyl bromide (0.36 mL, 4.1 mmol). After 20 min, the reaction was quenched with sat. aq. 
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NH4Cl (10 mL), and diluted with EtOAc (10 mL). The aqueous layer was extracted with EtOAc (2 
x 10 mL), and the organic extracts washed with brine, dried (Na2SO4), filtered and concentrated in 
vacuo. The crude product was purified by flash chromatography (petroleum ether/EtOAc 9:1) to 
afford title compound 1.315 (89 mg, 56 %) as a colourless oil. Material was used directly in the 
following step. 
 
2-allylbenzylamine 1.316 
To a suspension of LiAlH4 (0.13 g, 4.5 mmol) in Et2O (10 mL) was added dropwise a 
solution of 2-allylbenzonitrile 1.315 (0.20 g, 1.4 mmol) in Et2O (2.0 mL) at 0 °C. After 
being stirred for 2 h, the mixture was re-cooled to 0 °C and sat. aq. potassium sodium 
tartrate (15 mL) added slowly. The biphasic mixture was allowed to stir at room temperature for 16 
h then extracted with Et2O (2 x 20 mL). The organic extracts were washed with water (50 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (EtOAc:NEt3 98:2) to yield title compound 1.316 (0.13 g, 63%) as a colourless oil. 
Analytical data observed were in accordance with literature values.[100] 
 
 
2-allyl-N-tosylbenzylamine 1.317 
To a solution of (2-allylphenyl)methanamine 1.316 (1.3 g, 8.8 mmol) and tosyl 
chloride (1.7 g, 8.8 mmol) in CH2Cl2 (15 mL) was added triethylamine (1.9 mL, 14 
mmol) at room temperature and stirred for 1 h. The reaction mixture was washed with 
water (15 mL) and the organic phase dried (Na2SO4), filtered and concentrated in vacuo. Crude 
product was recrystallised with Et2O to afford title compound 1.317 (2.1 g, 79%) as a colourless 
crystalline solid. Analytical data observed were in accordance with literature values.[116] 
 
 
2-allyl-N-Boc-benzylamine 1.323 
To a solution of (2-allylphenyl)methanamine 1.316 (74 mg, 0.50 mmol) in 1:1 
THF/H2O (3.0 mL) was added a solution of NaHCO3 (0.13 g, 1.5 mmol) and di-tert-
butyl-dicarbonate (0.13 g, 0.60 mmol) in 1:1 THF/H2O (7.0 mL) at 0 °C. The 
solution was warmed to room temperature and stirred overnight, before being diluted with Et2O (10 
mL). The aqueous phase was extracted with Et2O (2 x 10 mL) and the organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (CH2Cl2/petroleum ether 1:1) to afford title compound 1.323 (0.11 g, 86%) as an 
amorphous crystalline solid. 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.18 (4H, m, Ar-H), 5.98 (1H, 
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ddt, J = 17.1, 10.1, 6.2 Hz, ArCH2CHCH2), 5.09 (1H, dd, J = 10.1, 1.5 Hz, CH-Ha), 5.00 (1H, dd, J 
= 17.1, 1.6 Hz, CH-Hb), 4.76 (1H, brs, NH), 4.34 (2H, d, J = 5.5 Hz, ArCH2NHBoc), 3.44 (2H, d, J 
= 6.2 Hz, ArCH2CHCH2), 1.47 (9H, s, Boc-(CH3)3); 13C NMR (125 MHz, CDCl3) δ 155.8 (C), 138.0 
(CH), 137.1 (C), 136.6 (CH), 130.1 (C), 128.7 (CH), 127.8 (CH), 126.8 (CH), 116.1 (CH2), 79.5 (C), 
42.3 (CH2), 37.0 (CH2), 28.5 (CH3); IR (thin film) 3356, 2972, 1682; HRMS (CI/Isobutane) exact 
mass calculated for C15H22NO2 [M+H]+ m/z 248.1651; found m/z 248.1648. 
 
 
2-(2-methylallyl)benzonitrile 1.328 
Following a modification of a literature procedure,[100] to a mixture of magnesium 
turnings (0.076 g, 3.3 mmol) and a crystal of iodine in THF (5.0 mL) was added dropwise 
bromobutane (0.30 mL, 2.8 mmol). To the resulting solution was added a solution of n-
butyllithium (2.1 M in hexanes, 2.6 mL, 5.5 mmol) at 0 °C. The solution was stirred for 
10 min, before addition of a solution of 2-bromobenzonitrile 1.314 (1.0 g, 5.5 mmol) in THF (10 
mL) at –40 °C and stirring for 30 min, followed by addition of a solution of copper (I) cyanide (0.14 
g, 1.7 mmol) and lithium chloride (0.14 g, 3.3 mmol) in THF (10 mL), then addition of 3-chloro-2-
methylpropene (2.0 mL, 19 mmol). After 20 min, the reaction was quenched with sat. aq. NH4Cl (25 
mL), and diluted with EtOAc (25 mL). The aqueous layer was extracted with EtOAc (2 x 25 mL), 
and the organic extracts washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. The 
crude product was purified by flash chromatography (petroleum ether:EtOAc 9:1) to afford title 
compound 1.328 (0.74 g, 85 %) as a colourless oil. Material was used directly in the following step. 
 
2-(2-methylallyl)-benzylamine 1.329 
To a suspension of LiAlH4 (1.6 g, 43 mmol) in Et2O (90 mL) was added dropwise a 
solution of 2-(2-methylallyl)benzonitrile 1.328 (2.1 g, 13 mmol) at 0 °C. After being 
stirred for 4 h, the mixture was re-cooled to 0 °C and sat. aq. potassium sodium tartrate 
(100 mL) added slowly. The biphasic mixture was allowed to stir at room temperature 
for 16 h then extracted with Et2O (2 x 100 mL). The organic extracts were washed with water (50 
mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (EtOAc:NEt3 98:2) to afford title compound 1.329 (1.7 g, 79%) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 7.21 – 7.12 (4H, m, Ar-H), 4.80 (1H, s, C=CH), 4.50 (1H, s, C=CH), 
3.82 (2H, s, ArCH2NH2), 3.35 (2H, s, ArCH2C), 1.73 (3H, s, CH3), 1.42 (2H, brs, NH2); 13C NMR 
(125 MHz, CDCl3) δ 145.1 (C), 141.8 (C), 137.0 (C), 130.6 (CH), 127.8 (CH), 126.9 (CH), 126.8 
(CH), 111.9 (CH2), 43.8 (CH2), 41.1 (CH2), 22.8 (CH3); IR (thin film) 2932, 1647; HRMS 
(CI/Isobutane) exact mass calculated for C11H16N [M+H]+ m/z 162.1283; found m/z 162.1280. 
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2-(2’-methylallyl)-N-mesyl-benzylamine 1.333 
To a solution of 2-(2-methylallyl)-benzylamine 1.329 (0.50 g, 3.1 mmol) and 
triethylamine (0.47 mL, 3.4 mmol) in CH2Cl2 (5.0 mL) was added mesyl chloride 
(0.24 mL, 3.1 mmol) at 0 °C. The mixture was stirred for 1 h, before being quenched 
by addition of brine (10 mL). The aqueous phase was extracted by CH2Cl2 (3 x 10 
mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The 
crude product was purified by flash chromatography (CH2Cl2/AcOH 99.5:0.5) to afford title 
compound 1.333 as a colourless oil (0.59 g, 80%). 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.18 (4H, 
m, Ar-H), 4.85 (1H, s, 4’-CH), 4.66 (1H, brs, NH), 4.48 (1H, s, 4’-CH), 4.29 (2H, d, J = 6.4 Hz, 
ArCH2NHMs), 3.40 (2H, s, 1’-CH2), 2.85 (3H, s, Ms-CH3), 1.76 (3H, s); 13C NMR (125 MHz, 
CDCl3) δ 145.3 (C), 138.0 (C), 134.9 (C), 131.2 (CH), 129.5 (CH), 128.5 (CH), 127.2 (CH), 112.3 
(CH2), 45.0 (CH2), 41.2 (CH2), 40.9 (CH3), 22.9 (CH3); IR (thin film) 3215, 1595, 1159; HRMS (ESI 
negative) exact mass calculated for C12H16NO2S [M–H]– m/z 238.0907; found m/z 238.0905. 
 
 
2-(2-methylallyl)-N-tosylbenzylamine 1.331 
To a solution of (2-(2-methyl)-allylphenyl)methanamine 1.324 (0.41 g, 2.5 mmol) in 
1:1 THF/H2O (25 mL) was added a solution of NaHCO3 (0.63 g, 7.5 mmol) and di-
tert-butyl-dicarbonate (0.67 g, 3.0 mmol) in 1/1 THF:H2O (25 mL) at 0 °C. The 
solution was warmed to room temperature and stirred overnight, before being diluted 
with Et2O (30 mL). The aqueous phase was extracted with Et2O (2 x 30 mL) and the organic extracts 
were dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (CH2Cl2) to afford title compound 1.331 (0.52 g, 80%) as a colourless oil. 1H NMR 
(500 MHz, CDCl3) δ 7.30 – 7.15 (4H, m, Ar-H), 4.82 (1H, s, C=CH), 4.70 (1H, brs, NH), 4.49 (1H, 
s, C=CH), 4.31 (2H, d, J = 5.5 Hz, ArCH2NH), 3.35 (2H, s, ArCH2C), 1.74 (3H, s, CH3), 1.45 (9H, 
s, Boc-(CH3)3); 13C NMR (125 MHz, CDCl3) δ 155.8 (C), 146.9 (C), 144.9 (C), 137.1 (C), 130.7 
(CH), 128.7 (CH), 127.6 (CH), 126.9 (CH), 112.1 (CH2), 85.3 (C), 42.4 (CH2), 41.2 (CH2), 28.6 
(CH3), 22.9 (CH3); IR (thin film) 2970, 1718; LRMS (ESI positive) exact mass calculated for 
C16H23NO2Na [M+Na]+ m/z 284.2; found m/z 284.2. 
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2-allylaniline 1.333 
Following a literature procedure,[117] to a solution of N-allylaniline 1.335 (1.0 g, 7.5 
mmol) in toluene (15 mL) in a microwave vial, was added dropwise BF3.OEt2 (1.1 mL, 
9.0 mmol) at –78 °C. The mixture was allowed to warm to room temperature, before 
warming by microwave irradiation at 180 °C for 2 h. The mixture was quenched by addition NaHCO3 
(10 mL), and the aqueous phase was extracted with EtOAc (3 x 15 mL). The organic extracts were 
dried (Na2SO4), filtered and concentrated in vacuo. The crude material was purified by column 
chromatography (petroleum ether/EtOAc 19:1) to afford title compound 1.333 (0.75 g, 75%) as a 
yellow oil. Analytical data observed were in accordance with literature values.[117]  
 
N-Boc-2-allylaniline 1.337 
To a stirred solution of di-tert-butyl-dicarbonate (0.39 g, 1.8 mmol) and sodium 
bicarbonate (0.37 g, 4.4 mmol) in 1:1 THF/H2O (30 mL) was added a solution of 2-
allylaniline 1.333 (0.20 g, 1.5 mmol) in THF (1.0 mL) at 0 °C. The mixture was stirred 
for 1 h, before warming to room temperature and stirring overnight. The aqueous phase was extracted 
with Et2O (3 x 30 mL) and the organic extracts were washed with brine (30 mL), dried (Na2SO4), 
filtered and concentrated in vacuo. The crude product was purified by column chromatography 
(CH2Cl2/petroleum ether 1:1) to afford title compound 1.337 (0.29 g, 83%) as a white powdered 
solid. Analytical data observed were in accordance with literature values.[103] 
1.4.4: Aminoallylation Reactions 
 
3-(but-3’-en-1’-yl)-2-tosyl-3,4-dihydroisoquinolin-1-one 1.192 
A 4 mL screw-top glass vial was charged with 2-allyl-N-tosyl-benzamide 1.189 
(50 mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), KH2PO4 (44 mg, 0.32 
mmol), allyl chloride (0.067 mL, 0.79 mmol) and Pd(hfacac)2 (4.2 mg, 0.0082 
mmol). The vial was sealed under ambient atmosphere and the mixture was 
heated by immersion of the entire vial into a pre-heated aluminium block at 50 °C for 21 h. The 
mixture was cooled to room temperature, and subjected directly to flash chromatography (petroleum 
ether/EtOAc, 9:1) to afford title compound 1.192 as an amorphous solid (47 mg, 84%). 1H NMR 
(500 MHz, CDCl3) δ 8.03 – 7.95 (3H, m, Ar-H) 7.50 – 7.46 (1H, m, Ar-H), 7.34 – 7.19 (4H, m, Ar-
H), 5.76 (1H, ddt, J = 16.9 Hz, 10.3 Hz, 6.5 Hz, 3’-CH), 5.06 – 4.95 (3H, m, 4’-CH2 & 3-CH), 3.35 
(1H, dd, J = 16.2 Hz, 5.5 Hz, CH-4), 2.97 (1H, dd, J = 16.3 Hz, 1.8 Hz, CH-4), 2.41 (3H, s, Ts-CH3), 
134 
 
2.17 – 2.10 (2H, m, CH2-2’) 1.91 – 1.80 (1H, m, CH-1’), 1.68 – 1.49 (1H, m, CH-1’); 13C NMR (125 
MHz, CDCl3) δ 163.0 (C), 144.8 (C), 137.0 (C), 136.9 (CH), 136.9 (C), 133.8 (CH), 129.5 (CH), 
129.1 (CH), 129.1 (CH), 128.3 (C), 128.3 (CH), 127.6 (CH), 115.8 (CH2), 55.5 (CH), 32.8 (CH2), 
32.4 (CH2), 30.7 (CH2), 21.8 (CH3); IR (thin film) 2924, 1684; HRMS (CI/Isobutane) exact mass 
calculated for C20H22NO3S [M+H]+ m/z 356.1320; found m/z 356.1319. 
 
 
3-(3’-methylbut-3’-en-1’-yl)-2-tosyl-3,4-dihydroisoquinolin-1-one 1.199 
A 4 mL screw-top glass vial was charged with 2-allyl-N-tosyl-benzamide 1.189 
(50 mg, 0.16 mmol), toluene (0.32 mL), H2O (0.32 mL), KH2PO4 (44 mg, 0.32 
mmol), (2-methyl)allyl chloride (0.088 mL, 0.79 mmol) and Pd(hfacac)2 (8.4 
mg, 0.016 mmol). The vial was sealed under ambient atmosphere and the 
mixture was heated by immersion of the entire vial into a pre-heated aluminium block at 50 °C for 
21 h. The mixture was cooled to room temperature, and subjected directly to flash chromatography 
(petroleum ether/EtOAc, 9:1) to afford title compound 1.199 as an amorphous solid (42 mg, 71%). 
1H NMR (400 MHz, CDCl3) δ 8.01 – 7.95 (3H, m, Ar-H & Ts-H), 7.48 (1H, dt, J = 7.5, 1.3 Hz, Ar-
H), 7.39 – 7.29 (3H, m, Ar-H & Ts-H), 7.20 (1H, d, J = 7.6 Hz, Ar-H), 4.97 – 4.91 (1H, m, 3-CH), 
4.73 (1H, s, 4’-CHa), 4.67 (1H, s, 4’-CHb), 3.34 (1H, dd, J = 16.2, 5.5 Hz, 4-CHa), 2.99 (1H, dd, J = 
16.3, 1.8 Hz, 4-CHb), 2.41 (3H, s, Ts-CH3), 2.13 – 2.04 (2H, m, 2’-CH2), 1.96 – 1.84 (1H, m, 1’-
CHa), 1.70 – 1.63 (4H, m, 3’-CH3 & 1’CHb); 13C NMR (100 MHz, CDCl3) δ 163.0 (C), 144.8 (C), 
144.2 (C), 136.93 (C), 136.86 (C), 133.8 (CH), 129.5 (2 x CH), 129.08 (CH). 129.05 (CH), 128.3 
(CH), 127.6 (CH), 111.0 (CH2), 55.6 (CH), 34.6 (CH2), 32.2 (CH2), 31.2 (CH2), 22.4 (CH3), 21.8 
(CH3); IR (thin film) 1684, 1342, 1169; HRMS (EI+) exact mass calculated for C21H23NO3S [M+H]+ 
m/z 369.1399; found m/z 369.1402. 
 
 
3-(but-3’-en-1’-yl)-2-tosyl-3,4-dihydropyrrolo[1,2-e]pyrazin-1-one 1.204 
A 4 mL glass screw-top vial was charged with 1-allyl-N-tosyl-pyrrole-2-
carboxamide 1.202 (48 mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), 
KH2PO4 (44 mg, 0.32 mmol), allyl chloride (0.067 mL, 0.79 mmol) and 
Pd(hfacac)2 (8.4 mg, 0.016 mmol). The vial was sealed under ambient 
atmosphere and the mixture was heated by immersion of the entire vial into a pre-heated aluminium 
block at 80 °C for 19 h. The mixture was cooled to room temperature, and subjected directly to 
column chromatography (petroleum ether/EtOAc, 90:10) to afford title compound 1.204 as an 
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amorphous solid (33 mg, 61%). 1H NMR (400 MHz, CDCl3) δ 7.99 (2H, d, J = 8.4 Hz, Ts-H), 7.31 
(2H, d, J = 8.1 Hz, Ts-H), 6.97 (1H, dd, J = 4.0 Hz, 1.5 Hz, Ar-H), 6.76 (1H, dd, 2.2, 1.7 Hz, Ar-H), 
6.23 (1H, dd, J = 4.0 Hz, 2.5 Hz, Ar-H), 5.80 (1H, ddt, J = 10.3, 6.5, 3.5 Hz, 3’-CH), 5.09 – 5.03 
(2H, m, 4’-CH2), 4.98 – 4.93 (1H, m, 3-CH), 4.29 (1H, dd, J = 13.2, 3.9 Hz, 4-CH), 4.15 (1H, dd, 
13.2, 1.5 Hz, 4-CH), 2.42 (3H, s, Ts-CH3), 2.17 (2H, m, 2’-CH2), 1.84 (1H, m, 1’-CH), 1.68 (1H, m, 
1’-CH); 13C NMR (125 MHz, CDCl3) δ 156.1 (C), 144.8 (C), 136.6 (C), 136.5 (CH), 129.4 (CH), 
129.0 (CH), 125.1 (CH), 122.5 (C), 116.8 (CH), 116.2 (CH2), 111.0 (CH), 55.6 (CH), 47.0 (CH2), 
31.5 (CH2), 30.2 (CH2), 21.7 (CH3); IR (thin film) 2359, 1670, 1161; HRMS (EI) exact mass 
calculated for C18H20N2O3S [M]+ m/z 344.1195; found m/z 344.1197. 
 
 
3-(but-3’-en-1’-yl)-2-tosyl-3,4-dihydropyrazino[5,6-a]indol-1-one 1.209 
A 4 mL glass screw-top vial was charged with 1-allyl-N-tosyl-indole-2-
carboxamide 1.208 (20 mg, 0.060 mmol), toluene (0.20 mL), H2O (0.20 mL), 
KH2PO4 (16 mg, 0.12 mmol), allyl chloride (0.025 mL, 0.30 mmol) and 
Pd(hfacac)2 (3.8 mg, 0.0060 mmol). The vial was sealed under ambient 
atmosphere and the mixture was heated by immersion of the entire vial into a pre-heated aluminium 
block at 80 °C for 48 h. The mixture was cooled to room temperature, and subjected directly to 
column chromatography (petroleum ether/CH2Cl2, 1:1) to afford title compound 1.209 as an 
amorphous solid (12 mg, 54%). 1H NMR (400 MHz, CDCl3) δ 8.03 (2H, d, J = 8.4 Hz, Ts-H), 7.67 
(1H, d, J = 8.2 Hz, Ar-H), 7.39 – 7.29 (5H, m, Ar-H), 7.19 – 7.15 (1H, m, Ar-H), 5.74 (1H, ddt, J = 
17.2, 10.3, 5.7 Hz, 3’-H), 5.12 – 5.02 (3H, m, 3-H & 4’-CH2), 4.48 (1H, dd, J = 12.9, 1.6 Hz, 4-H), 
4.27 (1H, dd, J = 12.9, 3.9 Hz, 4-H), 2.43 (3H, s, Ts-CH3), 2.21 – 2.15 (2H, m, 2’-CH2), 1.93 – 1.84 
(1H, m, 1’-CH), 1.73 – 1.64 (1H, m, 1’-CH); 13C NMR (125 MHz, CDCl3) δ 157.4 (C), 145.2 (C), 
137.1 (C), 136.5 (CH), 136.4 (C), 129.6 (CH), 129.2 (CH), 128.6 (C), 127.0 (C), 126.2 (CH), 123.3 
(CH), 121.4 (CH), 116.4 (CH2), 109.8 (CH), 109.4 (CH), 56.0 (CH), 43.5 (CH2), 32.1 (CH2), 30.5 
(CH2), 21.8 (CH3); IR (thin film) 2926, 1684, 1346; HRMS (EI) exact mass calculated for 
C22H22N2O3S [M]+ m/z 394.1351; found m/z 394.1353. 
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3-(but-3’-en-1’-yl)-3-methyl-2-tosyl-3,4-dihydroisoquinolin-1-one 1.262 
A 4 mL screw-top glass vial was charged with 2-(2-methyl)-allyl-N-tosyl-
benzamide 1.260 (52 mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), 
KH2PO4 (44 mg, 0.32 mmol), allyl chloride (0.067 mL, 0.79 mmol) and 
Pd(hfacac)2 (8.0 mg, 0.016 mmol). The vial was sealed under ambient 
atmosphere and the mixture was heated by immersion of the entire vial into a pre-heated aluminium 
block at 50 °C for 48 h. The mixture was cooled to room temperature, and subjected directly to flash 
chromatography (CH2Cl2) to afford title compound 1.262 as an amorphous solid (17 mg, 33%). 1H 
NMR (500 MHz, CDCl3) δ 7.95 (2H, d, J = 8.4 Hz, Ts-H), 7.80 (1H, d, J =  7.8 Hz, Ar-H), 7.48 – 
7.45 (1H, td, J = 7.5, 1.0 Hz, Ar-H), 7.31 – 7.22 (3H, m, Ts-H & Ar-H) 7.14 (1H, d, J = 7.8 Hz, Ar-
H), 5.74 (1H, ddt, J = 17.0, 10.3, 6.4 Hz, CH-3’), 5.00 (1H, dd, J = 17.1, 1.7 Hz, CHa), 4.95 (1H, dd, 
J = 10.1, 1.6 Hz, CHb), 3.07 (2H, s, CH2-4), 2.42 (3H, s, Ts-CH3), 2.23 – 2.10 (4H, m, (CH2)2-1’&2’), 
1.93 (3H, s, C3-CH3); 13C NMR (125 MHz, CDCl3) δ 165.1 (C), 144.1 (C), 138.8 (C), 137.7 (CH), 
136.3 (C), 133.6 (CH), 129.2 (C), 128.8 (CH), 128.7 (2 x CH), 127.6 (CH), 127.0 (CH), 115.3 (CH2), 
66.9 (C), 42.1 (CH2), 38.8 (CH2), 29.6 (CH2), 27.9 (CH3), 21.8 (CH3); IR (thin film) 3394, 1683, 
1348; HRMS (CI/Isobutane) exact mass calculated for C21H24NO3S [M]+ 370.1477; found 370.1475. 
 
 
3-(but-3’-en-1’-yl)-N-methoxy-3-methylisoindolin-1-one 1.293 
A 4 mL glass screw-top vial was charged with Pd(OAc)2 (2.3 mg, 0.010 mmol), SPhos 
(8.2 mg, 0.020 mmol) and toluene (0.40 mL). This mixture was stirred at room 
temperature for 10 min, before the addition of N-methoxy-2-isopropenylbenzamide 
1.292 (38 mg, 0.20 mmol), NaHCO3 (34 mg, 0.40 mmol) and allyl bromide (0.090 
mL, 1.0 mmol). The vial was sealed under ambient atmosphere and the mixture was heated by 
immersion of the entire vial into a pre-heated aluminium block at 80 °C for 24 h. The mixture was 
cooled to room temperature, and subjected directly to column chromatography (petroleum 
ether/EtOAc, 4:1) to afford title compound 1.293 as a pale yellow oil (18 mg, 40%). 1H NMR (400 
MHz, CDCl3) 7.83 (1H, d, J = 7.5 Hz, Ar-H), 7.57 (1H, td, J = 7.5, 1.1 Hz, Ar-H), 7.44 (1H, td, J = 
7.5, 1.0 Hz, Ar-H), 7.31 (1H, d, J = 7.6 Hz, Ar-H), 5.62 (1H, ddt, J = 17.8, 9.4, 6.5 Hz, 3’-CH), 4.89 
– 4.83 (2H, m, 4’-CH2), 4.05 (3H, s, NOCH3), 2.20 – 2.13 (1H, m, 2’-CHa), 1.98 – 1.90 (1H, m, 2’-
CHb), 1.80 – 1.73 (1H, m, 1’-CHa), 1.59 (3H, s, C3-CH3), 1.40 – 1.30 (1H, m, 1’-CHb); 13C NMR 
(125 MHz, CDCl3) δ 165.1 (C), 145.0 (C), 132.6 (CH), 132.4 (C), 129.6 (CH), 129.2 (CH), 128.3 
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(CH), 124.0 (CH), 121.1 (CH2), 65.6 (C), 65.4 (CH3), 36.6 (CH2), 29.8 (CH2), 22.1 (CH3); IR (thin 
film) 2361, 1705, 1467; HRMS (EI+) exact mass calculated for C14H17NO2 [M]+ m/z 231.1259; found 
m/z 231.1263. 
 
 
N-(benzyloxy)-3-(but-3’-en-1’-yl)-3-methylisoindolin-1-one 1.307 
 A 4 mL glass screw-top vial was charged with Pd(OAc)2 (2.3 mg, 0.010 mmol), SPhos 
(8.2 mg, 0.020 mmol) and toluene (0.40 mL). This mixture was stirred at room 
temperature for 10 min, before the addition of N-benzyloxy-2-isopropenylbenzamide 
1.65 (53 mg, 0.20 mmol), NaHCO3 (34 mg, 0.40 mmol) and allyl bromide (0.090 mL, 
1.0 mmol). The vial was sealed under ambient atmosphere and the mixture was heated by immersion 
of the entire vial into a pre-heated aluminium block at 80 °C for 24 h. The mixture was cooled to 
room temperature, and subjected directly to column chromatography (petroleum ether:EtOAc, 4:1) 
to yield the title compound 1.307 as a yellow oil (25 mg, 41%). 1H NMR (400 MHz, CDCl3) 7.85 
(1H, d, J = 7.4 Hz, Ar-H), 7.61 – 7.24 (8H, m, Ar-H), 5.59 (1H, ddt, J  = 17.7, 9.7, 6.4 Hz, 3’-CH), 
5.30 (1H, d, J = 10.2 Hz, OCHaPh), 5.20 (1H, d, J = 10.2 Hz, OCHbPh), 4.86 – 4.82 (2H, m, C4’-
CH2), 2.16 – 2.09 (1H, m, C2’-CH), 1.93 – 1.86 (1H, m, C2’-CH), 1.84 – 1.74 (1H, m, C1’-CH), 
1.43 (3H, s, C3-CH3), 1.39 – 1.29 (1H, m, C1’-CH); 13C NMR (100 MHz, CDCl3) δ 165.5 (C), 146.9 
(C), 137.4 (CH), 135.6 (C), 132.4 (CH), 129.7 (CH), 129.6 (C), 129.0 (CH), 128.7 (CH), 128.4 (CH), 
123.8 (CH), 121.1 (CH), 114.9 (CH2), 79.0 (CH2), 66.4 (C), 36.6 (CH2), 27.9 (CH2), 24.7 (CH3); IR 
(thin film) 2361, 1707. 1454; HRMS (EI+) exact mass calculated for C20H21NO2 [M]+ m/z 307.1572; 
found m/z 307.1569. 
 
 
3-(but-3’-en-1’-yl)-2-methoxy-3-methyl-3,4-dihydroisoquinolin-1-one 1.310 
A 4 mL glass screw-top vial was charged with Pd(OAc)2 (2.3 mg, 0.010 mmol), SPhos (8.2 mg, 
0.020 mmol) and toluene (0.40 mL). This mixture was stirred at room 
temperature for 10 min, before the addition of N-methoxy-2-(2-
methylallyl)benzamide 1.309 (41 mg, 0.20 mmol), NaHCO3 (34 mg, 0.4 
mmol) and allyl bromide (0.090 mL, 1.0 mmol). The vial was sealed under ambient atmosphere and 
the mixture was heated by immersion of the entire vial into a pre-heated aluminium block at 80 °C 
for 48 h. The mixture was cooled to room temperature, and subjected directly to column 
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chromatography (petroleum ether/EtOAc, 4:1) to afford title compound 1.310 as a colourless oil (16 
mg, 33%).  1H NMR (400 MHz, CDCl3) δ 8.12 (1H, td, J = 7.8, 1.1 Hz, Ar-H), 7.45 (1H, td, J = 7.5, 
1.4 Hz, Ar-H), 7.34 (1H, t, J = 7.5 Hz, Ar-H), 7.14 (1H, d, J = 7.5 Hz, Ar-H), 5.72 (1H, ddt, J = 17.0, 
10.2, 6.4 Hz, 3’-CH), 4.97 (1H, dd, J = 17.1, 1.7 Hz, 4’-Hb), 4.92 (1H, dd, J = 10.2, 1.7 Hz, 4’-Ha), 
3.94 (3H, s, NOCH3), 3.09 (2H, s, 4-CH2), 2.11 – 2.04 (2H, m, 2’-CH2), 1.93 – 1.86 (1H, m, 1’-CH), 
1.73 – 1.65 (1H, m, 1’-CH), 1.44 (3H, s, C3-CH3); 13C NMR (100 MHz, CDCl3) δ 164.8 (C), 138.0 
(CH), 136.0 (C), 132.6 (CH), 128.4 (C), 128.3 (CH), 127.6 (CH), 127.1 (CH), 115.0 (CH2), 64.7 (C), 
64.5 (CH3), 40.9 (CH2), 36.7 (CH2), 29.1 (CH2), 23.4 (CH3); IR (thin film) 2934, 1670, 1327; HRMS 
(ESI positive) exact mass calculated for C15H19NO2Na [M+Na]+ m/z 268.1308; found m/z 268.1306. 
 
1.4.5: Undesired side products 
N,2-diallyl-N-tosylbenzamide 1.196 
A 4 mL screw-top glass vial was charged with 2-allyl-N-tosyl-benzamide 1.189 (50 
mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), NaHCO3 (27 mg, 0.32 mmol), 
allyl chloride (0.067 mL, 0.79 mmol) and Pd(hfacac)2 (8.4 mg, 0.016 mmol). The 
vial was sealed under ambient atmosphere and the mixture was heated by 
immersion of the entire vial into a pre-heated aluminium block at 50 °C for 4 h. The mixture was 
cooled to room temperature, and subjected directly to flash chromatography (CH2Cl2) to afford title 
compound 1.196 (55 mg, 98%) as a colourless oil. 1H NMR (500 MHz, CDCl3) δ 7.78 (2H, d, J = 
8.4 Hz, Ts-H), 7.33 (1H, td, J = 7.5, 1.3 Hz, Ar-H), 7.28 (2H, d, J = 8.1 Hz, Ts-H), 7.20 – 7.07 (3H, 
m, Ar-H), 5.86 (1H, ddt, J = 17.2, 10.3, 5.9 Hz, CH-2’), 5.77 (1H, ddt, J = 17.1, 10.0, 6.7 Hz, CH-
2’’), 5.21 – 5.14 (2H, m, CH2-3’), 5.01 – 4.91 (2H, m, CH2-3’’), 4.36 (2H, d, J = 5.8 Hz, CH2-1’), 
3.16 (2H, d, J = 6.8 Hz, CH2-1’’), 2.43 (3H, s, Ts-CH3); 13C NMR (125 MHz, CDCl3) δ 170.6 (c), 
144.9 (C), 137.6 (C), 136.6 (C), 136.0 (CH), 134.8 (C), 133.0 (CH), 130.3 (CH), 129.7 (CH), 129.4 
(CH), 128.9 (CH), 126.8 (CH), 125.8 (CH), 118.9 (CH2), 116.8 (CH2), 50.0 (CH2), 37.1 (CH2), 21.7 
(CH3); IR (thin film) 3063, 1686, 1354; HRMS (CI/Isobutane) exact mass calculated for C20H22NO3S 
[M+H]+ m/z 356.1320; found m/z 356.1317. 
 
3-methyl-2-tosylisoquinolin-1-one 1.193 
A 4 mL screw-top glass vial was charged with N-tosyl-2-allylbenzamide 1.189 (44 mg, 
0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), KH2PO4 (44 mg, 0.32 mmol), allyl 
bromide (0.065 mL, 0.79 mmol) and Pd(hfacac)2 (8.4 mg, 0.016 mmol). The vial was 
sealed under ambient atmosphere and the mixture was heated by immersion of the 
entire vial into a pre-heated aluminium block at 50 °C for 20 h. The mixture was cooled to room 
temperature, and subjected directly to flash chromatography (petroleum ether/CH2Cl2 1:1) to yield 
the title compound 1.193 (3.9 mg, 8%) as a white powdered solid. Analytical data observed were in 
accordance with literature values.[75] 
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3-methylene-2-tosylisoindolin-1-one 1.215 
A 4 mL screw-top glass vial was charged with 2-vinyl-N-tosyl-benzamide 1.212 (48 
mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), KH2PO4 (44 mg, 0.32 mmol), allyl 
chloride (0.067 mL, 0.79 mmol) and Pd(hfacac)2 (8.4 mg, 0.016 mmol). The vial was 
sealed under ambient atmosphere and the mixture was heated by immersion of the entire vial into a 
pre-heated aluminium block at 50 °C for 20 h. The mixture was cooled to room temperature, and 
subjected directly to flash chromatography (CH2Cl2) to afford title compound 1.215 (38 mg, 80%) 
as a white powdered solid. 1H NMR (500 MHz, CDCl3) δ 8.00 (2H, d, J = 8.4 Hz, Ts-H), 7.79 (1H, 
d, J = 7.7 Hz, Ar-H), 7.70 – 7.65 (2H, m, Ar-H), 7.49 (1H, t, J = 7.1 Hz, Ar-H), 7.32 (2H, d, J = 8.1 
Hz, Ts-H), 6.20 (1H, d, J = 2.1 Hz, C-CH2), 5.54 (1H, d, J = 2.1 Hz, C-CH2), 2.41 (3H, s, Ts-H); 13C 
NMR (125 MHz, CDCl3) δ 165.1 (C), 145.5 (C), 138.1 (C), 137.6 (C), 136.0 (C), 134.3 (CH), 130.2 
(CH), 129.9 (CH), 128.6 (C), 128.3 (CH), 124.5 (CH), 120.2 (CH), 96.8 (CH2), 21.8 (CH3); IR (thin 
film) 1750, 1172; LRMS (CI/Isobutane) mass calculated for C16H14NO3S [M+H]+ m/z 300.1; found 
m/z 300.1.  
 
3,3,5-trimethyl-1-tosyl-pyrrol-2-one 1.233 
A 4 mL screw-top glass vial was charged with 2,2-dimethyl-N-tosyl-pent-4-enamide 1.230 
(44 mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), KH2PO4 (44 mg, 0.32 mmol), 
allyl chloride (0.067 mL, 0.79 mmol) and Pd(hfacac)2 (8.4 mg, 0.016 mmol). The vial was 
sealed under ambient atmosphere and the mixture was heated by immersion of the entire 
vial into a pre-heated aluminium block at 50 °C for 20 h. The mixture was cooled to room 
temperature, and subjected directly to flash chromatography (petroleum ether/CH2Cl2 1:1) to afford 
title compound 1.233 (37 mg, 83%) as a colourless oil. 1H NMR (500 MHz, CDCl3) δ 7.88 (2H, d, J 
= 8.4 Hz), 7.32 (2H, d, J = 8.1 Hz), 5.07 (1H, d, J = 1.4 Hz), 2.43 (3H, s), 2.27 (3H, d, J = 1.4 Hz), 
1.08 (6H, s); 13C NMR (125 MHz, CDCl3) δ 181.3 (C), 145.0 (C), 137.2 (C), 136.3 (C), 129.8 (CH), 
127.9 (CH), 116.5 (CH), 45.4 (C), 23.8 (CH3), 21.8 (CH3), 16.8 (CH3); IR (thin film) 1755, 1369, 
1176; HRMS (CI/Isobutane) exact mass calculated for C14H18NO3S [M+H]+ m/z 280.1007; found 
m/z 280.1006. 
 
3-methyl-2-tosyl-2-azaspiro[4.5]dec-3-en-1-one 1.240 
A 4 mL screw-top glass vial was charged with 1-allyl-N-tosyl-cyclohexanecarboxamide 
1.232 (51 mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), KH2PO4 (44 mg, 0.32 
mmol), allyl chloride (0.067 mL, 0.79 mmol) and Pd(hfacac)2 (8.4 mg, 0.016 mmol). 
The vial was sealed under ambient atmosphere and the mixture was heated by immersion of the entire 
vial into a pre-heated aluminium block at 50 °C for 20 h. The mixture was cooled to room 
temperature, and subjected directly to flash chromatography (petroleum ether/CH2Cl2 1:1) to yield 
the title compound 1.240 (37 mg, 73%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 7.87 (2H, 
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d, J = 8.3 Hz, Ts-H), 7.31 (2H, d, J = 8.1 Hz, Ts-H), 5.38 (1H, d, J = 1.4 Hz, CH), 2.42 (3H, s, Ts-
CH3), 2.29 (3H, d, J = 1.4 Hz, CH3), 1.71 – 1.26 (10H, m, cy-10H); 13C NMR (125 MHz, CDCl3) δ 
180.8 (C), 145.0 (C), 137.6 (C), 136.3 (C), 129.8 (CH), 127.9 (CH), 113.6 (CH), 50.1 (C), 33.1 
(CH2), 25.3 (CH2), 22.2 (CH2), 21.8 (CH3), 17.0 (CH3); IR (thin film) 2936, 1750, 1369, 1175; HRMS 
(CI/Isobutane) exact mass calculated for C17H22NO3S [M+H]+ m/z 320.1320; found m/z 320.1319. 
 
3,3-dimethyl-2-tosyl-3,4-dihydroisoquinolin-1-one 1.264 
 A 4 mL screw-top glass vial was charged with 2-(2-methyl)-allyl-N-tosyl-benzamide 
1.260 (52 mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), allyl chloride (0.067 
mL, 0.79 mmol) and Pd(hfacac)2 (8.4 mg, 0.0080 mmol). The vial was sealed under 
ambient atmosphere and the mixture was heated by immersion of the entire vial into a pre-heated 
aluminium block at 50 °C for 48 h. The mixture was cooled to room temperature, and subjected 
directly to flash chromatography (CH2Cl2) to afford title compound 1.264 as a colourless oil (42 mg, 
80%). 1H NMR (500 MHz, CDCl3) δ 8.20 (1H, dd, J = 7.9, 0.8 Hz, Ar-H), 7.93 (2H, d, J = 8.3 Hz, 
Ts-H), 7.51 (1H, td, J = 7.5, 1.3 Hz, Ar-H), 7.35 – 7.28 (3H, m, Ts-H & Ar-H), 7.10 (1H, d, J = 7.5 
Hz, Ar-H), 2.95 (2H, s, ArCH2), 2.42 (3H, s, Ts-CH3), 1.28 (6H, s, (CH3)2); 13C NMR (100 MHz, 
CDCl3) δ 162.6 (C), 143.0 (C), 139.5 (C), 136.8 (C), 134.5 (CH), 130.1 (CH), 129.0 (CH), 128.4 
(CH), 128.0 (CH), 127.8 (CH), 124.5 (C), 83.4 (C), 38.9 (CH2), 26.7 (CH3), 21.7 (CH3); IR (thin 
film) 1684, 1549, 1310, 1163; HRMS (EI) exact mass calculated for C18H19NO3S [M+H]+ m/z 
329.1086; found m/z 329.1087. 
 
3-(But-3-enyl)-3-methylisobenzofuran-1-one 1.268 
A 4 mL screw-top glass vial was charged with N-Boc-2-isopropenylbenzamide 1.265 
(0.16 g, 0.63 mmol), toluene (1.3 mL), KH2PO4 (0.17 mg, 1.3 mmol), allyl chloride (0.26 
mL, 3.2 mmol) and Pd(OAc)2 (14 mg, 0.06 mmol). The vial was sealed under ambient 
atmosphere and the mixture was heated by immersion of the entire vial into a pre-heated 
aluminium block at 110 °C for 48 h. The mixture was cooled to room. temperature, and 
subjected directly to flash chromatography (petroleum ether/CH2Cl2 1:1) to afford title compound 
1.268 as a white powdered solid (87 mg, 73%). 1H NMR (500 MHz, CDCl3) δ 7.87 (1H, dd, J = 7.6, 
0.9 Hz, Ar-H), 7.66 (1H, td, J = 7.5, 1.1 Hz, Ar-H), 7.50 (1H, td, J = 7.5, 0.8 Hz, Ar-H), 7.36 (1H, 
d, J = 7.7 Hz, Ar-H), 5.74 – 5.66 (1H, m, 3-CH), 4.94 – 4.89 (2H, m, 4-CH2), 2.15 (1H, ddd, J = 
13.6, 11.2, 4.8 Hz, 1-CH), 2.10 – 2.02 (1H, m, 2-CH), 1.96 (1H, ddd, J = 13.7, 11.0, 4.6 Hz, 1-CH), 
1.80 – 1.73 (1H, m, 2-CH), 1.65 (3H, s, CH3); 13C NMR (125 MHz, CDCl3) δ 169.9 (C), 153.9 (C), 
137.3 (CH), 134.2 (CH), 129.1 (CH), 126.5 (C), 126.0 (CH), 121.0 (CH), 115.2 (CH2), 87.3 (C), 39.3 
(CH2), 28.0 (CH2), 26.3 (CH3); IR (thin film) 1751, 1285, 1030; HRMS (EI) exact mass calculated 
for C13H14O2 [M]+ m/z 202.0994, found m/z 202.0991. 
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3,3'-(ethene-1,2-diyl)bis(2-methoxy-3-methylisoindolin-1-one) 1.295 
A 4 mL glass screw-top vial was charged with Pd(OAc)2 (2.3 mg, 0.010 mmol), 
SPhos (8.2 mg, 0.020 mmol) and toluene (0.40 mL). This mixture was stirred 
at room temperature for 10 min, before the addition of N-methoxy-2-
isopropenylbenzamide 1.292 (38 mg, 0.20 mmol), NaHCO3 (34 mg, 0.40 
mmol) and allyl bromide (0.090 mL, 1.0 mmol). The vial was sealed under ambient atmosphere and 
the mixture was heated by immersion of the entire vial into a pre-heated aluminium block at 80 °C 
for 24 h. The mixture was cooled to room temperature, and subjected directly to column 
chromatography (petroleum ether:EtOAc, 1:1) to afford title compound 1.295 as a pale yellow oil 
(5.0 mg, 6%). 1H NMR (400 MHz, CDCl3) δ 7.96 (2H, m, Ar-H), 7.17 – 7.10 (2H, m, Ar-H), 7.08 – 
7.01 (2H, m, Ar-H), 6.93 – 6.78 (2H, ddt, J = 13.4, 7.5, 1.0 Hz, Ar-H), 5.75 – 5.72 (2H, m, C=CH), 
3.85 – 3.82 (6H, m, NOCH3), 1.29 – 1.25 (6H, m, C-CH3); 13C NMR (100 MHz, CDCl3) δ 
164.5/164.4 (major/minor diastereomer) (C), 146.64/146.59 (C), 133.0 (CH), 132.83/132.79 (CH), 
128.9 (CH), 128.73/128.66 (C), 124.30/124.27 (CH), 121.8/121.7 (CH), 66.2/66.1 (C), 65.5/65.4 
(CH3), 21.91/21.85 (CH3); IR (thin film) 2936, 1705, 1614, 1468; HRMS (ESI positive) exact mass 
calculated for C22H22N2O4Na [M]+ m/z 410.1477; found m/z 401.1464. 
 
3-(bromomethyl)-2-methoxy-3-methylisoindolin-1-one 1.296 
A 4 mL glass screw-top vial was charged N-methyloxy-2-isopropenylbenzamide 
1.292 (38 mg, 0.20 mmol), NaHCO3 (34 mg, 0.40 mmol), DME (0.40 mL), allyl 
bromide (0.090 mL, 1.0 mmol) and Pd(OAc)2 (2.3 mg, 0.010 mmol). The vial was 
sealed under ambient atmosphere and the mixture was heated by immersion of the 
entire vial into a pre-heated aluminium block at 50 °C for 24 h. The mixture was cooled to room 
temperature, and subjected directly to column chromatography (petroleum ether:EtOAc, 4:1) to 
afford title compound 1.296 as a colourless oil (11 mg, 20%).  1H NMR (400 MHz, CDCl3) δ 7.86 
(1H, d, J = 7.6 Hz, Ar-H), 7.61 (1H, td, J = 7.5, 1.0 Hz, Ar-H), 7.51 (1H, td, J = 7.5, 1.0 Hz, Ar-H), 
7.40 (1H, d, J = 7.6 Hz, Ar-H), 4.12 (3H, s, NOCH3), 3.82 (1H, d, J = 10.8 Hz, CHBr), 3.76 (1H, d, 
J = 10.8 Hz, CHBr), 1.73 (3H, s, C-CH3); 13C NMR (100 MHz, CDCl3) δ 165.1 (C), 145.0 (C), 132.6 
(CH), 129.6 (C), 129.2 (CH), 124.0 (CH), 121.1 (CH), 65.6 (C), 65.4 (CH3), 36.7 (CH2), 22.2 (CH3); 
IR (thin film) 2930, 1699, 1659, 1317; HRMS (EI+) exact mass calculated for C11H12NO2Br [M]+ 
m/z 269.0051; found m/z 269.0050. 
 
2-methoxy-3,3-dimethylisoindolin-1-one 1.304 
A 4 mL glass screw-top vial was charged with Pd(OAc)2 (2.3 mg, 0.010 mmol), SPhos 
(8.2 mg, 0.020 mmol) and toluene (0.40 mL). This mixture was stirred at room 
temperature for 10 min, before the addition of N-methoxy-2-isopropenylbenzamide 
1.292 (38 mg, 0.20 mmol), NaHCO3 (34 mg, 0.40 mmol) and allyl chloride (0.081 mL, 1.0 mmol). 
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The vial was sealed under ambient atmosphere and the mixture was heated by immersion of the entire 
vial into a pre-heated aluminium block at 50 °C for 24 h. The mixture was cooled to room 
temperature, and subjected directly to column chromatography (petroleum ether:EtOAc, 4:1) to 
afford title compound 1.304 as an amorphous solid (8 mg, 21%).  1H NMR (500 MHz, CDCl3) δ 7.83 
(1H, d, J = 7.6 Hz, Ar-H), 7.56 (1H, td, J = 7.6, 1.1 Hz, Ar-H), 7.44 (1H, td, J = 7.5, 1.0 Hz, Ar-H), 
7.35 (1H, d, J = 7.6, Ar-H), 4.06 (3H, s, NO-CH3), 1.56 (6H, s, (CH3)2); 13C NMR (125 MHz, CDCl3) 
δ 164.1 (C), 148.9 (C), 132.3 (CH), 128.6 (C), 128.3 (CH), 124.0 (CH), 120.8 (CH), 65.4 (CH3), 63.6 
(C), 25.2 (CH3); IR (thin film) 2931, 1705, 1287 ; HRMS (ESI positive) exact mass calculated for 
C11H13NO2Na [M+Na]+ m/z 214.0838; found m/z 214.0835. 
 
N-benzyloxy-3,3-dimethylisoindolin-1-one 1.308 
A 4 mL glass screw-top vial was charged with Pd(OAc)2 (2.3 mg, 0.010 mmol), SPhos 
(8.2 mg, 0.020 mmol) and toluene (0.40 mL). This mixture was stirred at room 
temperature for 10 min, before the addition of N-benzyloxy-2-isopropenylbenzamide 
1.65 (53 mg, 0.20 mmol) and allyl chloride (0.081 mL, 1.0 mmol). The vial was sealed under ambient 
atmosphere and the mixture was heated by immersion of the entire vial into a pre-heated aluminium 
block at 80 °C for 24 h. The mixture was cooled to room temperature, and subjected directly to 
column chromatography (petroleum ether:EtOAc, 4:1) to afford title compound 1.308 as a colourless 
oil (15 mg, 28%).  1H NMR (400 MHz, CDCl3) δ 7.85 (1H, d, J = 7.6 Hz, Ar-H), 7.58 – 7.32 (8H, 
m, Ar-H), 5.26 (2H, s, OCH2Ph), 1.44 (6H, s, (CH3)2); 13C NMR (100 MHz, CDCl3) δ 164.7 (C), 
149.2 (C), 135.6 (C), 132.3 (CH), 129.8 (CH), 129.0 (CH), 128.6 (CH), 128.3 (CH & C), 123.9 (CH), 
120.9 (CH), 79.2 (CH2), 63.6 (C), 25.1 (CH3); IR (thin film) 2336, 1705, 1616; HRMS (ESI positive) 
exact mass calculated for C17H17NO2Na [M]+ m/z 290.1151; found m/z 290.1151. 
 
3-methyl-2-tosyl-1,2-dihydroisoquinoline 1.322  
A 4 mL screw-top glass vial was charged with N-(2-allylbenzyl)-4-
methylbenzenesulfonamide 1.319 (44 mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 
mL), KH2PO4 (44 mg, 0.32 mmol), allyl chloride (0.067 mL, 0.79 mmol) and 
Pd(hfacac)2 (8.4 mg, 0.016 mmol). The vial was sealed under ambient atmosphere and the mixture 
was heated by immersion of the entire vial into a pre-heated aluminium block at 50 °C for 20 h. The 
mixture was cooled to room temperature, and subjected directly to flash chromatography (petroleum 
ether/CH2Cl2 1:1) to afford title compound 1.322 (30 mg, 64%) as a white powdered solid. Analytical 
data observed were in accordance with literature values.[75] 
 
N-Boc-3-methyl-1,2-dihydroisoquinoline 1.326 
A 4 mL screw-top glass vial was charged with 2-allyl-N-Boc-benzylamine 1.323 (44 
mg, 0.16 mmol), toluene (0.64 mL), H2O (0.64 mL), KH2PO4 (44 mg, 0.32 mmol), 
allyl chloride (0.067 mL, 0.79 mmol) and Pd(hfacac)2 (8.0 mg, 0.02 mmol). The vial 
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was sealed under ambient atmosphere and the mixture was heated by immersion of the entire vial 
into a pre-heated aluminium block at 50 °C for 20 h. The mixture was cooled to room temperature, 
and subjected directly to flash chromatography (petroleum ether/CH2Cl2 1:1) to afford title 
compound 1.326 (27 mg, 69%) as a colourless oil. Analytical data observed were in accordance with 
literature values.[118] 
 
2-methylindole 1.334 
 A 4 mL screw-top glass vial was charged with 2-allylaniline 1.333 (37 mg, 0.16 mmol), 
toluene (0.32 mL), H2O (0.32 mL), KH2PO4 (44 mg, 0.32 mmol), allyl chloride (0.067 
mL, 0.79 mmol) and Pd(hfacac)2 (8.0 mg, 0.02 mmol). The vial was sealed under 
ambient atmosphere and the mixture was heated by immersion of the entire vial into a pre-heated 
aluminium block at 50 °C for 48 h. The mixture was cooled to room temperature, and subjected 
directly to flash chromatography (CH2Cl2) to yield the title compound 1.334 (18 mg, 88%) as a 
colourless oil. Analytical data observed matched analysis of commercially available compound. 
 
N-Boc-2-methylindole 1.340 
A 4 mL screw-top glass vial was charged with 2-allyl-N-Boc-aniline 1.337 (44 mg, 0.16 
mmol), toluene (0.64 mL), H2O (0.64 mL), KH2PO4 (44 mg, 0.32 mmol), allyl chloride 
(0.067 mL, 0.79 mmol) and Pd(hfacac)2 (8.0 mg, 0.02 mmol). The vial was sealed under 
ambient atmosphere and the mixture was heated by immersion of the entire vial into a pre-heated 
aluminium block at 50 °C for 20 h. The mixture was cooled to room temperature, and subjected 
directly to flash chromatography (petroleum ether/CH2Cl2 1:1) to afford title compound 1.340 (21 
mg, 57% )as a colourless oil. Analytical data observed were in accordance with literature values.[119] 
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Chapter 2: Identification and Activity of Inhibitors of the 
Essential Nematode-Specific Metalloprotease DPY-31. 
2.1: Introduction 
2.1.1: Background 
Parasitic nematodes are known to infect humans and livestock worldwide, leading to chronic, 
debilitating and potentially lethal infections. Over 1 billion humans globally, particularly in the 
developing regions in Asia, Latin America and sub-Saharan Africa, suffer from nematode infections 
resulting in substantial mortality and morbidity.[120,121] 
 
Despite these vast nematode-infected populations, relatively little research funding is directed to 
nematode treatments compared to HIV/AIDS, malaria and tuberculosis. Several nematode-induced 
diseases were included on a recent World Health Organisation list of neglected tropical diseases 
aimed at increased funding.[122]  
 
The socio-economic impact on the agricultural industry due to costs of treatments and livestock loss 
is significant, with the annual cost of sheep and cattle infections in Australia alone estimated at $1 
billion.[123] There are also major losses in plant-based food production, estimated at $80 billion 
annually, due to nematode infections in important crops.[124]  
 
Parasitic nematodes (also known as roundworms), one of the two major phyla of Helminth, include 
intestinal parasites and filarial worms. Diseases caused by parasitic nematode infections are diverse. 
Ascariasis lumbricoides, an intestinal parasite and the most prevalent nematode worldwide, causes 
Ascariasis infection which in most cases present no symptoms whatsoever, whereas Brugia malayi, 
a filarial nematode, causes lymphatic filariasis, more commonly known as elephantiasis, which is a 
horribly debilitating disease. A comprehensive review of Helminth infections has been undertaken 
by Hotez and co-workers.[125] 
 
GI-tract nematode infections in mammals usually occur via ingestion of contaminated water or food. 
Infections to the food supply add an additional risk for humans eating contaminated livestock. Filarial 
infections are transmitted by blood-feeding insects, most commonly mosquitos. The site of 
development of filarial nematodes varies between species, and human filarial infections are known 
to occupy subcutaneous fat, the lymphatic system and the thoracic muscle.[126] 
 
Parasitic nematode infections are currently treated through preventative chemotherapy through mass 
anthelmintic drug administration. Conventional anthelmintic drugs were initially developed for 
treatment of veterinary parasites and were subsequently applied to human parasites. Huge advances 
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in the field of veterinary anthelmintics were made between 1960 and 1980, and effective doses are 
now in the micromolar range, a small fraction compared to the gram doses necessary for the 
treatments used 20 years previously.[127,128,129] 
 
The most commonly used anthelmintic drugs fall into two categories: Avermectins and 
benzimidazoles, although there is a significant number of other treatments which do not fall into 
these categories.[127] Avermectins are macrocyclic lactone containing drugs, used as a broad spectrum 
treatment for parasitic nematode infections. The most commonly used avermectin, and indeed the 
most widely used anthelmintic, for nematode infections is Ivermectin, a mixture of Avermectin B1a 
and B1b (Figure 2.1). The global significance of Ivermectin is highlighted by the inclusion on the 
World Health Organisation’s model list of essential medicines.[4] 
 
 
Figure 2.1: Structure of Ivermectin 
 
Ivermectin has a broad therapeutic range of nematode targets, and is commonly used to medicate 
lymphatic filariasis, Onchocerciasis (caused by nematode Onchocerca volvulus) as well as several 
intestinal roundworms, and non-nematode helminths. Avermectins are known to cause paralysis of 
nematode mobility, eventually leading to expulsion. The exact mode of action is unknown, but 
studies have identified several different effects exhibited by Ivermectin.[130,131,132,133] 
 
The other major class of anthelmintics are benzimidazoles, which are a large group of drugs for the 
treatment of nematode infections of general structure shown (Figure 2.2). The group can be further 
classified into thiazoles (e.g. thiabendazole) and carbamates (e.g. albendazole). Benzimidazoles are 
generally used for the treatment of GI-tract nematodes in a broad range of species. The therapeutic 
action of benzimidazoles is through direct binding to nematode β-tubulin, and consequently inhibits 
the formation of microtubulin. Lack of microtubulin formation eventually leads to cell lysis.[134] 
 
 
Figure 2.2: Benzimidazoles 
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The chemotherapeutic strategy of mass administration, however, is one which will be progressively 
selective for drug resistance in nematode populations. GI parasites in livestock have demonstrated 
multiple drug resistance to current anthelmintic treatments,[135,136,137,138] and there are already 
examples of selective drug resistances developing in human filarial nematode populations.[121,139] As 
a consequence, there is significant concern that multidrug resistance will develop in human nematode 
populations. There have been only a limited number of novel treatment methods discovered in recent 
years,[140] thus limiting the prospects for effective control in either human or veterinary parasites. 
 
Attempts to increase the efficacy of current anthelmintic drugs have been thoroughly researched. For 
example, resistance to benzimidazoles has been associated with reduced affinity to nematode β-
tubulin.[141] Attempts to combat the resistance has centred on increasing the exposure time of the 
therapeutic to β-tubulin, primarily through modifications to drug metabolism. A combination of two 
benzimidazoles, oxfendazole and parbendazole (Figure 2.3), has demonstrated slowed metabolism, 
however they have not reached market for commercial reasons.[142,143] Another novel strategy 
targeted sensitising nematodes to current treatments through interruption of detoxification 
pathways.[124] Attempts have been made towards the development of a vaccine, although no product 
has yet reached the market.[144,145]  
 
  
Figure 2.3: Structures of Oxfendazole and Pardendazole 
 
The success of the strategies, however, has been limited. Furthermore, very few drugs with novel 
modes of action have become available in recent years, consequently limiting the ability to control 
nematode populations in livestock. As a result, the identification of new targets is at a critical stage 
and new drug candidates are urgently required. 
 
2.1.2: Nematode Astacin Metalloproteases 
Recently, the nematode cuticle has been identified as a potential target for chemotherapeutic 
intervention.[146] All nematodes are encased by a protective cuticle exoskeleton, primarily comprised 
of collagen proteins, which surrounds the nematode, protecting it from the external environment 
during development. The lifecycle of parasitic nematodes requires a moulting process at several 
stages during maturation.[147] The moulting process involves the biosynthesis of a new cuticle and 
simultaneous exsheathment of the old. The cuticle biogenesis process is a complex, multi-enzyme 
process.[148] 
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Free-living nematode Caenorhabditis elegans (C. elegans) is a non-parasitic nematode which has 
been subject to significant research as a model organism.[147] C. elegans expresses cuticle sequence 
homology throughout the nematode phyla, for example, in Teladorsagia circumcincta and 
Haemonchus contortus,[149,150] two major causes of veterinary infections. Furthermore, many of the 
cuticle synthesising enzymes and proteases crucial to C. elegans cuticle biosynthesis are also present 
in parasitic counterparts.[146] 
 
Astacin metalloprotease enzymes have demonstrated key functionality in cuticle biosynthesis in C. 
elegans.[148] Astacin metalloproteases contain a penta-coordinated zinc ion in the N-terminal active 
site.[151] DPY-31 (also known as NAS-35), a nematode-specific astacin, is a zinc endopeptidase 
which has demonstrated essential functionality the cuticle biosynthesis. DPY-31 has been established 
to cleave at the short C-terminal domain of essential cuticle collagen SQT-3.[152] 
 
Suppression of the gene encoding DPY-31 causes failure in the processing of procollagens, such as 
SQT-3, and consequently results in severe morphological defects (Figure 2.4). Compared to wildtype 
C. elegans (A), DPY-31 suppressed mutants (B) appear shorter and fatter. This non-viable phenotype 
is known as “dumpy” (DPY).  
 
 
Figure 2.4: C. elegans demonstrating lethal morphology defect caused by suppression of DPY-31 
gene 
 
Although the crystal structure of DPY-31, or indeed any nematode-specific astacin metalloprotease, 
is yet to be ascertained, the crystal structure of astacin metalloprotease enzyme from Astacus astacus, 
a freshwater crayfish, has been determined.[151] Furthermore, the enzyme has also been crystallised 
with a phosphinate inhibitor bound in the catalytic site, revealing important information about 
substrate-inhibitor interactions.[153] The crayfish astacin metalloprotease has 76% amino-acid 
sequence homology with DPY-31, and is thus proposed to be an effective model for nematode astacin 
metalloproteases.[154,155] The functionality of crayfish astacin has been subject to significant research, 
and the findings may be directly employable towards the development of DPY-31 inhibitors. It has 
also been established that DPY-31 retains significant structural homology between different 
nematode species.[156] 
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2.1.3: Hydroxamates as Zinc metalloprotease inhibitors 
Hydroxamic acids have long been known to exhibit strong binding to, and consequently inhibition 
of, zinc metalloprotease enzymes.[157,158] Hydroxamate functionality provides a strong bidentate 
chelation of the catalytic Zn2+ ion, through binding with each oxygen of the hydroxamate 
functionality (Figure 2.5). Furthermore, it has been demonstrated that the hydroxamate nitrogen is 
protonated during binding, and may function as a hydrogen bond donor.[159] Due to this bidentate 
interaction, hydroxamate containing compounds exhibit superior binding to Zn2+ than other 
metalloprotease inhibitors, including the widely utilised phosphinic acid group.[160]  
 
 
Figure 2.5: Hydroxamate interaction with catalytic zinc in metalloprotease matrilysin 
 
In 1990, Wolz and co-workers established the applicability of amino acid hydroxamates to inhibition 
of crayfish astacin metalloprotease (Figure 2.6).[161] The most potent inhibitors were demonstrated to 
be those with aromatic side-chains, and tyrosine-hydroxamate (IC50 = 175 µM) represented the then-
most potent reversible inhibitor of crayfish astacin metalloprotease. The report demonstrated the 
significant effect that the N-1 amino acid residue imparts on inhibitor binding.  
 
 
Figure 2.6: Hydroxamate inhibitors of crayfish astacin metalloprotease 
 
Various reports have shown that hydroxamate-based compounds also exhibit efficacious inhibition 
of Bone morphogenetic protein-1 (BMP-1). BMP-1 is a vertebrate procollagen C-proteinase (PCP), 
also a member of the astacin metalloprotease family,[155] which is known to play a crucial role in 
bone/cartilage formation by breakdown of procollagen to allow formation of collagen in humans. In 
2000, Ovens and co-workers demonstrated several potent hydroxamic acids inhibitors of PCP (Figure 
2.7).[162] Hydroxamate dipeptide 2.1 was demonstrated to be a powerful inhibitor of PCP, preventing 
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the cleavage of procollagen. The importance of the non-zinc binding hydroxamate-NH was 
demonstrated by the lack of inhibition exhibited by N-methylated analogue 2.2. 
 
 
Figure 2.7: Hydroxamate inhibitor of PCP 
 
Two further reports from Pfizer in 2007 and 2008 reported oxadiazole PCP inhibitors with improved 
potency, from which compounds 2.3 and 2.4 were selected as drug candidates (Figure 2.8).[163,164]  
 
 
Figure 2.8: Pfizer PCP-inhibitor drug candidates 
 
As was discussed previously, DPY-31 is a homologue of BMP-1, so it was hypothesised that these 
hydroxamate compounds may also exhibit inhibition of DPY-31, and thus affect the morphology, 
potentially lethally, of the nematode. Page and co-workers tested a range of hydroxamic acid drug 
candidates against T. circumcincta DPY-31 (Table 2.1).[165] Actinonin and oxadiazoles 2.3–2.6 have 
previously been shown to exhibit efficacious and reversible inhibition of Pro-collagen peptidases. 
When screened against nematode DPY-31, actinonin and pyridyl-oxadizole 2.5 proved effective 
inhibitors, albeit at a high concentration. Furthermore, phenotypic testing against C. elegans 
demonstrated that compounds 2.3 – 2.6 all caused morphological defects, leading to the “dumpy” 
phenotype. 
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Table 2.1: Hydroxamate inhibitors of DPY-31 
 
Compound IC50 rDPY-31 (T. circumcincta) Phenotypic 
effect against C. Elegans 
Actinonin 50 µM “Dumpy”, immobility 
2.3 N/A “Dumpy”, immobility 
2.4 N/A “Dumpy”, immobility 
2.5 40 µM “Dumpy”, immobility 
2.6 <100 µM “Dumpy”, immobility 
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2.2: Results and Discussion 
2.2.1: Introduction and aim 
The increased resistance of parasitic nematodes towards current anthelmintic drug treatments, 
coupled with the limited number of drugs candidates in recent years, has left the field of nematode 
infection treatment at a critical point: novel drug targets are urgently required.[165] Inhibition of cuticle 
exsheathment (ICE), through targeted binding to zinc metalloprotease DPY-31, is proposed as a 
novel method for the treatment. Previous work has shown that nematode astacin enzyme DPY-31 
plays a significant role in the moulting process of the nematode collagen exoskeleton.[152] Non-
expression of DPY-31 causes severe morphological defects and results in the lethal phenotype 
“dumpy”.[165] There are currently no drugs on the market for the treatment of nematode infections 
which act via the DPY-31 therapeutic target. 
 
The aim of this project was the design and synthesis of new metalloprotease inhibitors to allow the 
validation of ICE as a potential strategy for the treatment of parasitic nematode infections. The 
project represents the first step towards the development a totally novel mechanism for drug 
intervention. 
 
Compounds containing hydroxamic acid functionality have previously demonstrated inhibition of 
zinc metalloproteases and, more specifically, have demonstrated inhibition of astacin 
metalloprotease enzymes Pro-collagen C proteinase BMP-1 and in crayfish Astacus astacus. 
Collaborators tested a range of known hydroxamic acid drug candidates against T. circumcincta 
DPY-31 (section 2.1.3, table 2.1), demonstrating the potential for treatment of nematode infections 
via inhibition of cuticle exsheathment, but with low potency.[165] While phosphinate compounds have 
also been proved to exhibit zinc metalloprotease inhibition,[166,167,168] hydroxamates form stronger 
bonds to the active-site zinc and at a faster rate.[161,169] Thus, phosphinic acid inhibitors were not 
targeted. 
 
Several different compound design approaches were undertaken in an attempt to discover potent 
inhibitors of nematode DPY-31: 1) mimics of the known DPY-31 cleavage site in C. elegans; 2) 
using SAR data published for well-researched metalloproteases, such as Astacus astacus (crayfish) 
astacin and Pro-collagen C proteinase BMP-1 which are known to exhibit high structural homology 
to nematode astacin DPY-31 inhibitors and; 3) Known metalloprotease inhibitor marimastat was 
synthesised for in vivo testing as a treatment for inhibition of parasitic nematode DPY-31 and to 
allow for the synthesis of analogues. 
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2.2.2: Hydroxamic acid SQT-3 cleavage site mimics 
Design 
A mutant suppressor screen in C. elegans identified the target of astacin metalloprotease DPY-31 to 
be essential cuticle collagen SQT-3, and highlighted the specific peptide sequence at which DPY-31 
cleaves the collagen in the C-terminal domain (Figure 2.9).[152,170] Although the overall sequence 
homology of each member of the SQT-3 sub-family (SQT-3, RAM-4, DPY-13 and DPY-4) is ca. 
60%, the C-terminal putative cleavage site of SQT-3 is highly conserved, with near identical 
sequence of amino acid residues.  
 
 
Figure 2.9: Analysis of DPY-31 cleavage site on C-terminus of collagens of the SQT-3 subfamily 
 
At the DPY-31 cleavage site in the SQT-3 collagens, there is a common alanine-leucine/isoleucine 
motif at the binding site of DPY-31. It was proposed that by mimicking this amino acid sequence, 
effective binding to DPY-31 can be achieved. Towards this goal, dipeptide hydroxamates 2.7 and 
2.8 were targeted for synthesis (Figure 2.10).  
 
 
Figure 2.10: Proposed SQT-3 mimics. 
 
Compound synthesis 
Alanine-Leucine dipeptide was synthesised in three steps from commercially available amino acids 
(Scheme 2.1). Peptide coupling of leucine-methyl ester 2.9 and Boc-protected alanine under DCC 
coupling conditions, followed by ester hydrolysis yielded dipeptide 2.11 in an 80% yield over 2 steps. 
Subsequent conversion to the hydroxamate under amide-coupling conditions afforded hydroxamic 
acid 2.7. 
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Scheme 2.1: Synthesis of hydroxamic acid 2.7 
 
In order to comprehend the effect of the amine-protection, the non-protected dipeptides of acid 2.11 
and hydroxamic acid 2.7 were also synthesised (Scheme 2.2). Trifluoroacetic acid-mediated 
carbamate hydrolysis, followed by anion exchange, yielded hydrochloride salts 2.12 and 2.13 in good 
yields. 
 
 
Scheme 2.2: Deprotection of amino acid 2.11 and hydroxamic acid 2.7 
 
The same protocol was utilised for the synthesis of alanine-isoleucine hydroxamic acid 2.8 (Scheme 
2.3). The DCC-mediated coupling between Boc-protected alanine and isoleucine-methyl ester, 
followed by ester hydrolysis yielded dipeptide amino acid 2.15 in a 76% yield over two steps. 
Subsequent transformation to hydroxamic acid 2.8 proceeded smoothly to yield dipeptide 2.8. 
 
 
Scheme 2.3: Synthesis of hydroxamic acid 2.8 
 
As discussed previously, the non-protected amines were required for testing (Scheme 2.4). 
Carbamate hydrolysis proceeded efficiently to garner alanine-isoleucine amino acid 2.16 and 
alanine-isoleucine hydroxamate 2.17 in good yield. 
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Scheme 2.4: Deprotection of diamides 2.15 and 2.8 
 
Biological screening 
An astacin assay screen was performed on the synthesised alanine-leucine dipeptides to determine 
the inhibitory activity against recombinant DPY-31 from T. circumcincta and B. malayi.[165] The 
screens were undertaken by researchers at Institute of Biodiversity at the University of Glasgow. The 
results of the absorbance assay undertaken against T. circumcincta DPY-31 is displayed below 
(Figure 2.11). As expected, dipeptides 2.11 and 2.12 exhibited no inhibitory activity. Boc-protected 
hydroxamic acid 2.7 exhibited inhibition of DPY-31 at high concentrations. Non-protected 
hydroxamic acid dipeptide 2.13 demonstrated no inhibition of DPY-31.  
 
 
 
Figure 2.11: Absorbance assay results for alanine-leucine dipeptides against T. circumcincta 
 
In contrast to the assay screen against T. circumcincta, screening against recombinant DPY-31 from 
human filarial nematode T. malayi did not identify any compound exhibiting inhibition (Figure 2.12). 
As expected, amino acids 2.11 and 2.12 did not demonstrate activity. Hydroxamic acids 2.7 and 2.13 
also failed to demonstrate any significant inhibition. 
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Figure 2.12: Absorbance assay results for alanine-leucine dipeptides against Brugia malayi 
 
A more detailed analysis of Boc-protected hydroxamate 2.7 allowed confirmation that it acts as a 
weak inhibitor of T. circumcincta DPY-31 but displays little effect against B. malayi DPY-31, with 
both trends extending at higher concentrations (Figure 2.13).  
 
 
Figure 2.13: Detailed absorbance assay analysis of hydroxamic acid 2.7 
 
Absorbance assay screening of alanine-isoleucine dipeptides recombinant DPY-31 from T. 
circumcincta, H. contortus and B. malayi demonstrated similar results to the alanine-leucine 
dipeptides discussed above. Amino acids 2.15 and 2.16 failed to exhibit inhibition of either T. 
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circumcincta or B. malayi DPY-31 (Figure 2.14). This result reaffirms the lack of activity of 
carboxylic acids against parasitic nematode DPY-31.  
 
 
 
Figure 2.14: Assay testing of compounds 2.15 to 2.16 against T. circumcincta 
 
Hydroxamic acid alanine-leucine dipeptides 2.8 and 2.17 were subsequently subjected to absorbance 
assay testing (Figure 2.15). As was demonstrated for hydroxamic acid 2.13, non-protected 
hydroxamic acid 2.17 demonstrated no inhibition of T. circumcincta DPY-31. Boc-protected 
analogue 2.8, however, demonstrated weak inhibition of T. circumcincta DPY-31 and H. contortus 
DPY-31.  
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Figure 2.15: Assay testing of compounds 2.8 to 2.17 against Brugia malayi 
 
Phenotypic screening of the dipeptide hydroxamic acid 2.7 resulted in morphological defects in 
parasitic nematodes T. circumcincta and H. contortus, resulting in either cuticle blistering, or 
retention of an old cuticle by a new larval stage. Promisingly, phenotypic testing against non-parasitic 
C. elegans displayed the “dumpy” phenotype – a severe morphological defect. 
2.2.3: Hydroxamic acid analogues of potent phosphinic pseudopeptide 
Compound design and synthesis 
The crystal structure for crayfish (Astacus astacus) astacin has been determined and has subsequently 
been subject to significant research (Section 2.1.3). The structural homology between crayfish and 
nematode astacin is high (ca. 76%).[154] It was consequently proposed that information gathered 
regarding the inhibition of crayfish astacin metalloproteases can be directly applicable to the 
inhibition of nematode astacin DPY-31. Phosphinic acid pseudopeptide 2.18 has demonstrated 
nanomolar range inhibitory activity against crayfish astacin (Figure 2.16).[171] The crystallisation of 
a similar phosphinic acid in the Crayfish astacin binding pocket demonstrated important inhibitor-
substrate binding between each amino-acid residue.[153] Hydroxamic acids have demonstrated 
stronger and faster binding than phosphinic acid counterparts,[161,169] and consequently, hydroxamic 
acid 2.19 was proposed to be a highly potent nematode astacin inhibitor. 
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Figure 2.16: Phosphinic acid 2.18 and proposed hydroxamic acid 2.19 
 
In order to fully grasp any change in potency provided through change in amino acid residue, 
modifications relative to hydroxamic acids 2.7 and 2.8 were introduced stepwise. Hydroxamic acid 
dipeptide 2.20 (Figure 2.17) was designed to probe the inclusion of an aromatic amino acid residue 
at the P1 position, as exhibited by phosphinic acid 2.18. The inclusion of an aromatic amino acid 
residue at the P1 position has previously been demonstrated to exhibit stronger inhibitor–enzyme 
binding of hydroxamic acids to astacin metalloproteases.[161] 
 
 
Figure 2.17: Proposed inhibitor 2.20 
 
Hydroxamate 2.20 was synthesised via the same protocol described for leucine and isoleucine 
analogues (Scheme 2.5). Dipeptide 2.21 was synthesised from phenylalanine-methyl ester and Boc-
alanine fragments using peptide coupling conditions. Ester hydrolysis and subsequent hydroxamic 
acid formation afforded desired dipeptide 2.20. The unprotected hydroxamic acid was not sought, 
because previous results demonstrated inactivity of the amine to DPY-31. 
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Scheme 2.5: Synthesis of dipeptide 2.20 
 
A 1995 report discussed inhibitors with significantly improved inhibition of astacin metalloprotease 
activity by inclusion of a proline residue at P3 position of a phosphinic acid inhibitors. [171] The same 
report established that the crayfish astacin binding pocket is long, and an increased number of amino 
acid residues produced greater substrate binding, and consequently, greater potency. Boc- and Fmoc-
protected proline containing hydroxamic acids 2.23 and 2.24 were proposed to improve the inhibition 
of nematode DPY-31 (Figure 2.18). 
 
 
Figure 2.18: Proposed nematode astacin inhibitors 2.23 and 2.24 
 
Previously synthesised dipeptide 2.21 was deprotected to yield the amine 2.25, which was 
subsequently coupling with a Boc-protected proline residue, yielding tripeptide 2.26 (Scheme 2.6). 
Ester hydrolysis, followed by hydroxamic acid formation yielded the desired substrate 2.23. 
 
 
Scheme 2.6: Synthesis of tripeptide 2.23 
160 
 
 
Fmoc-protected tripeptide 2.24 was synthesised via the same protocol as above (Scheme 2.7). 
Unprotected-dipeptide 2.25 was coupled with Fmoc-protected proline to yield tripeptide 2.28. Ester 
hydrolysis, followed by hydroxamic acid formation yielded desired substrate 2.24. 
 
Scheme 2.7: Synthesis of tripeptide 2.24 
 
Testing results: 
Hydroxamic acids 2.20, 2.23 and 2.24 were submitted to absorbance assay testing[165] to determine 
inhibitory activity of recombinant DPY-31 from three parasitic nematodes: T. circumcincta, H. 
contortus and B. malayi. Alanine–phenylalanine dipeptide 2.20 demonstrated inhibition of T. 
circumcincta at similar concentrations to non-aromatic dipeptides 2.7 and 2.8. Tripeptides 2.23 and 
2.24, however, exhibited significantly improved potency, with Fmoc protected hydroxamic acid 2.24 
exhibiting the greatest potency (Figure 2.19). 
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Figure 2.19: Absorbance assay results for the inhibition of recombinant T. circumcincta DPY-31 
by hydroxamic acids 2.20, 2.23 and 2.24 
 
Similar results were demonstrated for the inhibition of recombinant H. contortus DPY-31 (Figure 
2.20). Alanine–phenylalanine dipeptide hydroxamic acid 2.20 demonstrated comparable activity to 
alanine–isoleucine dipeptide 2.7. Tripeptide hydroxamic acids 2.23 and 2.24 exhibited significantly 
greater potency.  
 
 
 
Figure 2.20: Absorbance assay results for the inhibition of recombinant H. contortus DPY-31 by 
hydroxamic acids 2.20, 2.23 and 2.24 
 
Tripeptides 2.23 and 2.24 were then tested for inhibition against DPY-31 from human parasite Brugia 
malayi (Figure 2.21). No compound previously synthesised as part of this project has demonstrated 
inhibition against B. malayi DPY-31. Encouragingly, both Boc- and Fmoc protected tripeptides 2.23 
and 2.24 were demonstrated to be effective inhibitors. 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 100 200 300 400 500
A
b
so
rb
an
ce
 a
t 
4
0
5
 n
m
Compound concentration (µM)
H. Contor. absorbance assay for hydroxamic acid 
analogues of phosphinic acid pseudo-peptide
2.20
2.23
2.24
162 
 
 
 
Figure 2.21: Absorbance assay results for the inhibition of recombinant B. malayi DPY-31 by 
tripeptide hydroxamic acids 2.23 and 2.24 
 
The IC50 values calculated for tripeptides 2.23 and 2.24 and are displayed below (Table 2.2). Both of 
the tripeptide hydroxamic acids synthesised as part of this project (2.23 and 2.24) exhibited low µM 
range inhibition against rDPY-31 from veterinary parasite T. circumcincta. Promisingly, Fmoc-
protected tripeptide 2.24 also exhibits low µM range inhibition against rDPY-31 from human filarial 
parasite B. malayi. These results are consistent with the proposed homology between DPY-31 
enzymes across nematode species.[156] At this time, Fmoc-protected tripeptide 2.24 exemplifies the 
most potent inhibitor of nematode DPY-31 currently known. 
 
The results compare favourably to previously the values calculated for oxadiazole 2.5 and marimastat 
which were measured under the same absorbance assay conditions. Oxadiazole 2.5 exhibited similar 
activity to Fmoc-protected hydroxamic acid 2.24 against both T. circumcincta and B. malayi, but 
marimastat was a significantly poorer inhibitor of nematode DPY-31. Interestingly, phosphinic acid 
2.30, which contains an identical N-terminal amino-acid sequence to phosphinic acid 2.30, was 
inactive in this assay. 
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Table 2.2: IC50 values recorded for tripeptides 2.23 and 2.24 and comparison to values recorded for 
known hydroxamic acids 2.5 and marimastat and phosphinic acid 2.30 
 
Compound 
IC50 rDPY-31(µM) 
   B. malayi       T. circumcincta 
2.23 76 26 
2.24 26 34 
2.5 22 40 
Marimastat 181 71 
2.30 > 500 > 500 
 
Phenotypic screening of tripeptides 2.23 and 2.24 was undertaken to assess any morphological 
defects caused. Wild-type free-living nematode C. elegans (A) is displayed below (Figure 2.22). 
Treatment with 50 µM of Boc-protected tripeptide 2.23 (B) resulted in the shorter, fatter morphology 
called “dumpy”. This phenotype is consistent with the loss of function of DPY-31.[152] 
 
 
Figure 2.22: Phenotypic screen of wild-type C. elegans  
 
Similar results were observed upon treatment of TP224 (C) – a T. circumcincta DPY-31 
transgenically-rescued C. elegans DPY-31 mutant (Figure 2.23). Treatment with 100 µM of Boc-
protected tripeptide 2.23 (D) also demonstrated the “dumpy” phenotype.  
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Figure 2.23: Phenotypic screen of TP224 
 
Furthermore, veterinary parasite T. circumcincta (E) was treated with 500 µM of Fmoc-protected 
tripeptide 2.24 (Figure 2.24). A higher concentration was required, but the “dumpy” phenotype was 
observed, confirming the DPY-31 inhibitory effect. 
 
 
Figure 2.24: Phenotypic screen of parasitic nematode T. circumcincta 
2.2.4: Marimastat: 
Marimastat is a hydroxamic acid which has demonstrated pharmaceutical activity, initially designed 
as a broad spectrum zinc metalloprotease inhibitor for the treatment of cancer and has demonstrated 
promising pharmacokinetic properties in mice (Figure 2.25).[172] It has previously exhibited 
metalloprotease inhibition,[173] but was less effective against parasitic nematode DPY-31 than 
compounds previously synthesised in this project (Table 2.2). The combination of the known 
pharmacokinetic properties of marimastat and activity against recombinant DPY-31 motivated a 
study into the in vivo efficacy for the treatment of nematode infections in mice which was undertaken 
in collaboration with a group at the University of Edinburgh. It was proposed that synthesising the 
compound, rather than purchasing, would afford the opportunity to efficiently construct analogues.  
 
 
Figure 2.25: Marimastat structure 
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In 2000, Davenport et al. reported an improved synthesis of marimastat.[173] The key step of the 
reaction sequence was the construction of the central amide bond by coupling carboxylic acid 
fragment 2.31 with amine fragment 2.32. Fragments 2.31 and 2.32 are made from commercially 
available starting materials, L-(–)-malic acid and Boc-tert-leucine respectively (Scheme 2.8). 
Importantly, the late stage fragment coupling is conducive to rapid synthesis of analogues. 
 
 
Scheme 2.8: Retrosynthetic analysis of Marimastat 
 
The synthesis of acid fragment 2.31 began with Fischer esterification of L-(–)-malic acid to yield (S)-
diisopropylmalate. The allylation of (S)-diisopropylmalate to yield 2.33 was successful using LDA 
and methallyl iodide (Scheme 2.9). 
 
 
Scheme 2.9: Esterification and allylation of Malic acid 
 
Attempts towards the allylation were undertaken with the freshly prepared methyl iodide, as well as 
methallyl chloride and bromide due to their ready availability (Table 2.3). Methallyl chloride (entry 
1) did not result in desired product 2.33. Methallyl bromide (entry 2) gave a 7:1 diastereomeric ratio 
of separable diastereomers 2.33 to 2.34, and an isolated yield of 32%. Methallyl iodide (entry 3) gave 
an improved diastereomeric ratio of 9:1 in the crude product, with a slightly improved yield. 
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Table 2.3: Optimisation of allylation 
 
Entry X 2.33:2.34 Yield of 2.33 
1 Cl - Not observed 
2 Br 7 : 1 32% 
3 I 9 : 1 35% 
 
The diastereoselectivity of the allylation reaction is proposed to arise from cyclic intermediate 2.35 
(Scheme 2.10).[174] Chelation between the lithium enolate and the alkoxide of the malate dianion 
hinders approach of the electrophile on the bottom face, giving rise to diastereoselectivity of up to 
10:1 in favour of anti-product 2.33. 
 
 
Scheme 2.10: Explanation of diastereoselectivity 
 
Acid fragment 2.31 was prepared from 2.33 following a known procedure (Scheme 2.11).[172] 
Hydrogenation of olefin 2.33 proceeded with excellent yield to yield diester 2.36, which was 
subsequently hydrolysed under basic conditions. Lactonisation of dicarboxylic acid 2.37 produced 
the acetonide and completed the synthesis of Acid fragment 2.31 in 5 steps. 
 
 
Scheme 2.11: Synthesis of carboxylic acid fragment 2.31 
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Amine fragment 2.32 was synthesised in two steps from Boc-tert-Leucine (Scheme 2.12). 
Methylamide formation proceeded smoothly to yield Boc-protected amine 2.38. Deprotection using 
trifluoroacetic acid gave fragment 2.32 as the trifluoroacetate salt in a 70% yield over 2 steps. 
 
 
Scheme 2.12: Synthesis of amine fragment 2.32 
 
With both fragments in hand, attempts were made towards the coupling of fragments 2.31 and 2.32 
(Table 2.4). The protocol previously utilised by Davenport and co-workers were tested, but the 
coupling to the bulky tert-leucine fragment proved to be unsuccessful under these conditions.[173] Use 
of CDI (entry 2) proved to have no improvement. In both cases, activation of the carboxylic acid 
(fragment 2.31) was observed, but the subsequent amide bond formation with fragment 2.32 was 
unsuccessful. Addition of nucleophilic catalyst DMAP (entry 3) successfully allowed the coupling 
of fragment 2.32 to the activated species derived from fragment 2.31, and desired peptide 2.39 was 
obtained in a 69% yield.   
 
Table 2.4: Attempted coupling of fragments 2.31 and 2.32 
 
Entry Conditions Result (isolated yield of 2.39) 
1 EDC, NEt3, CH2Cl2, RT, 40 h No conversion of B 
2 CDI, NEt3, THF, RT, 40 h No conversion of B 
3 EDC, DMAP, DMF, 0 °C, 24 h Full conversion (69%) 
 
With acetonide 2.39 in hand, the synthesis of marimastat was completed by direct acetonide attack 
from hydroxylamine (Eq. 2.2). Repeated crystallisation provided highly pure marimastat which was 
suitable for in vivo trials. 
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Testing results: 
In situ biological testing was undertaken by researchers at the Institute of Structural and Molecular 
Biology at the University of Edinburgh. Mice infected by Heligmosomoides polygyrus (common 
rodent intestinal nematode parasite) were treated with marimastat, injected by gavage (an oral 
administration method). Treatment with marimastat showed a reduction in faecal egg count 
compared to gavage injection of water (Figure 2.26). Mice with no gavage however, demonstrated 
significantly lower faecal egg counts, suggesting that gavage injection has a negative effect on the 
immune response of the mouse.  
 
Figure 2.26: Faecal egg count after 14 days of marimastat treatment 
 
Although the egg count after treatment with marimastat was 50% lower, there was no reduction in 
the total worm count (Figure 2.27). This would suggest that marimastat was having a negative 
effect on the health of the nematode, but does not reliably eliminate the worm.  
 
Figure 2.27: Worm count after 14 days of marimastat treatment  
2.2.5: Conclusions 
Boc-protected hydroxamic acid dipeptides 2.7 and 2.8 demonstrated weak inhibition against DPY-
31 in recombinant T. circumcincta and H. contortus (Figure 2.28). Alanine–leucine dipeptide 2.7 has 
also been demonstrated to cause morphological defects in parasitic nematodes. The results also 
provided evidence that amino-acids and non-protected hydroxamic acids are not effective 
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metalloprotease inhibitors. It is also important to consider that no major improvement in activity was 
demonstrated by introducing an aromatic P1 amino acid residue (dipeptide 2.20), as opposed to the 
apolar aliphatic residues utilised in compounds 2.7 and 2.8. This is contrary to the proposal that the 
aromatic moiety would allow stronger substrate–inhibitor binding,[161] although is in agreement with 
the alternate proposal that the P1 position plays only a minor role in substrate binding.[175] 
 
 
Figure 2.28: Dipeptide hydroxamic acids exhibiting nematode DPY-31 inhibition 
 
More promising results were obtained from tripeptide hydroxamic acids 2.23 and 2.24 (Figure 2.29). 
Both the Boc- and Fmoc-protected analogues have demonstrated inhibition of DPY-31 in 
recombinant B. malayi (human filarial nematode) and T. circumcincta (sheep GI parasite) assay 
testing. Furthermore, phenotypic screening against several nematode strains displayed significant 
occurrence of the DPY phenotype, a non-viable body morphology associated with the inhibition of 
DPY-31, supporting the findings. Fmoc-protected tripeptide 2.24 is currently the most potent known 
inhibitor of nematode DPY-31. 
 
 
Figure 2.29: Hydroxamic acids 2.23 and 2.24 
 
Taken together, these results represent a start point in developing new metalloprotease inhibitors for 
the treatment of nematode infections through inhibition of DPY-31, a totally novel chemotherapeutic 
target. 
 
2.2.6: Future work 
Towards the long-term goal of the discovery of viable drug candidates for the inhibition of DPY-31, 
significantly more potent compounds must be discovered. Additionally, there is currently no data on 
pharmacokinetic of ADMET properties of the synthesised hydroxamic acids and, consequently, it is 
unknown if the tripeptide compounds are suitable drug candidates. 
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The results obtained, however, are particularly promising because tripeptide 2.19, the lysine analogue 
of 2.24, the current most potent inhibitor of DPY-31 (Figure 2.30) may provide improved substrate–
inhibitor binding, increased drug potency.[171]  
 
 
 
Figure 2.30: Target hydroxamic acid 2.19 
 
Due to time constraints, the desired analogues of marimastat were not synthesised. It is proposed, 
however, that coupling carboxylic acid fragment 2.31 with different, longer chain, amino acid 
sequences would allow for improved inhibition of DPY-31 (Figure 2.31). Proposed analogue 2.40 
was designed using the C-terminus of potent pseudo-phosphinic acid 2.18.  
 
 
Figure 2.31: Proposed analogue of marimastat 
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2.3 Supporting Information 
2.3.1 General Methods 
General methods are as described in Section 1.4.1. 
2.3.2: General Procedures 
General Procedure A: Amide bond formation 
 
 
To a stirred solution of amino acid-methyl ester.HX (1.1 equiv.) in CH2Cl2 (0.50 M) at 0 °C was 
added carbamate protected amino acid (1.0 equiv.). The resulting suspension was stirred for 10 mins, 
before addition of a solution of dicyclohexylcarbodiimide (1.2 equiv.) and triethylamine (1.1 equiv.). 
The solution was warmed to room temperature and allowed to stir for 4 h, before cooling to 0 °C and 
filtering. The filtrate was washed with sat. aq. NaHCO3, and the resultant mixture was extracted with 
CH2Cl2 (x 3). The combined organics were dried (Na2SO4), filtered and concentrated in vacuo.  
 
General Procedure B: Methyl ester hydrolysis 
 
Methyl ester (1.0 equiv.) was stirred in 3:2 ethanol:1.0 M aq. NaOH (0.10 M) at room temperature 
for 1 h. Upon reaction completion, ethanol was removed in vacuo, and the aqueous solution was 
washed with EtOAc. The aqueous layer was acidified to pH 1 with 0.10 M aq. HCl and extracted 
with EtOAc (x 3). The combined organic extracts were dried (Na2SO4), filtered and concentrated in 
vacuo.  
 
General Procedure C: Hydroxamic acid synthesis 
 
To a solution of N-protected amino acid (1.0 equiv.) in THF (0.050 M) was added carbonyl 
diimidazole (1.2 equiv.). The solution was stirred at room temperature for 1 h, before the addition of 
O-trimethylsilyl hydroxylamine (3.2 equiv.). The resultant mixture was stirred for 16 h at room 
temperature, before the quenching with MeOH. The solution was stirred for 1 h, and concentrated in 
vacuo.  
 
 
 
172 
 
 
 
General Procedure D: Removal of Boc protecting group 
 
To a stirred solution of Boc-protected amino acid (1.0 equiv.) in CH2Cl2 (0.50 M) was added 
trifluoroacetic acid (1:2 v/v w.r.t. CH2Cl2) at room temperature. The solution was stirred at room 
temperature for 1 h, before concentrating in vacuo. The resultant solution was taken up in water, 
washed with EtOAc (x 3) and concentrated in vacuo to yield the trifluoroacetate salt. 
 
2.3.3: Compound Synthesis 
SQT-3 Cleavage site mimics: 
 
 
Boc-Ala-Leu-OMe 2.10 
Following general procedure A, Boc-Ala-OH (1.9 g, 10 mmol) and leucine 
methyl ester hydrochloride 2.9 (2.0 g, 11 mmol) were coupled. The crude 
material was used directly in the following step.  
 
Boc-Ala-Leu-OH 2.11 
Following general procedure B, Boc-Ala-Leu-OMe (10 mmol) was hydrolysed 
to afford title compound 2.11 (2.6 g, 87% over 2 steps). No further purification 
was required. Observed analytical data was in accordance with literature 
values.[176]  
 
Boc-Ala-Leu-NHOH 2.7 
Following general procedure C, Boc-Ala-Leu-OH 2.11 (0.50 g, 1.7 mmol) 
was transformed into the corresponding hydroxamate. The crude product was 
taken up in H2O (10 mL) and washed with Et2O (3 x 10 mL). The aqueous 
phase was then extracted with EtOAc (3 x 10 mL). The combined organic 
extracts were dried (Na2SO4), filtered and concentrated to afford title compound (0.14 g, 27%) as a 
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white powdered solid. 1H NMR (400 MHz, DMSO-d6) δ 10.63 (1H, s, NHOH), 8.84 (1H, s, NHOH), 
7.73 (1H, m, NH-Leu), 6.93 (1H, d, J = 7.6 Hz, NH-Ala), 4.24 – 4.18 (1H, m, Ala- αCH), 3.96 (1H, 
t, J = 7.3 Hz, Leu-αCH), 1.59 – 1.51 (1H, m, Leu-CH(CH3)2), 1.49 – 1.31 (11H, m, Boc-(CH3)3 & 
Leu-CH2), 1.13 (3H, d, J = 7.0 Hz, Ala-CH3), 0.88 – 0.81 (6H, m, Leu-(CH3)2); 13C NMR (125 MHz, 
DMSO) δ 172.2 (C), 168.4 (C), 155.1 (C), 78.1 (C), 49.7 (CH), 48.5 (CH), 41.4 (CH2), 28.2 (CH3), 
24.0 (CH3), 22.8 (CH), 21.9 (CH3), 18.0 (CH3); IR (thin film) 1670, 1640, 1528; HRMS (ESI 
negative) exact mass calculated for C14H26N3O5 [M–H]– m/z 316.1878; found m/z 316.1867. 
 
H-Ala-Leu-NHOH.HCl 2.13 
Following general procedure D, Boc-Ala-Leu-NHOH 2.7 (0.30 g, 0.95 mmol) 
was deprotected to yield the trifluoroacetate salt. The salt was taken up in 0.1M 
aq. HCl and concentrated in vacuo to afford title compound 2.13 (0.13 g, 54%) 
as a powdered solid. 1H NMR (400 MHz, DMSO-d6) δ 10.79 (1H, s, NHOH), 
8.93 (1H, s, NHOH), 8.58 – 8.53 (1H, m, Leu-NH), 8.32 – 7.88 (3H, m, NH3), 4.31 – 4.21 (1H, m, 
Ala-αCH), 3.88 – 3.80 (1H, m, Leu-αCH), 1.69 – 1.39 (3H, m, Leu-CH2 & Leu-CH(CH3)2), 1.36 – 
1.29 (3H, m, Ala-CH3), 0.92 – 0.82 (6H, m, Leu-(CH3)2); 13C NMR (125 MHz, DMSO) δ 173.4 (C), 
169.6 (C), 50.5 (CH), 47.9 (CH2), 24.2 (CH), 22.9 ((CH3)2), 21.2 (CH), 17.1 (CH3); IR (thin film) 
1659, 1547, 1184; HRMS (ESI positive) exact mass calculated for C9H20N3O3 [M+H]+ m/z 218.1499; 
found m/z 218.1495. 
 
 
H-Ala-Leu-OH.HCl 2.12 
Following general procedure D, Boc-Ala-Leu-OH 2.11 (0.40 g, 1.3 mmol) was 
deprotected to yield the trifluoroacetate salt. The salt was taken up in 0.1 M aq. 
HCl and concentrated in vacuo to afford title compound 2.12 (0.31 g, 99%) as an 
amorphous solid. No further purification was required. 1H NMR (400 MHz, 
DMSO-d6) δ 8.83 (1H, d, J = 7.5 Hz, NH), 8.25 (3H, s, NH3), 4.42 – 4.21 (1H, m, Ala-αCH), 3.87 
(1H, m, Leu-αCH), 1.79 – 1.44 (3H, m, Leu-CH(CH3)2 and CH2), 1.42 – 1.31 (3H, d, J = 7.0 Hz, 
Ala-CH3), 0.90 – 0.86 (6H, m, Leu-(CH3)2). 13C NMR (125 MHz, DMSO) δ 173.6 (C), 169.6 (C), 
50.6 (CH), 48.0 (CH2), 24.2 (CH), 22.9 (CH3), 21.2 (CH), 17.1 (CH3); IR (thin film) 1702, 1661, 
1184, 1138; HRMS (ESI positive) exact mass calculated for C9H19N2O3 [M]+ m/z 203.1390; found 
m/z 203.1381. 
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Boc-Ala-Ile-OMe 2.14 
Following general procedure A, Boc-Ala-OH (2.0 g, 11 mmol) and isoleucine 
methyl ester hydrochloride (1.9 g, 10 mmol) were coupled. The crude material 
was used directly in the following step. 
 
Boc-Ala-Ile-OH 2.15 
Following general procedure B, Boc-Ala-Ile-OMe 2.14 (10 mmol) was 
hydrolysed to afford title compound 2.15 (2.3 g, 76% over 2 steps). No further 
purification was required. Observed analytic data is in accordance with 
literature values.[177]  
 
Boc-Ala-Ile-NHOH (2.8) 
Following a modification to general procedure C, where the reaction mixture 
was heated to 60 °C for 48 h, Boc-Ala-Ile-OH 2.15 (0.60 g, 2.0 mmol) was 
transformed into the corresponding hydroxamate. The crude product was 
taken up in CH2Cl2 (10 mL) and extracted with H2O (3 x 10 mL). The 
combined aqueous extracts were acidified to pH 3 using 0.1 M aq. HCl and extracted with CH2Cl2 
(3 x 10 mL). The combined organic extracts were washed with sat. aq. NaHCO3 (10 mL), dried 
(Na2SO4), filtered and concentrated in vacuo to afford title compound 2.17 (0.31 g, 49%) as an 
amorphous solid. 1H NMR (400 MHz, DMSO-d6) δ 10.59 (1H, s, NHOH), 8.86 (1H, s, NHOH), 7.67 
(1H, d, J = 9.4 Hz, Ile-NH), 6.99 (1H, d, J = 7.4 Hz, Ala-NH), 4.15 (1H, dd, J = 9.3, 6.5 Hz, Ile-
αCH), 4.01 (1H, m, Ala-αCH), 1.74 – 1.64 (1H, m, Ile-CH), 1.37 (9H, s, Boc-(CH3)3), 1.31 – 1.09 
(5H, m, Ala-CH3 and Ile-CH2), 0.89 – 0.74 (6H, m, 2 x Ile-CH3).; 13C NMR (100 MHz, DMSO) δ 
172.6 (C), 167.6 (C), 155.0 (C), 78.1 (C), 54.9 (CH), 53.4 (CH), 49.4 (CH), 37.1 (CH2), 28.1 (CH2), 
25.5 (CH3), 18.2 (CH3), 14.5 (CH3); IR (thin film) 1647, 1522, 1165; HRMS (ESI negative) exact 
mass calculated for C14H26N3O5 [M–H]– m/z 316.1862; found m/z 316.1862. 
 
H-Ala-Ile-NHOH.HCl 2.17 
Following general procedure D, Boc-Ala-Ile-NHOH 2.8 (0.21 g, 0.66 mmol) 
was deprotected to yield the trifluoroacetate salt. The salt was taken up in 0.1 
M aq. HCl and concentrated in vacuo to afford title compound 2.17 as a white 
amorphous solid (0.11 g, 66%). No further purification was required. 1H NMR 
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(500 MHz, DMSO-d6) δ 10.75 (1H, s, NHOH), 8.55 (1H, s, NHOH), 8.11 (4H, s, NH3 & NH), 4.35 
– 4.19 (1H, m, Ile-αCH), 4.04 – 3.86 (1H, m, Ala-αCH), 1.77 – 1.72 (1H, m, Ile-CH), 1.44 – 0.97 
(5H, m, Ile-CH2 and Ala-CH3), 0.84 (6H, m, 2 x Ile-CH3); 13C NMR (125 MHz, DMSO) δ 169.5 (C), 
167.0 (C), 54.9 (CH), 53.8 (CH), 48.2 (CH), 37.1 (CH2), 26.4 (CH3), 25.5 (CH3), 11.3 (CH3); IR (thin 
film) 1651, 1202, 1140; HRMS (ESI negative) exact mass calculated for C9H19N2O3 [M–H]– m/z 
216.1348; found m/z 216.1320. 
 
 
H-Ala-Ile-OH.HCl 2.16 
Following general procedure D, Boc-Ala-Ile-OH 2.15 (0.50 g, 1.7 mmol) was 
deprotected to yield the trifluoroacetate salt. The salt was taken up in 0.1 M aq. 
HCl and concentrated in vacuo to afford title compound 2.16 (0.39 g, 96%) as a 
powdered solid. No further purification was required. 1H NMR (400 MHz, 
DMSO-d6) δ 8.54 (1H, d, J = 8.3 Hz, Ile-NH), 8.22 (3H, s, NH3), 4.29 – 4.16 (1H, m, Ile-αCH), 3.94 
(1H, s, Ala-αCH), 1.88 – 1.77 (1H, m, Ile-CH), 1.48 – 1.35 (1H, m, Ha), 1.35 (3H, d, J = 7.0 Hz, Ala-
CH3), 1.22 (1H, m, Hb), 0.93 – 0.81 (6H, m, 2 x Ile-CH3); 13C NMR (125 MHz, DMSO) δ 172.4 (C), 
169.7 (C), 56.5 (CH), 47.8 (CH), 36.3 (CH), 24.6 (CH2), 17.2 (CH3), 15.6 (CH3), 11.3 (CH3); IR (thin 
film) 1709, 1663, 1186, 1138; HRMS (ESI positive) exact mass calculated for C9H19N2O3 [M]+ m/z 
203.1390; found m/z 203.1387. 
 
Hydroxamate analogues of phosphinic acid pseudopeptide: 
 
 
Boc-Ala-Phe-OMe 2.21 
Following general procedure A, Phenylalanine methyl ester hydrochloride 
(1.2 g, 5.5 mmol) was coupled with Boc-Ala-OH (0.95 g, 5.0 mmol). The 
crude mixture was purified by column chromatography (Petroleum 
Ether:EtOAc, 7:3) to afford title compound 2.21 (1.4 g, 80%) as a white 
powdered solid. Analytical data observed were in accordance with literature values.[178] 
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Boc-Ala-Phe-OH 2.22 
Following general procedure B, Boc-Ala-Phe-OMe (0.35 g, 1.0 mmol) was 
hydrolysed to afford title compound 2.22 (0.31 g, 89%). No further purification 
was required. Analytical data observed were in accordance with literature 
values.[178] 
 
Boc-Ala-Phe-NHOH 2.20 
Following general procedure C, Boc-Ala-Ile-OH (0.34 g, 1.0 mmol) was 
transformed into the corresponding hydroxamate. The crude product was 
taken up in CH2Cl2 (10 mL) and extracted with H2O (3 x 10 mL). The 
combined aqueous extracts were acidified to pH 3 using 0.1 M aq. HCl and 
extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were washed with sat. aq. 
NaHCO3 (10 mL), dried (Na2SO4), filtered and concentrated in vacuo to afford title compound as a 
white powdered solid (0.13 g, 37%). 1H NMR (400 MHz, DMSO-d6) δ 10.60 (1H, s, NHOH), 8.89 
(1H, s, NHOH), 7.97 – 7.74 (1H, m, Phe-NH), 7.40 – 7.04 (5H, m, 5 x Phe-CH), 6.97 – 6.80 (1H, m, 
Ala-NH), 4.41 – 4.35 (1H, m, Phe-αCH), 3.95 – 3.88 (1H, m, Ala-αCH), 3.14 – 2.70 (2H, m, Phe-
CH2), 1.51 – 1.15 (9H, m, Boc-(CH3)3), 1.18 – 0.99 (3H, m, Ala-CH3); 13C NMR (100 MHz, DMSO) 
δ 171.8 (C), 167.2 (C), 159.7 (C), 137.2 (C), 128.9 (CH), 127.7 (CH), 125.9 (CH), 78.0 (C), 51.2 
(CH), 50.0 (CH), 33.1 (CH2), 28.0 (CH3), 17.8 (CH3); IR (thin film); 1695, 1660, 1445; HRMS (ESI 
positive) exact mass calculated for C17H25N3O5Na [M+Na]+ m/z 374.1669; found m/z 374.1686. 
 
 
H-Ala-Phe-OMe.TFA 2.25 
Following general procedure D, Boc-Ala-Phe methyl ester (0.50 g, 1.4 mmol) 
was deprotected to yield title compound 2.25 (0.48 g, 92%) as a white 
powdered solid. The material was used directly in following steps. 
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Boc-Pro-Ala-Phe-OMe 2.26 
Following general procedure A, H-Ala-Phe methyl ester trifluoroacetate 
2.25 (0.60 g, 1.7 mmol) was coupled with Boc-Pro-OH (0.32 g, 1.5 mmol). 
The crude mixture was purified by column chromatography (Petroluem 
ether:EtOAc, 2:3) to afford title compound 2.26 (0.45 g, 60%) as a 
colourless oil. 
 
Boc-Pro-Ala-Phe-OH 2.27 
Following general procedure B, Boc-Pro-Ala-Phe-OMe 2.26 (0.7 g, 2.0 
mmol) was hydrolysed to yield the title compound 2.27. The crude material 
subjected directly to the following transformation. 
 
 
Boc-Pro-Ala-Phe-NHOH 2.23 
Boc-Pro-Ala-Phe-OH 2.27 (0.43 g, 1.0 mmol) was subjected to general 
procedure C. The crude mixture was diluted with water and acidified to 
pH 3 with 0.1 M aq. HCl. The mixture was extracted with CH2Cl2 (3 x 15 
mL) and the combined organics were washed with sat. aq. NaHCO3 (3 x 
15 mL), dried (Na2SO4), filtered and concentrated to afford title compound 2.23 (0.15 g, 33%) as an 
amorphous solid. 1H NMR (500 MHz, DMSO-d6) δ 10.60 (1H, m, NHOH), 8.90 (1H, s, NHOH), 
8.01 – 7.88 (2H, m, 2 x NH), 7.26 – 7.17 (5H, m, 5 x Ar-H), 4.37 – 4.06 (3H, m, 3 x α-CH), 3.27 – 
3.16 (2H, m, Pro-NCH2), 2.93 – 2.77 (2H, m, Ph-CH2), 2.08 – 2.00 (1H, m, Pro-CHa), 1.79 – 1.71 
(3H, m, Pro-NCH2CH2 & Pro-CHb), 1.37 – 1.29 (9H, m, Boc-(CH3)3), 1.18 – 1.13 (3H, m, Ala-CH3); 
13C NMR (125 MHz, DMSO) δ 172.0 (C), 171.6 (C), 167.3 (C), 153.2 (C), 137.4 (C), 129.1 (CH), 
128.0 (CH), 126.3 (CH), 78.3 (C), 59.2 (CH), 51.5 (CH), 47.9 (CH), 46.5 (CH2), 37.9 (CH2), 30.8 
(CH2), 28.0 (CH3), 23.1 (CH2), 18.3 (CH3); IR (thin film) 1686, 1661, 1634, 1537, 1416; HRMS (ESI 
positive) exact mass calculated for C22H32N4O6Na [M+Na]+ m/z 471.2209; found m/z 471.2214. 
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Fmoc-Pro-Ala-Phe-OMe 2.28 
Following general procedure A, H-Ala-Phe methyl ester trifluoroacetate 
2.25 (0.20 g, 0.55 mmol) was coupled with Fmoc-Pro-OH (0.17 g, 0.50 
mmol). The crude material was subjected directly to the following 
transformation. 
 
Fmoc-Pro-Ala-Phe-OH 2.29 
To a solution of Fmoc-Pro-Ala-Phe methyl ester 2.28 (0.10 g, 0.18 mmol) 
in isopropanol (7.0 mL) was added a calcium chloride (0.80 M aq. 
solution, 3.0 mL) and sodium hydroxide (8.5 mg, 0.21 mmol). The mixture 
was stirred at room temperature for 2 h, before quenching with AcOH (20 
mg), and concentrating in vacuo. The crude material subjected directly to the following 
transformation.  
 
Fmoc-Pro-Ala-Phe-NHOH 2.24 
Fmoc-Pro-Ala-Phe-OH 2.29 (0.40 g, 0.75 mmol) was subjected to 
general procedure C. The crude mixture was diluted with water and 
acidified to pH 3 with 0.1 M aq. HCl. The mixture was extracted with 
CH2Cl2 (3 x 10 mL) and the combined organics were washed with sat. 
aq. NaHCO3 (3 x 10 mL), dried (Na2SO4), filtered and concentrated to afford Fmoc-Pro-Ala-Phe 
hydroxamate (0.12 g, 28%) as a white amorphous solid. 1H NMR (500 MHz, DMSO-d6) δ 10.63 – 
10.55 (1H, m,  NHOH), 9,55 (1H, s, NHOH), 8.27 – 7.82 (4H, m, 2 x Fmoc Ar-CH & 2 x NH), 7.71 
– 7.58 (2H, m, 2 x Fmoc Ar-H), 7.48 – 7.13 (9H, m, 5 x Ar-H & 4 x Fmoc Ar-H), 4.44 – 4.07 (6H, 
m, 3 x α-CH & Fmoc-CH2 & Fmoc-CHCH2), 3.49 – 3.40 (2H, m, Pro-NCH2), 3.09 – 3.01 (1H, m, 
Ha), 2.96 – 2.86 (1H, m, Hb), 2.25 – 2.01 (1H, m, Hc), 1.96 – 1.57 (3H, m, Pro-NCH2CH2 & Hd), 1.20 
– 1.09 (3H, m, Ala-CH3); 13C NMR (125 MHz, DMSO) δ 171.9 (C), 171.7 (C), 171.4 (C), 154.0 (C), 
140.7 (C), 140.6 (C), 137.3 (C), 129.2 (CH), 128.9 (CH), 128.2 (CH), 128.0 (CH), 127.6 (CH), 127.1 
(CH), 125.3 (CH), 67.0 (CH2), 66.5 (CH), 59.0 (CH), 54.9 (CH), 48.2 (CH), 46.7 (CH2), 36.7 (CH2), 
31.3 (CH2), 21.0 (CH2), 18.2 (CH3); IR (thin film) 1732, 1697, 1668, 1649, 1433; HRMS (ESI 
positive) exact mass calculated for C32H34N4O6Na [M+Na]+ m/z 593.2366; found m/z 593.2371. 
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Marimastat: 
 
(2S)-diisopropylmalate 
To a solution of L-(−)-Malic acid (20 g, 150 mmol) in isopropyl alcohol (60 mL) 
was added conc. sulfuric acid (0.4 mL, 1 mol. %). The mixture was warmed at 
reflux for 72 h. The mixture was allowed to cool to room temperature before the 
addition of sat. aq. NaHCO3 (100 mL). The mixture was extracted with Et2O (3 x 50 mL). The 
combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo to afford (2S)-
diisopropylmalate (43 g, 66 %) as a colourless oil. No further purification was necessary.  
 
(2S,3R)-diisopropyl-3-(2’-methylallyl)malate 2.33 
To a stirred solution of diisopropylamine (14 mL, 100 mmol) in THF (50 mL) was 
added dropwise a solution of n-butyllithium (2.1 M in hexanes, 47 mL, 99 mmol) 
at −78 °C. The solution was warmed to 0 °C and stirred for 15 mins before cooling 
to −78 °C. A solution of (2S)-diisopropylmalate (9.8 g, 45 mmol) in THF (150 mL) 
was added dropwise. The solution was allowed to warm to −20 °C, whereupon it was stirred for 2 h, 
before the addition of methallyl iodide (8.2 g, 45 mmol). The solution was warmed to room 
temperature and stirred for 16 h. The reaction mixture was quenched with sat. aq. NH4Cl (150 mL) 
and the aqueous extracted with Et2O (3 x 150 mL). The combined organic extracts were washed with 
brine (100 mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified 
by flash chromatography (15% EtOAc/Petroleum ether) to afford title compound 2.33 (4.3 g, 35%) 
as a colourless oil. Observed analytic data is in accordance with literature values.[172] 
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(2S,3R)-diisopropyl-3-isobutylmalate 2.36 
 To a stirred suspension of palladium on carbon (0.43 g, 10% w/w w.r.t. 2.33) in 
EtOH (35 mL) held under an inert atmosphere was added a solution of (2S,3R)-
diisopropyl-3-(2’-methylallyl)malate 2.33 (4.3 g, 16 mmol) in EtOH (35 mL). The 
reaction mixture was flushed with hydrogen, and stirred for 24 h at room 
temperature. The crude reaction mixture was flushed with argon, and filtered through Celite®. The 
filtrate was concentrated in vacuo to afford title compound 2.36 (4.1 g, 16 mmol, 98%). No further 
purification was necessary. Observed analytic data is in accordance with literature values.[172] 
 
(2S,3R)-3-isobutylmalic acid 2.37 
To a solution of (2S,3R)-diisopropyl-3-isobutylmalate 2.36 (4.1 g, 16 mmol) in 
Dioxane/H2O (1:1 v/v, 30 mL) was added 3.5 M aq. KOH (13.5 mL, 48 mmol). The 
mixture was warmed to 90 °C for 24 h. The aqueous mixture was extracted with 
Et2O (3 x 30 mL), and acidified to pH 2 with 1 M aq. HCl. The acidified aqueous 
mixture was extracted with Et2O (3 x 30 mL), and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo to afford title compound 2.37 as a white powdered solid 
(3.0 g, quant.). No further purification was required. Observed analytic data is in accordance with 
literature values.[172] 
 
(R)-2-((S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)-4-methylpentanoic acid 2.31 
 To a solution of (2S,3R)-3-isobutylmalic acid 2.37 (3.0 g, 16 mmol) in 2,2-
dimethoxypropane (200 mL) was added p-toluenesulfonic acid (0.30 g, 1.6 mmol). 
The mixture was stirred at room temperature for 16 h. The reaction mixture was 
concentrated in vacuo. The crude mixture was purified by flash chromatography (4:1 
EtOAc/Petroleum ether) to afford 2.31 (1.8 g, 50%) as a colourless oil. Observed 
analytic data is in accordance with literature values.[172] 
 
(R)-N-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-2-((S)-2,2-dimethyl-5-oxo-1,3-
dioxolan-4-yl)-4-methylpentanamide 2.39 
 To a solution of carboxylic acid 2.31 (1.1 g, 4.8 mmol) in DMF (15 mL) was 
added HOBT (0.78 g, 5.8 mmol), and EDC (1.1 g, 5.8 mmol) at 0 °C. After 
15 min, a solution of tert-leucine methylamide.TFA 2.32 (1.4 g, 5.8 mmol) 
and DMAP (0.12 g, 1.0 mmol) in DMF (5 mL) was added, followed by 
iPr2NEt (1.0 mL, 5.8 mmol). The mixture was stirred at room temperature for 16 h, before the 
addition of H2O (20 mL). The aqueous mixture was extracted with Et2O (2 x 30 mL), and the 
combined organic extracts were washed with H2O (5 x 20 mL), brine (20 mL), dried (Na2SO4), 
filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (1:1 
EtOAc/Petroleum ether) to afford title compound 2.39 (0.95 g, 56%) as a colourless oil.  
181 
 
Marimastat 
To a solution of 2.39 (0.95 g, 2.7 mmol) in THF (2 mL) was added 50% 
w/v aq. hydroxylamine (0.95 mL). The mixture was heated to reflux for 
3 h. The reaction mixture was concentrated in vacuo and the crude 
product was washed with water, resulting in a white precipitate. The 
precipitate was collected by filtration to afford marimastat (0.58 g, 65%) as a white crystalline solid. 
Observed analytic data is in accordance with literature values.[172] 1H NMR (500 MHz, DMSO-d6) δ 
10.54 (1H, s), 8.86 (1H, s), 7.85 (1H, q, J = 4.5 Hz), 7.47 (1H, d, J = 9.5 Hz), 5.35 (1H, d, J = 8.0 
Hz), 4.17 (1H, d, J = 9.5 Hz), 3.71 (1H, t, J = 8.1 Hz), 2.72 – 2.66 (1H, m), 2.56 (3H, d, J = 4.5 Hz), 
1.49-1.31 (2H, m), 0.96 – 0.91 (1H, m), 0.89 (9H, s), 0.82 – 0.76 (6H, m); 13C NMR (125 MHz, 
DMSO) δ 172.2, 170.5, 168.8, 71.3, 59.8, 47.8, 37.4, 34.1, 26.6, 25.3, 25.2, 23.4, 21.8; Anal. Calc. 
for C15H29N3O5: C, 54.38; H, 8.76; N, 12.69; Found: C, 54.21; H, 8.87; N, 12.55. 
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